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Introduction
1.1 Autocrine growth
Growth of cells and tissues is controlled by a large variety of polypeptides and 
hormones that surround them. The classic beliefs were that of endocrine control, 
whereby these substances were produced at locations not necessarily close to the 
tissues it affected, and subsequently transported by means of the circulation. Later 
the so-called paracrine control was described in organisms without circulatory or 
glandular endocrine systems. Then, in 1980, Sporn and Todaro152 suggested that 
control of cell growth is regulated by polypeptides and growth factors that are 
produced by the cells themselves and excreted in their microenvironment. The cell 
that produces the growth factor has functional external receptors for the growth 
factor so that they can respond to their own endogenous products. This was 
introduced as the autocrine growth control mechanism (Fig. 1).
Figure 1: Schematic rep resen ­
tation of autocrine, paracrine, and 
endocrine secretion (from Sporn 
and Todaro120).
With the subsequent characterization of polypeptides that cause phenotypic 
transform ation of cells36, the idea developed that tumorigenesis could be caused by 
the autocrine secretion of transforming growth factors135 136 153 154. Obviously, if these 
mechanisms are indeed key factors in development of malignancy, then control of 
aberrant autocrine loops could have significant implications for the treatm ent of 
cancer. Later work showed that the initial autocrine hypothesis was too restrictive, 
since other lesions could lead to the unrestrained cell proliferation characteristic of 
cancers including lesions in the receptor, lesions in the post-receptor signaling 
pathways, and lesions in the expression of the peptide itself135 136. Furthermore, the 
role of autocrine mechanisms is not restricted to cancer cells, but is also important 
in normal cellular processes including development. Hypotheses that the mechanisms 
of normal growth and development, inflammation, wound repair and carcinogenesis
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are all based on related cellular mechanisms were already eloquently suggested 
over two decades ago: “a wound may be regarded as a tumor which heals itself"64, 
and “tumors are wounds that do not heal"39.
Growth factors should therefore be regarded as a means of coupling the cell to its 
(micro)environment. By modulating the expression of the growth factor, its receptor, 
or signalling pathway, the cell can take m easures to respond to external or internal 
changes. However, although generally well-balanced, failure of this autocrine or 
paracrine homeostasis can lead to clinical disease. This thesis investigates the role 
of autocrine mechanisms involving TGF-p in musculoskeletal tumorigenesis.
1.2 TGF-p superfamily
The TGF-p superfamily of regulatory proteins includes not only the well-known 
TGF-p isoforms which rendered this rem arkable family its name, but also a large 
number of related proteins including activin and inhibin, Drosophila decapentaplegic 
protein (dpp), their mammalian counterpart the bone morphogenetic proteins (BMPs), 
and Mullerian inhibitory substance (MIS)(Fig. 2).
These related proteins have up to a 30% homology with TGF-p. Over the last 10
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Figure 2: Members of the TGF-p super­
family. The shorter the connecting links 
are, the more alike the proteins are 
(from Wozney and Rosen176a).
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years, a large volume of data has accumulated documenting how these related 
molecules regulate embryogenesis, development and repair in organisms ranging 
from flies, worms, sea urchins, chickens, frogs, and mice, to humans. Complex 
processes such as axis formation, tissue specification and homeostasis are tightly 
controlled by the receptors and proteins at picomolar concentrations. New TGF-p 
family mem bers are still being identified with the total now reaching over 75 in 
different species95. Sequencing of members of the TGF-p superfamily has shown 
that homology with the human or mouse genomes is generally restricted to the C- 
term inal m ature peptide22.
1.2.1 TGF-p protein
Transforming growth factor Beta (TGF-p) was originally described for its ability to 
transform  the phenotype of fibroblasts7133, and originally purified to homogeneity 
from human platelets2, human placenta51, and bovine kidney134. Although the highest 
concentration of TGF-p is found in blood platelets, bone is the most abundant source 
of these polypeptides2. It is formed as a homodimer of two 12-15 kDa chains, linked 
to each other by a single disulfide bond. It is produced by most cells in a so-called 
latent form, from which it can be activated by heat treatm ent, extremes in pH, 
throm bospondin, and by enzymatic trea tm en t with cathepsin D, plasm in, or 
glycosidases. The mechanism and control of activation of latent TGF-p are important 
in certain pathological and physiological processes in vivo.
There are five isoforms of TGF-p: -pi, -p2, -p3, -p4, and -p5, of which only -pi 
through -p3 have been described in mammalians. The other two have been identified 
in chicken (-p4, analogue to the mammalian -pi), and frogs (-p5) respectively. There 
is a very high level (more than 95%) of sequence homology for each isoform between 
species. Most TGF-ps exist in a homodimeric form, although heterodimers such as 
TGF-pi.2 and TGF-2.3 have been described113. All TGF-p isoforms have nine cysteine 
residues -one of which is involved in an interchain disulfide bond, the other eight 
are intrachain disulfide bonds- suggesting that this highly conserved group has an 
important structural function for this protein. The TGF-p2 monomer has a crystal 
structure that looks like a stretched hand113.
As is often seen with new cytokines and growth factors, discovery of TGF-p was 
only the tip of the iceberg. Since its description of “transforming" the phenotype of 
fibroblasts36, TGF-p has perplexed the scientific world with its myriad of activities 
and roles. It is a fundamental regulator of cell behaviour. The different TGF-p isoforms 
share many biological activities involved in normal processes such as morphogenesis 
and differentiation in embryogenesis, tissue repair, and wound healing69 123 133. Effects
13
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of TGF-p on cellular proliferation are characteristically inhibitory for epithelium- 
derived cells, and stimulatory for mesenchyme-derived cells133. Battegay et al.10 
showed that the proliferative effect of TGF-p on some mesenchymal cells is through 
endogenous induction of PDGF, and that it is, in fact, a bimodal effect in that low 
concentrations are stimulatory whereas higher concentrations are growth inhibitory.
According to extensive immunohistochemistry studies, expression of TGF-p occurs 
throughout embryogenesis, and is remarkably high in sites of chondrogenesis and 
osteogenesis24. Although no significant qualitative or quantitative differences have 
yet been identified between the three TGF-p isoforms regarding their effects on the 
skeletal system, they are differentially expressed during mouse embryogenesis and 
development. This suggests that they each have specific roles24,69 166.
The significance and complexity of TGF-p’s widespread roles were most strikingly 
shown by studies based on the TGF-p gene knock-out in mouse100. These animals 
were normal at birth, but died within 3-4 weeks due to an excessive inflammatory 
response. As Wahl stated, “We eagerly awaited the genetically engineered TGF-p 
loss-of-function m utation to answer all we ever wanted to know about TGF-p, 
including its role in inflammation and immune function, but we found that the TGF-p 
knockout has, as appears to be typical of this quixotic molecule, provided more 
questions than answers"171.
1.2.2 Bone Morphogenetic Proteins
These members of the TGF-p superfamily were originally identified as polypeptides 
that induced ectopic bone formation129. More recently it has become clear they have 
a more widespread role, also affecting growth, differentiation and apoptosis not 
only of chondroblasts and osteoblasts, but also of neural7284 and epithelial cells. 
Their homologue in Drosophila is decapentaplegic protein (dpp), which has been 
shown to be a crucial morphogen with promoting effects on formation of eyes, gut, 
and appendages. The structure of the BMPs is that of a 30-38 kDa disulfide-linked 
dimeric protein subclassified based on their amino acid sequence. Its th ree ­
dimensional structure is similar to that of other members of the TGF-p superfamily. 
To date there have been more than fifteen different BMPs identified; only BMP-1 is 
not a TGF-p superfamily member which has recently turned out to be a procollagen- 
C-proteinase involved in the morphogenesis of fibrillar collagen91129. In contrast to 
TGF-p, the BMPs do not need to be activated from their latent form. Moreover, there 
appear to be proteins (e.g. noggin, chordin in Xenopus and sog in Drosophila) that 
prevent BMP from binding to their receptors, thus regulating their activity91.
The role of BMPs in skeletal morphogenesis has been well described96 129 142. Most
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of the current interest is on the possible roles that BMPs can have in bone recon­
struction and fracture repair19117, as well as on their potential applications in spine 
fusions. They affect chondroblasts and osteoblasts and their progenitor cells in vitro 
as well as in vivo, and they have been shown to be localized in a temporal and 
spatial pattern in the developing skeleton. However, BMPs have also been shown to 
play a role in hematopoiesis and morphogenesis of other organs. BMP-4 for instance 
induces ventral mesoderm in Xenopus72. Information has been gained from the so 
called “short ear mutations" with a phenotype of abnormal growth of the skull and 
axial skeleton9697. This mutation is located very close to the BMP-5 gene, which 
implicates this gene in development of the skeletal tissue. Increased expression of 
BMP has been shown in certain pathological conditions such as hum an osteo- 
sarcom a186, fibrodysplasia ossificans progressiva150, and in prostate (osteoblastic) 
m etastatic disease4. Gene knock-outs for BMP-4 and BMP-7 have been reported to 
be lethal shortly after birth129.
1.2.3 Activin subfamily
Activins were originally identified in ovarian fluid as factors that stimulate the 
secretion of follicle stimulating hormone (FSH) from pituitary cells. Similar to their 
family members in the TGF-p superfamily, they have subsequently been shown to 
have multifunctional roles in that they modulate bone formation by BMP, stimulate 
erythroblast progenitor differentiation, and m esoderm  induction in Xenopus 
embryos181183. Activins are homo- or heterodimers of A or B subunits, with activin A 
being a homodimer of pA chains. Although on a molar base activin is 500-fold weaker 
than TGF-p1, it has TGF-p1 like effects in fetal ra t osteoblasts28. During mouse 
development there is a high expression of pA in mesenchymal tissues183. Its activity 
can be modulated by follistatin, an activin-binding protein, and by inhibin, an activin 
receptor antagonist composed of an activin chain linked to a so-called a-chain.
1.3 TGF-p superfamily receptors
1.3.1 TGF-p receptors
TGF-p superfamily members exert their effects though specific receptors on the 
cell surface (for review see refs. 3,113,184). Initially, three different receptors were 
identified. The original description of these molecules was based on cross linking 
assays with radio-labeled TGF-p: type I (TpR-I, 50-60 kDa), type II (TpR-II, 75-85
15
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kDa), and betaglycan or type III receptor (TpR-III, 280-330 kDa). The expression of 
these receptors has been shown to be widespread among species, excepting only rat 
phaeochromocytoma, and retinoblastoma cells94. All three receptor types have since 
been cloned and characterised.
Recently, multiple putative type I receptors TGF-p have been identified (for review 
see 103), but only a single type II receptor is known. Both the TGF-p type I and II 
receptors belong to a larger family of serine/threonine kinase receptors which all 
function as a ligand for TGF-p superfamily members. They are structurally similar, 
with a cystine-rich extracellular part, a single transm em brane domain, and an 
intracellular part that contains the sequences encoding a serine/threonine kinase. 
They are to be distinguished from the transm em brane receptors that have intrinsic 
tyrosine kinase activity. In addition to the three main receptor types, there are 
additional TGF-p binding proteins that have been described. Type IV receptor is a 
70-74 kDa receptor that binds TGF-p, activin, and inhibin, and has been detected 
only on the surface of a ra t pituitary cell line GH3. The type V receptor is a 400 kDa 
protein whose role is currently unknown. The type VI receptor (180 kDa) is found in 
L6 myoblasts and A549 lung adenocarcinoma cells. Endoglin (95 kDa) is another 
TGF-p binding protein which is expressed at low levels on the surface of erythroblasts, 
macrophages, and various myeloid and lymphoid cells, and at high levels on vascular 
endothelial cells and syncytiotrophoblasts60. Endoglin seems to have a role in 
inhibiting growth of endothelial cells. It binds TGF-p1 and TGF-p3 specifically, but is 
unable to bind TGF-p2. There is a structural similarity between TGF-p receptor type 
III and endoglin.
Our current understanding of the TGF-p signaling mechanism has come mostly 
through studies with mutated mink lung epithelial cells (Mv1Lu), the specifics of which 
are beyond the scope of this thesis. In short, the type I and II receptors are widely 
expressed and are both necessary for signal transduction. TpR-I needs TpR-II for 
ligand binding, and TpR-II needs TpR-I for signaling177. The type I receptor is not able 
to bind TGF-p, but it can recognize the TGF-p bound by TpR-II. Binding of this 
complex allows the formation of a very stable ternary complex in which the type I 
receptor is then transphosphorylated and thereby activated by the type II receptor, 
resulting in a TpR-I determined signaling specificity. This is also suggested by mutations 
in the type I receptor leading to a constitutively active receptor that transduces signals 
even in the absence of type II receptors and their ligand91. Phosphorylation, and thus 
activation of the TpR-I, leads to an intracellular downstream cascade of effector 
proteins, the so-called Smads, a process which is increasingly understood during the 
last few years. The type III receptor, also referred to as betaglycan, is expressed at
16
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high levels at most cell surfaces, but does not contain signaling motifs. This receptor 
is not directly involved in signal transduction but acts as a storage site for TGF-p 
presenting ligands to the type I and type II receptors107. The type III receptor binds 
all three TGF-p isoforms with equal affinity, as opposed to the type II receptor that 
binds TGF-p2 with less affinity than TGF-p1 and -p3. Another feature of the type III 
receptor is that it can be present in a soluble form in the extracellular area that is 
still able to bind TGF-p thus providing another mechanism for TGF-p binding control.
In addition to interaction with these membrane-bound receptors, there are a number 
of soluble proteins that are able to bind TGF-p, such as a-2-macroglobulin, decorin, 
thrombospondin, a-fetoprotein, and biglycan3. The significance of these interactions 
are still largely unknown, but these proteins seem to function as scavengers of excess 
TGF-p and restrict the activity of TGF-p to specific sites in the body.
1.3.2 BMP and Activin receptors
Although the receptor mechanism for TGF-p has been best described so far among 
the members of the TGF-p superfamily, it is likely that the receptor mechanism for 
BMP, Activin and other related TGF-p superfamily members is fairly similar. Two 
specific BMP type I receptors have been described in mammals: BMPR-IA, also known 
as activin-like-kinase (ALK)-3 and BMPR-IB, also known as ALK-6, which have 84% 
sequence identity. As opposed to the TGF-p receptors, there is already binding of 
ligand to the BMP type I receptor in absence of the BMP type II receptor, although 
presence of the type II receptor accelerates binding to the type I receptor164 180. Both 
receptor types are needed, however, for BMP signaling105. Functional differences 
between these two types are still unknown, although their intracellular signaling 
pathways seem to be different91. BMPR-IA is widely expressed, whereas BMPR-IB is 
restricted to certain cell types91. In addition to the above BMP-specific type I receptors, 
the activin type I receptor ActR-I, also known as ALK-2, can also transduce signals 
from BMP-2, BMP-7, Activin and GDF-5. Analogously, three different type II receptors 
for BMPs are known in mammals: BMP type II receptor (BMPR-II), activin receptor 
type II (ActR-II), and activin receptor type IIB (ActR-IIB). BMPR-II is able to bind 
BMP-2, BMP-4, BMP-7 and GDF-5, whereas ActR-II and IIB binds BMP-2, BMP-7, 
GDF-5 and activin. Other receptors for BMPs have been isolated in invertebrates 
such as the da f receptors in C. elegans and Punt, Saxophone (Sax) and Thick veins 
(Tkv) in Drosophila, which are beyond the scope of this review. BMP receptor 
expression is widespread: high affinity receptors for BMP-2 were present on all 
major cell types including bone, muscle, skin, ling, liver, kidney, stomach, colon, 
prostate, neuronal78. Importance of these receptors is shown in different studies
17
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reviewed in Yamashita180, e.g. introduction of truncated forms of the BMPR-IA 
receptor with dominant-negative characteristics leads to conversion of ventral to 
dorsal mesoderm in Xenopus, and disruption of the BMPR-IA gene leads to defects 
in mesoderm formation during gastrulation in Xenopus. Another example is the 
presence of webbed feet and the transformation of scales to feathers in a model of 
BMPR-IB deficiency in chicken180 188. Recently there has been evidence that BMPR- 
IB receptors play a role in pathogenesis of gliomas179; enhanced expression of BMPR- 
IA and -IB receptor genes was seen in patients with ossification of the posterior 
longitudinal ligament68 185.
The matching of all the BMPs and the different receptor complexes will be lead to 
understanding of their roles in various developmental and morphogenetic processes. 
Analogously, this will undoubtedly lead to new treatment strategies in different disorders.
Two different Activin II receptors have been cloned, ActR-II and ActR-IIB, which 
function similarly to TpR-II. A total of 6 activin receptor-like-kinase (ALK) that function 
as type I receptors for the TGF-p superfamily have been identified (ALK-1 thru ALK-6). 
Their name is based on the fact that PCR primers based on the sequences of ActR-
II, yet most ALK do not work with activin (for review see ref. 164).
1.3.3 Intracellular mediators for TGF-p signaling
The initial focus in TGF-p receptor research was on the activation of serine/ 
threonine kinases. More recently, there has been an increasing understanding of 
the intracellular pathways involving the Mad-related family (Fig. 3). The Mad proteins 
(Mothers against decapentaplegic protein), which represen t the in tracellu lar 
mediators of TGF-p action, were discovered accidentally during genetic studies in 
Drosophila. Three Mad-homologs, called sma-2, -3, and -4 were found in the 
nem atode Caenorhabditis elegans66, and 8 homologs, named Smads 1-8 were 
subsequently found in humans and vertebrates. The Smad proteins (42-60 kDa) can 
be divided in three distinct classes which have a specific, a common, or an inhibitory 
action respectively. The first class consists of Smads that function as direct targets 
for the TGF-p superfamily members, and are called “pathway-restricted-Smads". 
They are comprised of Smad1, Smad5 and Smad8, which are substrates for the 
BMP type I receptors, whereas Smad2 and Smad3 are substrate of TGF-p and activin 
type I receptors. The interaction between these the receptors and Smads is transient70. 
The second class (common-mediator) of Smad proteins function as “co-Smads", such 
as Smad4 (=DPC or Deleted in Pancreatic Carcinoma locus 4)132 in humans and 
m edea in Drosophila, which heterodimerizes with the pathway-restricted Smads 
after their phosphorylation and subsequently directs them to the nucleus. The third
18
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Figure 3: Current understanding of the SMAD proteins in TGF-p receptor signaling. 
TGF-p binding leads to assembly of a heterotetrameric complex. In this complex the 
type II receptor phosphorylates and activates the type I receptor. Subsequent activation 
of pathway restricted SMAD’s leads to binding of Smad4, a common mediator SMAD, 
forming a complex that is translocated to the nucleus. Smad6 and Smad7 binding 
prevents this pathway (from Heldin et al.70).
class is represented by the “antagonistic Smads": Smad6 and Smad767. They are 
called antagonistic because they prevent binding of the pathway restricted Smads 
to their activated type I receptors. These “antagonistic Smads" can possibly be seen 
as part of a negative feedback loop that regulates the intensity and duration of TGF-p 
signaling, since they are induced in cells following TGF-p, activin and BMP action.
Specific mutations in some of these TGF-p receptors have already been linked to 
certain cancers as described in a later section, but also to other human diseases 
such as hereditary teleangiectasia (mutation in Alk-1, type I receptor, or in the 
endoglin receptor), and the Hunter-Thompson-type chondrodysplasie (mutation in 
the cartilage-derived morphogenetic protein 1 (CDMP1)165. Understanding of receptor 
signaling will ultimately lead us to more rational treatm ents of these conditions.
1.4 TGF-p and bone
1.4.1 TGF-p protein and bone 
As stated above, TGF-p was first identified from blood platelets, but soon after, 
two TGF-p isoforms, named cartilage inducing factors -A and -B (CIF-A, CIF-B), 
were isolated from bovine bone matrix. Cartilage-inducing factor A is now known
19
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Figure 4: Storage and release of TGF-p in bone. Latent TGF-p stored in bone where it is 
released in an active form by resorbing osteoclasts. Activation of TGF-p leads to 
chemotaxis and proliferation of osteoblasts (from Bonewald and Dallas15).
as TGF-pi and cartilage-inducing factor B as TGF-p234149. Since then it has become 
clear that TGF-p and its related family members such as BMPs and activin have a 
major role in the development and remodelling of bone. TGF-p is present in a latent 
form in bone, and it can be released from its inactive stage by alkalinization or 
acidification127(Fig. 4). The latent TGF-p complex in bone is somewhat smaller than 
the latent TGF-p complex in platelets114. TGF-p is estimated to exceed 200 mg/kg 
bone tissue149, and is thus on a tissue mass basis the highest storage site for TGF-p. 
The enormous amount of TGF-p stored and produced by the skeletal system suggests 
that it has an important role in development and homeostasis of bone, but also that 
perturbations in the balance of TGF-p could have widespread effects. When injected 
subperiosteally or in the subcutaneous tissue over the calvaria of normal rats or 
mice, for example, a significant increase in the width of the periosteal layer with 
accumulation of osteoid (=unmineralized new bone) was observed119.
From a developmental point of view there is differential expression of the three 
TGF-p isoforms. TGF-pi is expressed more in the differentiated bone-forming 
osteoblasts and bone-resorbing osteoclasts, and is seen in bone and cartilage, and 
in the later developmental stages and ossification centers. TGF-p2, on the other 
hand, is more prominent in the perichondrium, in precartilagenous areas, and long 
bone physeal regions. Lastly, TGF-p3 has the most diverse expression next to areas 
of in tram em braneous ossification, and perichondrium 28 166. Unfortunately, as 
mentioned above, the development of the much anticipated TGF-pi knock-out mice 
did not provide much new information on the role of TGF-p in the skeletal system 
since all animals died before changes in bone could be observed15. However, TGF-p3
20
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knock-out mice showed cleft palate and craniofacial defects128.
In vitro and in vivo studies have shown that TGF-p also has pluripotent, complex 
and often confusing effects on skeletal cells13'15,26'30,61 114 140; the function of TGF-p 
seems to change as the osteoblast differentiates, although the mechanism(s) through 
which this works is still unclear. In vitro studies have shown that TGF-p can enhance 
proliferation of osteoblast-enriched cultures from fetal rat calvaria in a bimodal 
fashion, meaning that high concentrations decrease its effectiveness26,29,163. This might 
be explained by the presence of binding-sites with high and low affinity26. The potency 
of TGF-p3 seemed 3-10 times higher than that of TGF-pi and -p2 as tested in 
osteoblast-enriched cultures form fetal bone26. In other culture systems such as 
some (more differentiated) osteosarcoma cell lines, TGF-p had inhibitory effects, 
which seem to depend on culture conditions such as dose and duration of the 
exposure, cell density29 and cell type population.
In general, TGF-p alters the expression of a few key proteins in the skeletal system. 
For instance, the level of procollagen type I mRNA increases after TGF-pi treatm ent29, 
as are osteonectin118 and osteopontin, an important protein in adhesiveness of the 
cells in the matrix, whereas osteocalcin, a noncollagenous molecule important for 
regulation of matrix calcification, is decreased119. Alkaline phosphatase, a m arker of 
differentiation, is decreased by TGF-p in fetal tissues, yet increased in more 
differentiated bone cells such as osteosarcoma cells118,127. Another important feature 
of TGF-p is that it can enhance chemotaxis of osteoblasts which might be important in 
fracture repair or new bone formation87 104 108. In vitro and in vivo studies have also 
shown that TGF-pi, -p2, and -p3 can regulate bone formation by inducing osteoblast 
and osteoclast proliferation, extracellullar matrix formation, and bone-related protein 
production28,86. TGF-p is also able to enhance its own expression at the transcriptional 
level, a feature shown both in osteoblasts and in osteosarcoma cells6,26,106,169. Injection 
of TGF-pi in the subperiosteal region of ra t femurs resulted in a stimulation of new 
bone formation resembling embryologic bone formation and fracture repair86. With 
its substantial production and presence in bone and its known role in skeletal 
development and remodeling affecting both absorption (osteoclasts) and production 
(osteoblasts) of bone at picomolar concentrations, a tight control mechanism of 
expression of TGF-ps and their receptors is needed.
Remodeling of bone is an ongoing process, implying the existence of mechanisms 
that link bone formation (osteoblast) with bone breakdown (osteoclast). The relations 
of TGF-p and the former have been described above. On the opposite side of the 
spectrum is the osteoclast, which is responsible for the breakdown of bone. These 
cells have also been shown to be affected by and to produce TGF-p9,121. Thus, it
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appears that TGF-p plays an important role in the coupling and uncoupling of bone 
metabolism. The area under the osteoclast -the ruffled border- is known to have a 
locally acidic pH, which is theoretically an ideal environm ent, for activation of latent 
TGF-p. Using immunohistochemistry Hosoi et al.73 suggested local delivery and possibly 
activation of TGF-p by osteoclasts in tissue. Although the exact role of TGF-p in the 
skeleton in vivo is still incompletely understood, recent insights using transgenic 
mice that overexpress TGF-p2 in their osteoblasts suggest that this isoform leads to 
osteoporosis, and may have an important role in conditions such as hyperpara­
thyroidism, and other metabolic bone disorders42.
Prior to the start of the work that comprises this thesis, there was no information 
on a possible link between TGF-p and osteosarcoma, a malignant bone tumor defined 
by the ability of the cells to produce osteoid. With the role of TGF-p in cancer and 
the large storage of TGF-p in bone, it seemed of great interest to investigate a link 
between TGF-p and osteosarcoma.
1.4.2 TGF-p receptors in bone
All three main TGF-p receptors have been shown to be present in bone by affinity- 
cross-linking studies in fetal osteoblast-enriched cell cultures2634 147 163 172. Kabasawa 
et al.90 suggested that TGF-p type II receptors were only present on pre-osteoblasts 
in rats, but not on differentiated osteoblasts. TGF-p3 binds with a higher affinity 
than TGF-pi in fetal ra t osteoblast-enriched cultures163. Glucocorticoids, which are 
known to decrease bone formation, decrease binding of TGF-pi to its type I and type 
II receptors27. On the other hand, BMP-2 decreases TGF-p binding to type II and III 
receptors, whereas it increases binding to the type I receptor. Thus, modulation of 
binding and/or its receptor profile is a means to regulate its biological effect on 
skeletal organogenesis27. A rapid flux of TGF-p receptors by BMP-2 was elegantly 
shown by Centrella et al.31, who suggested that rapid changes in receptor expression, 
protein synthesis, and ligand recognition function as modulators of TGF-p’s control 
of skeletal cells. A dominant loss of function in mice of the TpR-II resulted in 
osteoarthritic changes suggesting that TGF-p maintains cartilage homeostasis148.
1.5 TGF-p and disease
TGF-p has been implicated in several diverse disorders ranging from atherosclerosis, 
fibrosis, impaired wound healing, autoimmune diseases, and neoplasia. Although this 
may seem confusing at first, it all comes down to the classic features of TGF-p: matrix
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production (including blood vessels) and growth control (including immunosuppression). 
Diseases have been linked to either too much or too little TGF-p, prompting Wahl to call 
the functions of TGF-p “the good, the bad and the ugly"171. Most research interest has 
focused on the role of TGF-p in fibrotic disorders and in cancer, which will be 
summarized below.
1.5.1 TGF-p and fibrosis
One of the most important features of TGF-p is its ability to induce extracellular 
m atrix production and to prevent its breakdown. It has been shown both in vitro 
and in vivo that addition of TGF-p leads to increased production of fibronectin, 
collagen and other constituents of the matrix. In a classic paper, Roberts et al.137 
showed that subcutaneous injection of TGF-p in rats leads to a lump with highly 
vascularized granulation tissue within 6 hours. Apparantly, TGF-p increases the 
production of protease inhibitors and decreases the production of proteases, resulting 
in a net increase of matrix. Over the last few years these features have not only 
been shown to be important in embryogenesis and repair, but also in fibrotic disorders 
and the desmoplastic reaction as seen in cancer (Fig. 5). As will be discussed later, 
efforts are currently underway to interfere with these fibrogenic effects.
There are also interactions between the extracellular matrix (ECM) and TGF-p 
which can be bi-directional, and excessive ECM production can be caused by excessive 
TGF-p levels or aberrant signals from the ECM139. These features have been shown 
both in vivo and in vitro, and have been linked to diseases such as pulmonary 
fibrosis21, keloids12,124, glomerulonephritis16,18 and scar tissue187. This prompted Border 
to introduce this as the “the dark side of tissue repair."17 Recent reports suggest 
that the ratio of TGF-pi/TGF-p2 relative to TGF-p3 is important for the development 
of scarring and fibrosis46 120. The local use of TGF-p antibodies was shown to decrease 
scar form ation151. TG F-pi-induced g ranulation  tissue was characterized  by 
myofibroblasts expressing a-smooth muscle actin (a-SM) actin which is the hallmark 
of fibroproliferative disorders38.
A unique feature of TGF-p is that it is able to upregulate its own synthesis169, 
thereby adding an endogenous amplification loop and rendering it a chronically 
elevated cytokine which results in a potentially harmful feedback loop. In addition, 
fibrotic tissues generally have relative hypoxic environments which in itself induces 
TGF-p, as was shown for TGF-pi in human fibroblasts45.
As will be discussed in chapter 6, major research efforts are currently focused on 
the possible interaction of TGF-p with GM-CSF in tissue fibrosis and possible 
implications for treatm ent.
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Figure 5: Roles of TGF-p in a) normal repair processes, where production of extracellular 
matrix (ECM) is induced by TGF-p, and breakdown of ECM is decreased until the damaged 
tissue heals; and in b) fibrotic processes, where repeated injury, or a defect in TGF-p 
regulation, or both leads to fibrogenesis (from Border and Noble18).
1.5.2 TGF-p isoforms and cancer
With the m ultifunctional roles the TGF-p superfamily m em bers play in the 
development, growth and homeostasis in humans, it is not surprising that alterations 
in the expression of these growth factors and/or their receptors can have widespread 
effects, resulting in a large array of disorders. Thus, in addition to its ubiquitous 
presence in normal tissues, increased expression of TGF-p has been reported in 
many different tum ors8’11’17’37’40’49’50’58’59’71’77’79’80'83’112’160'162 168 178 175. Furtherm ore, 
increased expression of any one of the isoforms in different malignancies has been 
associated with disease-progression and decreased survival485057141. The role of TGF-p 
in the tumor environment is still largely a m atter of speculation.
Tumor development is a multistep process during which the normal balance between
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differentiation and proliferation have been disturbed. In contrast to the normal 
situation, tumors show autonomous proliferation driven somehow by activation of 
signaling pathways. There are a number of ways in which growth factors could 
contribute to tumor progression, aside from its possible role in the inducing “trans­
forming" steps. The concept of autocrine loops in hum an neoplasia is easily 
understandable for growth factors as insulin-like growth factor (IGF), and epidermal 
growth factor (EGF) that are stimulatory for cell proliferation. However, an autocrine 
loop for TGF-p is far more complex since it seems counterintuitive that an intrinsically 
growth-inhibitory growth factor would result in uncontrolled proliferation. One would 
expect that loss of growth control would be sufficient for uncontrolled proliferation, 
so why then would the tumor cells express more TGF-p in their micro-environment 
as is shown in multiple studies?
Although on a tissue mass basis, the epithelium comprises only a small part of the 
total weight of the human body, the vast majority of the human cancers arises there. 
Interestingly, as pointed out by Sporn and Roberts155, there is almost no cell division 
in the normal adult epithelium, but in times of repair there is rapid proliferation. It 
is unclear what prevents the autonomous growth of these normal epithelial cells, 
but TGF-p has been suggested as one of the major controlling forces. It has also 
been shown that certain cancer cell types are no longer responsive to TGF-p, which 
provides insight into the growth advantage of these cells138. This concept is now 
known in the literature as the “autocrine hypothesis for negative peptide growth 
factors"138’135.
Confusion remains, however, about the question why many different cancer cells 
express increased levels of TGF-p if loss of inhibitory control is the primary cause of 
their uncontrolled proliferation. What advantage does increased TGF-p expression 
provide for the tumor cells? It is possible that TGF-p, with its bi-directional effects, 
can allow the cancer cells to proliferate in vivo. It is known, for example, that TGF-p 
can switch from an inhibitor to a stimulator of tumor cell growth and invasion 
during colon75 and breast cancer progression. For mesenchyme-derived tumor cells, 
for which one would expect TGF-p to be stimulatory, it was indeed shown that growth 
is stimulated in vitro by exogenous TGF-p80-82 145 146.
Perhaps even more important than the direct effects on cellular proliferation, is 
the indirect stimulatory effect TGF-p can have on certain cells and functions. For 
instance TGF-p has been shown to stimulate the constituents of stromal tissue, 
angiogenesis47’65’125'126’182 and chemotaxis, while it also enhances cell migration and 
adhesion. Especially these first two issues are important for tumor progression since 
it is well established through Folkman’s work that tumor growth beyond a diameter
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of a few millimetres is dependent on the formation of new blood vessels47. TGF-p 
also is an immunosuppressant167 and its inhibiting effect on natural killer cells (NK) 
and lymphokine-activated cytotoxic T cells (LAK) would cause a decrease in immuno- 
surveillance and immune-cell mediated tumor destruction.
1.5.3 TGF-p receptors and cancer
In addition to reports on the increased expression of TGF-p in tum ors11’49’50’58’59’71’80' 
82’160'162 168 176, aberrant TGF-p receptor expression and activities in different tumors 
and tumor cell lines have also been reported20’23’41’49’52-54’62’76’88’89’92’101’109’110’111’157’170’173’174. 
The mechanisms responsible for this could be modulation of receptor number and 
affinity, or alterations in post-receptor pathways. The complete loss of cell surface 
receptors in tumors is a relatively infrequent cause of resistance to TGF-p. Of 70 
neoplastic and non-neoplastic cell lines screened, only 5 cell lines (4 retinoblastoma 
and 1 rat phaeochromocytoma) completely lacked TGF-p receptors94. One also has 
to keep in mind that there seems to be an inverse relation between the receptor 
number and affinity for the ligand172, so that having less receptors does not necessarily 
m ean that less ligand is bound.
Currently there is a rapidly growing amount of information on the expression of 
TGF-p receptors in human cancers. Although structural alterations in the TpR-I 
have been described in prostate cancer cells as early as 199692, most interest has 
been focused on aberrance of the TpR-II5’23’41’56’63’64’101 115 122 176. Williams et al.176 used 
immunohistochemical techniques to study the expression of TpR-II receptors in 
hum an prostate cancers, and found that decreased expression correlated with 
increasing histological (Gleason) grade of the tumor. These findings were confirmed 
by Kim et al.93, who showed that not only decreased expression of TpR-II but even 
more so of TpR-I was associated with a statistically higher recurrence rate and 
lower 4-year survival rate. Loss of TpR-II was seen to correlate with decreased 
tumorigenicity in gastric cancer cell lines32. Markowitz et al.110 showed an association 
between loss of the type II receptor and microsattelite instability in colon carcinoma 
cell lines, which prompted them to call the TpR-II a tumor suppressor gene. Park et 
al.122 reported on mutations in the TpR-II gene in gastric cancer cell lines, showing 
that differences in these receptors correlated with the sensitivity to growth inhibition 
by TGF-p. Sue et al.157 reported on a significant decrease in both TpR-I and TpR-II at 
the protein and mRNA level in human hepatocellular carcinoma tissue. Their results 
w ere confirmed by Bedossa et a l.11 using im m unohistochem ical techniques. 
Interestingly, TpR-II receptor protein was found in the cytoplasm of the tumor cells 
but not on their surface, suggesting a defect in the processing and translocation to
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the surface membrane. Reintroduction of a functional TpR-II in a breast cancer cell 
line that lack this receptor (MCF-7) restored the normal inhibitory effects of TGF-p 
on this cell line, resulting in the reversal of its malignant phenotype158. Similar 
results were shown by Coppa et al.35 in transformed thyroid cells, although they 
stated that the reintroduction of TpR-II was not sufficient to reverse the tumorigenic 
properties. Guo et al.63 showed that overexpression of TpR-II restored sensitivity 
and signaling in a hum an prostate cancer cells, leading to a lower expression of 
prostate specific antigen (PSA), suggesting that overexpression of the TpR-II can 
potentially suppress tumorigenic behaviour of these cells.
In contrast to the above studies that reported on decreased or m utated TpR-II 
receptors, others have reported increased expression of TGF-p receptor in cancer 
cells, including TpR-II in pancreatic cancer49 and in colorectal adenocarcinomas43 
and TpR-I and -II in glioblastoma tum ors178.
In addition, with the expanding knowledge on the intracellular components of the 
TGF-p signaling pathway, alterations have recently been noted in certain malignancies 
at the level of the Smad signal transducers. Such findings included mutations of 
Smad4 in pancreatic cancer (DPC4, deleted in pancreatic carcinoma locus 4)132, 
colorectal cancer159, juvenile polyposis74, breast, ovarian, head and neck, prostatic 
and gastro-esophageal cancers (for review see ref. 66). On the other hand, one can 
theorize that increased expression of the “antagonistic Smads" (Smad6 and Smad7) 
could also suppress TGF-p signaling. Recently, Sm adl, 3, 5 and 6 were shown to 
lack mutations in a large panel of tumor cell lines screened132.
The leading hypothesis at this time seems that at least in epithelial-derived tumors, 
there is an insensitivity to growth inhibition by TGF-p, likely due to a mutation of a 
TGF-p receptor. Subsequently, overexpression of TGF-p may function as tumor 
promotor by its angiogenic, immunosuppressive, and stroma-inducing effects, and 
possibly by conversion into a mitogenic stimulus.
Although many questions remain to be answered before the signaling pathways of 
TGF-p are elucidated, it is to be expected that in the next decade therapeutic interventions 
in certain human diseases on the level of TGF-p signaling will be developed. Along this 
line, eradication of intracranial rat gliomas by TGF-p antisense therapy as shown by 
Fakhrai et al.44 suggests a promising role for suppressing tumor-cell TGF-p expression.
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1.6 Homeobox genes
Oncogenesis and abnormal development or differentiation have been known to 
have certain similarities, represented by the expression of developmental m arkers 
in tumors on one hand, and by the growth and migratory characteristics of embryonal 
cells somewhat reminiscent of malignancy on the other hand. Clues to what leads to 
disturbance of the normally tightly controlled cell behaviour have remained unsolved. 
One group of candidates for these roles are transcription factors, which are nuclear 
proteins that regulate the expression of genes by binding to DNA. A subgroup of 
these transcription factors are the so-called homeobox genes155. Homeobox (Hox) 
genes were first identified in Drosophila as genes responsible for controlling their 
head-to-tail pattern102. The potency of these genes is exemplified by the fact that 
mutations in the Antennaepedia  gene led to development of legs instead of antennae 
in the fruit fly. They are characterized by the homeodomain, a 183 base pair (61 
amino acids) structure with a DNA-binding helix-turn-helix motif. By their binding 
to specific DNA sequences they regulate transcrip tion55’144. Their conservation 
throughout evolution suggests the important roles they have in growth, development 
and differentiation99. A total of 38 Hox genes has been described in humans, separated 
in four clusters of homeobox genes term ed Hox A, Hox B, Hox C and Hox D, located 
on chromosomes 7, 17, 12 and 2 respectively. A new nomenclature has recently 
been published143, with their name based on their relative position in the gene cluster. 
Additional homeobox genes have been described outside the clusters and are called 
diverged homeobox genes. Expression of the Hox genes during development is in a 
colinear fashion, in which each gene is sequentially activated in a spatiotemporal 
fashion, starting with the 3’-end. Over or underexpression results in transformations, 
e.g. of vertebra. The seemingly obvious expectation that Hox gene mutations play a 
role in human malformations, was only recently confirmed by Muragaki et al.116, 
who showed that mutations in the HOXD13 gene lead to an inherited abnormality of 
limb development. Evidence that homeobox genes are involved in cancer was first 
shown in leukemia25, while NIH3T3 transfectants bearing an activated HOXB8 gene 
induced fibrosarcomas in mice1. Later the (altered) presence of homeobox genes 
has been shown in several solid cancers25’130’131. It has been shown that expression 
of certain adhesion molecules that also have a role in tumorigenesis, such as neural 
cell adhesion molecule (N-CAM) can be regulated by homeobox proteins85. This could 
provide a link between homeobox genes and a malignant phenotype. The increasing 
understanding of the interlinks between cell growth, differentiation, homeostasis
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and tumorigenesis will undoubtedly lead to clinical advances in the treatm ent of 
cancer and related disorders.
Besides the enigmas of their complex roles, the control of expression of Hox genes is 
incompletely understood. Retinoic acid (RA) is a potent inducer of Hox genes98, and it is 
also believed that growth factors as fibroblast growth factor (FGF), BMPs and activin-B 
have a role.
1.7 Aims of this thesis
Since the introduction of the so-called autocrine hypothesis in the eighties36’152’156, 
and the subsequent implication of different growth factors in the development of 
malignancies153 154 156, an enormous amount of information on TGF-p has accumulated. 
Not only are its complex roles in the norm al developm ent and hom eostasis 
increasingly understood, but so are its effects in different disease states. The vast 
majority of work to date has focused on the loss of inhibitory control of TGF -p on the 
proliferation of epithelial cells. The emerging hypothesis is that the signaling 
pathways of TGF-p are somehow disturbed leading to uncontrolled growth of cells. 
Interestingly, in a large variety of tumors there is an increased expression of TGF-p, 
which at first glance, might seem paradoxical. If there is loss of growth inhibition by 
TGF-p, why would increased TGF-p put the cells at a growth advantage? Could it be 
that tumor cells are actually stimulated by autocrine TGF-p, or is it the growth 
advantage that is obtained by creating the optimal environment for the neoplasia to 
progress and spread? With the different responses of mesenchymal cells to TGF-p 
(growth stimulatory) as compared to epithelial-derived cells (growth inhibitory), it 
is unclear if the difference between epithelial-derived cells and mesenchymal cells 
would be reflected in their respective tumors. In the mesenchymal tumors such as 
sarcomas, or the benign fibroproliferative lesions, one could imagine that increased 
TGF-p expression would lead to increased cell proliferation. Therefore, the initial 
hypothesis of this thesis was that mesenchyme-derived tumors represented on one 
side by the benign fibroproliferative lesion of the palm ar fascia, better known as 
Dupuytren’s disease, and on the other side the malignant osteosarcoma should, at 
least in vitro, show evidence of an autocrine loop involving TGF-p. These studies 
form the basis for the second and fourth chapter of this thesis, with a review on the 
basic science of Dupuytren’s contracture in chapter 5. Once the initial evidence of 
TGF-p’s role in mesenchymal tumorigenesis was established, follow-on studies were
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aimed at ways of blocking this autocrine mechanism pharmaceutically in vitro. An 
experimental drug called suramin, with known capacity to block growth factor 
binding was evaluated in its capacity to interfere with TGF-p binding in osteosarcoma 
cell lines (Chapter 3). After having established evidence for an aberrant autocrine 
loop in osteosarcoma in vitro, studies were expanded to the in vivo situation by 
studying the expression of TGF-p isoforms and human osteosarcoma tissue, which 
is described in chapter 6.
It is obvious that carcinogenesis is a multistep process that cannot be explained by 
aberrant control of one single growth factor. Additional steps upstream  as well as 
downstream are important and need further elucidation. To further understand 
why certain cells become malignant and exhibit metastatic behavioral properties, a 
possible relation between 3 mem bers of the TGF-p superfamily (BMP, activin-A, and 
TGF-p) and the expression of the so-called homeobox genes was studied. These genes 
have important roles in the body patterning but also have been shown to have a role 
in malignancy. At the onset of our studies limited data were available on what controls 
the expression of these genes, and specifically not on a possible role for TGF-p in the 
expression of Hox genes. We set out to study a possible relationship between these 
genes and three m em bers of the TGF-p superfamily in two hum an tum or cell lines 
(U-2 OS and SK-N-SH) and one m urine osteoblast cell line (MC3T3-E1).
It was shown that TGF-p1 and BMP-2 were able to induce certain Homeobox 
genes in these cell lines (Chapter 7).
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Chapter 2
Transform ing Growth Factor-beta (TGF-b) is a polypeptide with m ultiple physio­
logical functions. Isoforms of this grow th factor have im portant roles in control of 
the cell cycle, in regulation of cell-cell interactions and in grow th and development. 
Malignant transform ation has been shown to be associated with increased expression 
of TGF-b. Since bone is the largest storage site and producer of TGF-b, we speculated 
on the existence of an  autocrine m echanism  in osteosarcom a, a m alignant bone 
tumor. Expression of TGF-b cell surface receptors, effects on growth of TGF-b and 
TGF-b antibodies and production of 2 TGF-b isoforms w ere studied in a panel of 7 
osteosarcom a cell lines. In contrast to m ost previous reports on the effects of TGF-b 
on osteosarcom a cell grow th, we found a m itogenic effect of TGF-b in 4 of 7 
osteosarcom a cell lines. Receptor profiles for TGF-b w ere ab e rran t in 5 of 7 cell 
lines tested, and production of TGF-b1 and TGF-b2 varied am ong cell lines. Addition 
of anti-TGF-b antagonized the effects of endogenous TGF-b. Our results suggest a 
potential role of TGF-b in autocrine grow th control of osteosarcom a cells.
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Bone stores and produces large am ounts of Transforming Growth Factor-p (TGF-p), 
a horm one-like peptide w ith im portant roles in num erous cellular and physiological 
processes (Roberts et al., 1990). M ature TGF-p is a 25-kDa hom odim er with a highly 
conserved amino acid sequence. Five isoforms have been described, 3 of which 
occur in hum ans in nearly  all cell types, both em bryonic and adult. Its ubiquitous 
presence is also reflected by the presence of TGF-p cell surface receptors on alm ost 
all cell types except retinoblastom a cell lines and ra t pheochrom ocytom a cell lines 
(Kimchi e t  al., 1988; M assague, 1992; Segarini, 1990; Wakefield et al., 1987). Three 
distinct receptors for TGF-p are identified on m ost cells studied thus far: type I (Mr 
65,000), type II (Mr 85,000-95,000), type III (Mr 250,000-350,000) (M assague, 1992). 
Types I and II a re  both glycoproteins, w hereas type III is a betaglycan. The specific 
function of each of these receptor subtypes is unknown, but types I and II are probably 
m ost im portan t for signaling, w hereas type III functions m erely as a storage site for 
TGF-p (Boyd and M assague, 1989; Geiser e t  al., 1992; M assague, 1992). Relative 
expression of the types I and II TGF-p recep to r appears therefore, m ost im portant 
for the effect of TGF-p on cells (Boyd and M assague, 1989; C hakrabarty  e t  al., 1989; 
Fafeur e t  al., 1990; Geiser e t  al., 1992; Ichijo e t  al., 1990; Ito e t  al., 1992; Linansk et  
al., 1990; M assague, 1992; Myoken e t  al., 1990). In general, TGF-p is grow th 
inhibitory for m ost epithelial cells such as hepatocytes, lymphocytes and keratino- 
cytes, w hereas it is growth stim ulatory for m esenchym al cells such as chondrocytes, 
fibroblasts and osteoblasts (Roberts e t  al., 1990). Although reports on the effects of 
TGF-p on osteoblast-like cells are  controversial, it is clear th a t it plays an  im portant 
role in osteoblast and osteoclast behavior (Robey e t  al., 1987; Seyedin e t  al., 1986).
Autocrine production of growth factors by tum or cells has been shown to be involved 
in tum origenesis. Many reports on different hum an epithelial m alignancies speculate 
on susta ined  au tocrin e /p aracrin e  production  of TGF-p com bined w ith  reduced  
sensitivity to its inhibitory effects on growth. However, the only evidence for an 
autocrine loop in m esenchym al tum ors involving TGF-p as a m itogenic stim ulus has 
been presen ted  by Jennings e t  al. (1991). They observed expression and secretion 
of TGF-p in gliomas w hich subsequently  served as an  endogenous regu la to r of 
proliferation (both mitogenic and inhibitory depending on the degree of anaplasia 
and karyotypic divergence). Local production and subsequen t sto rage of large 
am ounts of TGF-p in skeletal tissue com bined w ith its pivotal role in osteoblast 
behavior suggest the presence of a w ell-balanced autocrine control in norm al bone. 
A nalogous to m echan ism s d escrib ed  in o th e r tissu es  (R oberts e t  al., 1990), 
d eregu lation  of TGF-p au tocrine  contro l in bone could lead  to d isease s ta tes  
charac te rized  by decreased  bone form ation such as osteoporosis or m alignan t
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transform ation such as osteosarcom a.
In the present study, we characterize the in vitro effects of TGF-p1 and anti-TGF-p 
on DNA-synthesis, the expression of receptors for TGF-p and the expression of and 
production of TGF-p grow th factors in 7 osteosarcom a cell lines.
Material and methods
Cell lines
KHOS-312H, KH0S-240S, HOS, Saos-2, MG-63, and U-2 OS are  hum an osteo­
sarcom a cell lines (donated by S. Friend, MGH Cancer Center, Charlestown, MA); 
MGH-OSA is a m ouse osteosarcom a cell line established in our laboratory. Cells 
w ere routinely cultured in DMEM containing 10% FCS, 100 units/m l penicillin and 
100 mg/ml streptom ycin. Mink Lung epithelial cells (Mv1Lu) w ere obtained from 
ATCC (Rockville, MD). TGF-p1 and [125I]-labeled TGF-p1 w ere kindly provided by 
M.B. Sporn, NIH (Bethesda, MD). Anti TGF-p1-antibody, anti TGF-p2 antibody, and 
control Ig w ere obtained form  R&D Systems (Minneapolis, MN).
Effects of TGF-p1 on DNA-synthesis 
Cells w ere plated at different initial densities (2x104, 1x104, and 5x103 cells/well) 
in 96-well tissue culture plates and cultured in DMEM+10% FCS for 24 hr. Medium 
was replaced for serum -free m edium . After 48 hr, various concentrations of TGF-p1 
w ere added in serum -free m edium , and the cells w ere incubated for an  additional 
44 hr. [3H]thymidine (1.6 |j.Ci/well) was added for the last 24 hr. Cell layers w ere 
w ashed w ith PBS, and DNA was precipitated  with 10% trichloroacetic acid (TCA), 
and dissolved in NaOH. Aliquots w ere counted using a liquid scintillation counter. 
All experim ents w ere done in triplicate.
TGF-p binding assay  
TGF-p receptors w ere studied using affinity-labeling. Confluent cells in 6-well plates 
were w ashed with bicarbonate-free MEM, 25 mM Hepes, pH=7.4, and 1 mg/ml BSA; 
100 pM [125I]-labeled TGF-p1 was added, and the plate was placed on a rotating platform 
for 2.5 h r at 40 C. To show specificity of the binding, we incubated a control with both 
labeled and 100-fold excess unlabeled TGF-p1. Cells w ere w ashed, and disuccinimydil 
suberate  (cross-linking agent) was added. After 1 hr, cells w ere solubilized using a 
m ixture of Triton X-100, Tris, and EDTA. Supernatant was centrifuged and stored at 
-700 C until use. Solubilized cell proteins were separated using SDS-PAGE under reduced
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conditions on a precast 4-15% linear gradient gel (BioRad, Richmond, CA) Gels were 
dried and exposed for 14 days to X-ray at -700 C using an intensifying screen.
Preparation of serum-free conditioned medium 
Cells w ere plated at 1x105 per well in 6-well p lates in DMEM+10%FCS. After 24 hr, 
cells w ere w ashed extensively, and serum -free DMEM containing Hepes (25mM) 
and 0.5% BSA w as added. After 48 h r conditioned m edium  w as recovered and stored 
at -200 C until use. Cells w ere re leased  by trypsin and counted.
Mv1Lu inhibition assay  
TGF-p is a specific inhibitor of Mv1Lu cell proliferation. We estim ated the am ounts 
of TGF-p1 and -p2 in conditioned m edium  using the MTT assay, with purified TGF-p1 
as a s tandard . Since TGF-p is mainly produced as a la ten t (inactive) form  th a t can 
be activated by exposure to pH extrem es, we acidified sam ples of the conditioned 
m edium  to determ ine the total (latent+active) am ount of TGF-p-like activity (after 
acidification) com pared to the am ount of active TGF-p (before acidification). Results 
are  expressed as am ount of TGF-p per milliliter conditioned m edium  (ng/ml), since 
the total cell num ber conditioning the m edia was grossly sim ilar per cell line as 
determ ined using the cell counter. Mv1Lu w ere plated in 96-well plates at 1.5x104 
cells/well and allowed to attach  for 12 h r in DMEM+10%FCS. Wells w ere w ashed 
extensively w ith serum -free m edium , after which diluted sam ples of conditioned 
m edium  w ere added in a total of 100 ml/well. Samples w ere acidified by adding 10 ml 
1.2N HCl for 1 h r  a t room  tem peratu re  to activate la ten t TGF-p. Acidified sam ples 
w ere neutralized by adding 30 m l 0.72N NaOH. The Mv1Lu inhibitory effect of the 
conditioned m edium  was m easured  by a change in cell num ber after 48 h r as assayed 
with the colorim etric MTT-assay. This assay is based on reduction of MTT (26 ml of 
5mg/ml; Sigma, St. Louis, MO) by a m itochondrial succinyl dehydrogenase in viable 
cells to the (purple colored) insoluble form azan precipitate. After 2 .5-hr incubation 
at 370 C, 100 ml extraction buffer (20% SDS, 50% dimethyl form am ide, pH=4.7) was 
added and left overnight a t 370 C. After incubation, optical densities w ere m easured  
at 570 nm  using a m icroplate reader. Antibody neutralization  assays w ere done 
using anti-TGF-p1 and anti-TGF-p2 antibody at a final concentration of 30 mg/ml. At 
this concentration the antibodies completely blocked the inhibitory activity of 0 .3 ­
1.0 ng/ml of the respective iso-form (data not shown). A ntisera and sam ples w ere 
incubated for 1 h r at 370C prior to the addition to the Mv1Lu cells. Each experim ent 
was done in triplicate.
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Effects of TGF-p antibody on cell growth
Osteosarcom a cells w ere plated in DMEM supplem ented w ith 10% FCS at an  intial 
density of 4x103 cells/well in 96-well plates. After 12 hr, cells w ere w ashed with 
serum -free m edium  and incubated with DMEM containing 0.3% BSA with or w ithout 
pan-specific TGF-p antibody (25 mg/ml), control IgG (25 mg/ml), or TGF-p1 (1 ng/ml). 
After 24 hr, [3H]thymidine (1.6 mCi/well) was added. After an  addtional 24 hr, cell 
layers w ere w ashed with PBS and DNA was precipitated with 10% TCA and dissolved 
in 0.3 N NaOH. Aliquots w ere counted using a liquid scin tilla tion  counter. All 
experim ents w ere done in triplicate.
PCR
Osteosarcom a cells w ere cultured in flasks using DMEM supplem ented with 10% 
FCS. Just before confluence was reached , cellular RNA was ex tracted  from the 
m onolayer by a modification of the guanidinium  thiocyanate procedure using RNA 
stat-60 (Tel-test “B”, Biotecx, Friendswood, TX). RNA-PCR reactions w ere perform ed 
essentially as described earlier. Briefly, 1-2 mg of total RNA w as used as tem plate in 
a reverse transcrip tion reaction  w ith a specific anti-sense prim er for TGF-p1 cDNA 
or TGF-p2 cDNA (Derynck e t  al., 1985). cDNA was then  amplified by PCR, employing 
reaction conditions and oligonucleotide p rim er sequences outlined by Derynck et  
al.(1985); prim ers w ere patterned  after the TGF-p1 cDNA (Frazer e t  al., 1991) and 
TGF-p2 cDNA. DNA products w ere passed over chrom aspin-100 columns (Clontech, 
Palto Alto, Ca) prior to enzyme digestions and analyzed by agarose gel electrophoresis 
and  re stric tio n  enzym e digestion. Control RNA-PCR reactions lacking reverse  
transcrip tase  w ere perform ed to address potential cDNA contam ination.
Results
TGF-p1 has variable effects on DNA-synthesis in osteosarcoma cell lines
Addition of various concentrations of TGF-p1 resulted in growth stim ulation in 4 of 
7 osteosarcom a cell lines tested (KHOS-240S, KHOS-312H, SaOS-2 and U-2 OS). 
Characteristically, this effect was biphasic in a dose-dependent way: DNA-synthesis 
increased, usually peaking at the level of 1.0 ng/ml and decreased with higher amounts 
of TGF-p1. A high initial plating density (2x104 cells/well) usually resulted in the highest 
relative increase in DNA- synthesis. HOS was the only cell line virtually unaffected by 
TGF-p1; MG-63 and MGH-OSA w ere consistently inhibited by TGF-p1 (Fig. 1).
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KHOS-24QS KHOS-312H
TGF-B1 (ng/ml)
Saos-2
HOS
TGF-B1 (ng/ml)
TGF-B1 (ng/ml)
U-20S
TGF-B1(ng/ml)
MG-63
MGH-OSA
TGF-B1 (ng/ml)
Figure 1: Effects of TGF-pi on 
DNA-synthesis in osteosarcoma 
cell lines. Cells were plated in 96- 
wells plates at different initial 
densities ( A  =5x103 cells/well,
■  =1x104 cells/well, O  =2x104 
cells/well). Results are shown as 
co m p ared  to u n tre a te d  cells 
(=100%). Each point represents 
the m ean of triplicate tests. SEM 
was generally lower than 10%.
TGF-p receptor assay  
The receptor profile on osteosarcom a cells was exam ined by affinity labeling. 
Binding of [125I]-labeled TGF-p1 was specific for all cell lines, as shown by the absence 
of binding of labeled TGF-p1 in the presence of excess unlabeled TGF-p1 (Fig. 2). 
Expression of the type II receptor was undetectable or low com pared to the type I 
and II receptors in MG-63, HOS, KHOS-240S an KHOS-312H. Saos-2 did not express 
the type II receptor and showed an anom alous type III receptor with a lower than  
expected m olecular w eight (200 kDa). The mouse osteosarcom a cell line (MGH- 
OSA) showed an unusual p a tte rn  of doublets at the level of the type I and the type II 
TGF-p receptor, w ith abnorm al m igration for all 3 TGF-p receptor types.
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Figure 2: Results of affinity labelling of TGF-p receptors. Binding was shown to be 
specific by incubating the cells with 100 pM [125I]-TGF-p1 and excess unlabeled TGF- 
p l, as shown by the representative result in lane 2. Molecular weights m arkers are 
shown on the right. TGF-p receptor forms for the hum an osteosarcoma cell lines (lane 
1-7) are indicated on the left. Lane 8 represen ts the TGF-p receptors on mouse 
osteosarcom a cells (MGH-OSA) showing duplets at different levels which m akes it 
impossible to specify each receptor subtype.
Presence of TGF-p in the conditioned medium of cultured osteosarcoma 
cells
As show n in Table 1, TGF-p is sec re ted  in the cond itioned  m edium  of all 
osteosarcom a cell lines tested. The am ounts of total TGF-p produced ranged  from
3.1 ng/ml (MG-63) to 18 ng/ml (KHOS-240S). As expected, TGF-p was mostly produced 
in its la ten t form, active TGF-p produced ranging form 3% (MG-63) to 17% (U-2 OS 
and MGH-OSA). TGF-p-like activity in conditioned m edium  was only partly neutralized 
by anti-TGF-p1 antibody (30 mg/ml) or anti-TGF-p2 antibody (30 mg/ml) (Fig. 3), 
indicating th a t there are probably Mv1Lu grow th-inhibitory cytokines o ther than
TGF-B ACTIVITY
Cell Line Nanograms/ml. % Active TGF-B
KHOS-240S 18 16
KHOS-312H 13.5 7
Saos-2 10.3 3
U-2 OS 3.6 17
MGH-OSA 6 17
HOS 3.3 9
MG-63 3.1 3
Table 1: Production of TGF-pl (total 
ng/m l co n d itio n ed  m edium  and  
percentage of active) by different 
osteosarcoma cell lines. Data are the 
average of triplicate tests, with SEM 
smaller than 10%.
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1.4 ■ /
Figure 3: Neutralization of TGF-p1 and TGF-p2 present in acidified conditioned medium 
by specific antibodies (final concentration 30 mg/ml). ■  =no antibody, E3 =anti TGF-p1 
antibody, B  =anti TGF-p2 antibody. Data are the average of triplicate tests, with SEM 
smaller than 3%.
TGF-P1 and -p2 present in the conditioned medium. In 2 cell lines (MGH-OSA, U-2 OS) 
the addition of TGF-p neutralizing antibodies slightly inhibited Mv1Lu growth, the 
m echanism  of which rem ains to be elucidated. Non-immune Ig had no effect on
Mv1Lu growth (data not shown).
S  3500 i
CQ CQ CQ
U-2 OS KHOS-24QS M G-63
Figure 4: Effects of pan-specific 
TGF-p antibody, control IgG and 
TGF-p1 on osteosarcoma cell lines. 
Cells were plated at 4x103 cells/well. 
Results are shown as the average 
and SEM of 3-4 experiments.
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Figure 5: Analysis of TGF-p1 RNA-PCR products from osteosarcoma cell line RNA. 
Detection of TGF-p1 mRNA from HOS (lanes 1 and 2), and Saos-2 (lanes 3 and 4) was 
accomplished as described in “Materials and Methods.” The RNA-PCR products were 
incubated in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of the kpnl restriction 
enzyme. The uncut amplified DNA is 268 bp, while kpnl cleavage generates two 
fragments of 192 bp and 76 bp, as predicted from the cDNA (Derynck, 1985). Molecular 
weight m arkers are present in lane 5.
TGF-p antibody inhibits endogenous TGF-p regulation 
The ability of TGF-p antibodies to in terfere with a possible autocrine loop involving 
endogenous TGF-p was tested  on 3 osteosarcom a cell lines (KHOS-240S, U-2 OS and 
MG-63). We used a pan-specific TGF-p antibody th a t neutralizes various TGF-p 
isoforms. In cell lines that dem onstrated  a m itogenic response to exogenous TGF-pi 
(Fig. 1), the addition of pan-specific TGF-p antibody resu lted  in grow th inhibition 
(32% inhibition in KHOS-240S, 50% inhibition in U-2 OS) (Fig. 4). Addition of p an ­
specific TGF-p antibody to MG-63, which w as shown to be inhibited by exogenous 
TGF-pi (Figs. 1 and 4), resulted in weak growth stimulation (12% stimulation) (Fig. 4). 
Control IgG had  no or m inimal effects on cellular growth (Fig. 4).
TGF-p is expressed in osteosarcoma cell lines 
Figure 5 shows the products of the RNA-PCR reaction aim ed at detecting TGF-pi 
mRNA from 2 represen ta tive osteosarcom a cell cultures (HOS and Saos-2). For both 
cell lines, the expected 268-bp product w as obtained (lanes 1 and 3), containing the 
predicted kpnI restric tion site (lanes 2 and 4). Although Saos-2 expressed TGF-pi 
on the RNA level (Fig. 5), the resu lts of the M viLu bioassay using TGF-pi and TGF- 
p2 antibodies suggested th a t Saos-2 did produce mainly TGF-p2 (Fig. 3).
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Discussion
Cell proliferation is a tightly balanced process, d isturbance of which can lead to 
various types of disease. Growth factors are im portant in the m aintenance of this 
balance and abnorm al production and control of these polypeptides have been 
suggested  as in itia to rs of tum origenesis. This concept w as popularized  as the 
autocrine hypothesis (Sporn and Roberts, 1985). For an  autocrine loop to exist, 
there  m ust be endogenuous production of peptide growth factors acting on their 
producer cells via specific cell receptors. With TGF-p being inhibitory for epithelial 
cells, its proposed role in carcinogenesis is th a t of loss of TGF-p responsiveness 
(Sporn and Roberts, 1985). However in cell types th a t are grow th-stim ulated by 
TGF-p, such as fibroblasts and osteoblasts, production of endogenous TGF-p could 
have direct positive autocrine growth effects.
In this study, we show tha t 4  out of 6  osteosarcom a cell lines m eet the criteria  for 
this second hypothesis. Using the affinity labeling technique, we addressed the relative 
expression of the 3 TGF-p receptors [the total num ber of TGF-p receptors is relatively 
low in osteosarcom a cells (Wakefield e t al., 1987)]. In contrast to norm al osteoblasts, 
which express the 3 types of TGF-p recep tors in approxim ately equal am ounts 
(Segarini, 1990), the m ajority of the cell lines we tested exhibited an ab erran t TGF-p 
pattern . Most striking w as the absence or very low expression of the type II receptor 
in 4 cell lines (MG-63, HOS, KHOS-240S and KHOS-312H). Saos-2 not only lacked 
the type II receptor but also has an  anom alous type III receptor. It has been reported  
tha t Saos-2 cells have an  inactive endogenous Retinoblastom a (Rb) gene -a tum or- 
suppressor-gene- loss of w hich predisposes form ation of a variety of m alignant 
tum ors, including retinoblastom as, osteosarcom as and b reast and b ladder carci­
nom as. A possible link betw een loss of TGF-p receptors on retinoblastom a cell lines 
to loss of Rb-gene product has been reported  (Kimchi et al., 1988). Although aberran t, 
the TGF-p recep to rs on Saos-2 presum ably  m ediate the grow th stim ulation by 
exogenous TGF-p1 (Fig. 1), showing tha t loss of Rb-gene does not necessarily lead to 
com plete absence of TGF-p receptors. The exact m echanism  of TGF-p recep to r 
signaling is unclear at p resent, although a recen t study using dom inant negative 
m utan t of type II receptors to block type II recep to r signaling has suggested at least 
2 recep to r pathw ays. M odulation of the levels of both type I and the type II TGF-p 
receptors has been linked to an  altered  response to TGF-p (Faufeur et al., 1990; 
Geiser et al., 1992; Linansk et al. 1990). Although we found considerable differences 
in effects of TGF-p1 on DNA-synthesis in osteosarcom a cell lines, we could not relate
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this to a specific TGF-p receptor profile. TGF-p1 binding to cell lines that w ere growth- 
inhibited by TGF-p1 (MG-63 and MGH-OSA) appeared stronger than  to unaffected 
(HOS) and to growth-stimulated (KHOS-312H, KHOS-240H, Saos-2 and U-2 OS) (Fig. 2), 
but this could not be quantitated. Most likely, the differences in mitogenic effects of 
TGF-p1 among the cell lines tested occurs at a post-receptor level.
Autocrine grow th control also requires production and secretion of grow th factor 
by the cells them selves. We showed tha t secretion of TGF-p (both la ten t and active) 
is ubiquitous am ong the osteosarcom a cell lines tested. As anticipated, m ost of the 
TGF-p was in its laten t form. Mainly, TGF-p2 was produced in Saos-2, KHOS-240S 
and MG-63 cells, w hereas m ore TGF-p1 th an  TGF-p2 w as produced by KHOS-312H 
and HOS. Although TGF-p1 mRNA w as expressed in Saos-2 cells (Fig. 5), based on 
the Mv1Lu bioassay using TGF-p1 and -p2 antibodies, it appeared  tha t no TGF-p1 
was produced. This confirms the finding of others tha t TGF-p1 m ay be expressed 
w ithout detectable pro tein  secretion (Boyd and Kaufm an, 1990 and references 
therein). With the exception of U-2 OS, cell lines tha t w ere grow th-stim ulated by 
exogenous TGF-p1 (KHOS-240S, KHOS-312H and Saos-2) produced m ore to tal 
(active+latent) TGF-p th an  cell lines th a t w ere growth inhibited (MG-63 and MGH- 
OSA) or unaffected (HOS) by exogenous TGF-p1 (Fig. 1; Table I). The am ount of 
active TGF-p tha t was produced by the different cell lines (0.1-2.9 ng/ml) w as in the 
sam e range as tha t used for our proliferation studies (0.1-10 ng/ml). This shows 
tha t autocrine-produced TGF-p w as able to provide a m itogenic stim ulus to 4 of 6 
hum an osteosarcom a cell lines tested. The in vivo m echanism  of activation of latent 
TGF-p is unknow n at present; disclosure of this m echanism  will provide im portant 
inform ation on regulation and localization of TGF-p.
The th ird  requ irem ent for the existence of an  autocrine loop is an  effect on growth 
in response to added ligand. T here have been m any reports on the effects of TGF-p 
on DNA synthesis in osteosarcom a cell lines, mostly using either ROS 17/2.8 (rat 
osteosarcom a) (Bonewald et al., 1990; G uenther et al., 1988; Noda et al. 1987; 
Pfeilschifter e t al. 1987; Robey et al., 1987; Tokuyama and Tokuyama, 1989), or 
MG-63 (hum an osteosarcom a) (Bonew ald e t  al., 1992; Mioh and  Chen, 1989; 
Pontbriant e t al. 1990; Tokuyama and Tokuyama, 1989). Most of the above reports 
indicate th a t TGF-p is grow th-inhibitory for osteosarcom a cells. To our knowledge, 
there has only been one study showing a stim ulatory effect of TGF-p on hum an 
osteosarcom a cells (HOS TE85) (Reed et al., 1993). Using very sim ilar experim ental 
conditions, they found a biphasic effect of TGF-p (50% growth stimulation at 0.5 ng/ml 
TGF-p). Our results on TGF-p effects on DNA-synthesis do not contradict the above­
m entioned studies in tha t MG-63 showed a sim ilar growth inhibition, w hereas a
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50% growth stim ulation in HOS TE85 cells (Reed e t  al., 1993) is com parable to some 
of our cell lines. Since testing conditions such as serum -deprivation and plating 
density varied am ong the different studies, we feel th a t the im portance of our study 
resides in th a t ra th e r than  focusing on one cell line only, we tested  a panel of 7 
osteosarcom a lines under exactly sim ilar conditions, showing tha t 4 of 6 hum an 
lines (66%) w ere growth stim ulated  by TGF-p1. The mitogenic effect of TGF-p1 
revealed altered  kinetics com pared to o ther m itogens, being m axim al after 36 h r 
(data not shown). This is com parable to reports on other m esenchym al cells, such 
as fibroblasts and chondrocytes, and m ay be explained by the presence of an  indirect 
m itogenic effect through the induction of o ther cytokines, such as platelet-derived 
growth factor (PDGF) (Battegay e t  al., 1990).
A widely used m ethod to dem onstrate the biological significance of an  autocrine 
loop is to antagonize endogenously produced grow th factors w ith neutra liz ing  
antibody. We showed tha t a pan-specific TGF-p antibody stim ulated DNA synthesis 
in cells tha t w ere inhibited by exogenous TGF-p1 (MG-63), w hereas this antibody 
inhibited DNA synthesis in cells th a t w ere stim ulated by exogenous TGF-p1 (KHOS- 
240S and U-2 OS). The inability to completely block DNA synthesis using neutralizing 
TGF-p antibody in KHOS-240S and U-2 OS and the ability of MG-63 to proliferate in 
serum -free m edium  suggest th a t th ere  are  probably several au tocrine loops in 
osteosarcom a cells, involving grow th factors o ther th an  TGF-p1. Likely candidates 
for these additional loops a re  insulin-like growth factors I and II (IGF-I and -II) and 
PDGF. A report studying MG-63 osteosarcom a cells has speculated on an  IGF-related 
autocrine m echanism  (Pollak et al., 1990), though the production and secretion of 
IGF by MG-63 cells w as not studied.
Considering the abundance of TGF-p in bone, it could have an  im portant role in 
the growth of m alignant bone tum ors, not only by providing grow th advantage but 
also via paracrine effects related  to angiogenesis needed for tum or expansion, strom a 
induction and im m unosuppression (see references in Roberts and Sporn, 1990). 
TGF-p enhances its own transcrip tional level, a m echanism  tha t interestingly is 
m ost potent in osteosarcom a cells (Van-Obberghen-Schilling e t  al., 1988), suggesting 
a n endogenous amplification step in an  autocrine loop leading to an  even stronger 
mitogenic response. Based on a review of the published results and on our findings, 
it is likely that autocrine loops are im portant in mesenchym al tumorigenesis; however, 
the developm ent of an  osteosarcom a is a complex process involving several genetic 
alterations, one of which could be deregulation of autocrine TGF-p growth control.
In conclusion, our w ork offers evidence for autocrine grow th control in osteo­
sarcom a cells in vitro: TGF-p1 and/or TGF-p2 w ere produced and secreted, TGF-p
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receptors w ere present, cell growth was affected by exogenous TGF-p1 and anti- 
TGF-p antagonized the autocrine m echanism .
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Chapter 3
Autocrine production of growth factors has been show n to be involved in the 
m ultistep process of tumorigenesis. The ability of suram in, a polyanionic anti-parasitic 
drug, to block growth factor-induced cell proliferation m akes it a potential an tineo­
plastic drug. We studied the effects of suram in  on seven osteosarcom a cell lines. 
Using clinically achievable concentrations of suram in  (50-400 mg/ml) we found a 
time- and dose-dependent inhibition of [3H]thymidine incorporation. We also showed 
tha t suram in is able, dose-dependently, to prevent binding of transform ing growth 
factor (TGF)-pi to its receptors. DNA synthesis inhibition by suram in was attenuated  
by TGF-pi in some cell lines. Two cell lines th a t w ere inhibited by TGF-pi w ere 
affected sim ilarly by su ram in  as cell lines th a t w ere stim ulated  by TGF-pi. In 
conclusion, in five out of seven osteosarcom a cell lines, we showed a correlation 
betw een inhibition of grow th factor-stim ulated m itogenesis and binding of TGF-pi 
to its receptor. Similar effects in TG F-pi-inhibited osteosarcom a cell lines suggest 
involvement of o ther m echanism s and/or growth factors. However, suram in proves 
to be a potent inhibitor of osteosarcom a cell proliferation in vitro.
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Introduction
The growth of norm al cells and tissues is a delicately balanced system  in which a 
key role is played by m ultiple polypeptide grow th factors. One of these factors is 
Transform ing Growth Factor-p (TGF-p) a 25 kDa hom odimer, originally described 
as being able to induce phenotypic transform ation of norm al ra t  fibroblasts (1-3). 
Subsequently, TGF-p has been shown to be m ultifunctional, and to be expressed 
ubiquituously, being im portant for cell growth and differentiation as well as w ound 
healing. In contrast to its w ell-characterized inhibitory effects on epithelial derived 
cells, TGF-p stim ulates p ro liferation  of m esenchym al cells (1-4). A lthough the 
pathw ays of TGF-p are still unclear, they are  m ediated through th ree different cell 
surface receptors: type I (53 kDa), type II (70-100 kDa) both proteoglycans, and type 
III (280-330 kDa) a betaglycan (5).
In 1978 Todaro and DeLarco suggested th a t endogenuous production of growth 
factors m ay be involved in tum origenesis (6). Sporn and Todaro modified this concept 
in the so-called “autocrine hypothesis", which postulates th a t production of growth 
factors by cells them selves m ight contribute to tum our form ation (7). Overexpression 
of growth factors and/or their receptors have since been reported  in m any neoplastic 
cell types (8-10).
Although TGF-p is produced by alm ost all cells, on a tissue/m ass basis, bone is 
both the largest p roducer and storage site (11), and it has become clear th a t TGF-p 
plays an  im portant role in the m etabolism  of bone (12). We becam e in terested  in the 
possibility tha t an  autocrine loop involving TGF-p m ay be involved in the aetiology 
and proliferation of osteosarcom as. We have previously dem onstrated  in v itro  that 
the prerequisites needed for an  autocrine loop involving TGF-p exist for hum an 
osteosarcom a cells, i.e. TGF-p receptors, production of TGF-p by the cells, and effects 
on DNA synthesis by exogenuosly added TGF-p (13). If an  autocrine loop involving 
TGF-p is crucial for the grow th of osteosarcom a cells, then  having the ability to 
interfere with such an autocrine loop m ay represen t a potential avenue for therapeutic 
intervention. This could theoretically be done by inhibiting expression of growth 
factors and/or growth factor receptors, or by preventing binding of the growth factor 
to its receptor. One of the prototypes of drugs currently  being investigated in this 
respect is suram in, a polysulfonated com pound originally developed nearly  75 ago 
for use as an  antitrypanocidal agent (14-16). Suram in was found not only to inhibit 
a variety of key enzymes, such as DNA-polymerase (17) and reverse transcrip tase  
(18), bu t also prevent m itogenic effects of grow th factors (14-16). E ither both of
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these effects elicited by suram in could explain the inhibition of the in vitro  growth 
of a num ber of cell lines by suram in. We set out to study the effect of suram in  on 
DNA-synthesis in seven different osteosarcom a cell lines, and its in terference with 
TGF-p effects on these cells.
Materials and methods
Cell lines
The hum an osteosarcoma cell lines KHOS-312H, KHOS-240S, HOS, U-2 OS, Saos-2, 
and MG-63 were a gift from S.H. Friend (MGH Cancer Center, Charlestown, Massachusetts, 
U.S.A). A mouse osteosarcoma cell line MGH-OSA was earlier established in our laboratory. 
Cells were routinely cultured in DMEM containing 10% fetal calf serum (FCS), 100 units/ 
ml penicillin, 100 mg/ml streptomycin. Suramin was obtained from FBA Pharmaceutical 
(New Haven, Connecticut, U.S.A.). TGF-p1 was obtained from R&D Systems (Minneapolis, 
Minnesota, U.S.A.) and 125I-labeled TGF-p1 was a gift from M.B. Sporn (NIH, Bethesda, 
Maryland, U.S.A.).
Effects of Suramin and/or TGF-p1 on DNA-synthesis
The effect of different doses of suram in  was tested  on seven osteosarcom a cell 
lines. We used su ramin concentrations of 0, 50, 200, and 400 mg/ml, which have 
been shown to be clinically achievable (14-16). Cells w ere plated at 1x104 cells/well 
in 96-well plates in DMEM+10% FCS. After 24 hr, wells w ere w ashed extensively 
and serum -free DMEM was added. Cells rem ained in serum -free m edium  for 48 hr, 
after which different concentrations of suram in  in serum -free m edium  w ere added. 
[3H]Thymidine w as added (1.6 |mCi/well) after 20 hr. After a 24-hr incubation, DNA- 
synthesis was m easured  by w ashing the cell layers w ith phosphate buffered saline 
(PBS), precipitation of DNA with 10% trichloroacetic acid (TCA), and dissolving in 
sodium hydroxide. A liquots w ere  counted  using a liquid sc in tilla tion  counter. 
Experim ents w ere perform ed in triplicate.
Since our m ain in terest w as in a possible autocrine loop in osteosarcom a cells 
involving TGF-p, we investigated the effects of suram in  on DNA-synthesis in these 
cells in the presence and absence of TGF-p1. Two representative hum an osteosarcom a 
cell lines w ere studied: KHOS-240S, for w hich DNA-synthesis was show n to be 
stim ulated 1.8 fold by TGF-p1, and MG-63 w hich DNA-synthesis was shown to be 
inhibited down to 60% by TGF-p1 (13). The kinetics of [3H]thymidine incorporation 
into DNA in MG-63 and KHOS-240S cells tha t w ere trea ted  with TGF-p1 and/or
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suram in  w ere m easured. Cells w ere plated at 1x104 cells/well in 96-well plates in 
DMEM+10% FCS for 24 hr. Cells w ere then  w ashed extensively and left in seru m ­
free m edium for 48 hr. Suram in (200 mg/ml) and/or TGF-p1 (1 ng/ml) was added in 
serum -free  m edium . Then 4-hr pulses of [3H]thym idine w ere added  afte r 6-hr 
intervals for a period of 44 hr. DNA synthesis w as m easured  as described above. 
Experim ents w ere done in triplicate.
Effects of suramin on TGF-p1 binding 
TGF-p recep tors w ere affinity-labeled as described by M assague (19). Briefly, 
confluent cells in six-wells w ere w ashed w ith bicarbonate-free MEM, 25 mM Hepes, 
pH=7.4, and 1 mg/ml bovine serum  album in (BSA). 125I-labeled TGF-p1 (100 pM) 
was added in the presence or absence of different amounts of suram in (25, 600 mg/ml). 
The plate w as put on a ro tating platform  for 2.5 h r at 40C. To show specificity of the 
binding, we incubated a control with 125I-labeled TGF-p1 and 100-fold excess of 
unlabeled TGF-p1. Cells w ere w ashed and disuccinimydil suberate  (cross-linking 
agent) w as added. After 1 hr, the cells w ere solubilized using a m ixture of Triton-X, 
Tris and EDTA. The su p ern atan t w as centrifuged and stored at -700C until use. The 
solubilized proteins w ere separa ted  using SDS-polyacrylamide gel electrophoresis 
under reduced conditions on a p recast 4-15% linear gradient gel (BioRad, New York, 
U.S.A.). Gels w ere dried and X-ray exposed for 14 days at -700 degrees C using an 
intensifying screen.
Results
Effects of suramin on DNA-synthesis 
Suram in m arkedly inhibited DNA-synthesis in a dose-dependent m an n er in all 
seven osteosarcom a cell lines tested  as shown in Figure 1. Even at the low concen­
tration  of 50 mg/ml, there was a significant inhibitory effect. Effects w ere shown to 
be cytostatic ra th e r th an  cytotoxic, as evaluated by direct microscopic evaluation of 
cell viability using m ethylene blue staining (data not shown).
Figure 2 shows a time course of the effects of suram in (200 mg/ml) and/or TGF-p1 
(1 ng/ml) in two osteosarcom a cell lines. These cell lines w ere representa tives of cell 
lines w ith  d iffe ren t re sp o n ses  to TGF-p1. They w ere  chosen  a f te r  p rev ious 
investigations had shown th a t MG-63 w as inhibited by TGF-p1, w hereas KHOS- 
240S was stim ulated by TGF-p1 (13). The m axim um  DNA inhibitory effect of suram in 
on KHOS-240S cells occured after 30 h r incubation, a t which time the DNA synthesis
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Figure 1. Dose-dependent effect of suramin 
on 7 osteosarcoma cell lines as determined 
by [3H]thymidine incorporation. Control 
(untreated cells) is 100%. % of control=cpm 
(treated cells)/cpm (untreated cells). Results 
represent m ean of triplicate experiments 
with a S.E.M. less than 5%.
w as only 10% of the u n trea ted  cells. A fter 30 h r incubation , we saw  a g rad u a l 
in crease  in DNA synthesis to a value of 30% of its control value at a fte r 44 hr. 
The inh ibitory  effects of su ram in  w ere clearly  a tten u a ted  by the p resence of 
TGF-p1 (1 ng/ml). TGF-p1 by itself showed a delayed kinetics response with a peak 
after about 30 hr, at which time the DNA synthesis w as 1.6 times th a t of its control 
value. This was followed by a decline in mitogenic activity to 1.25 times that of its 
control at 36 hr, followed by an increase to 1.75 tim es of its control.
Figure 2. A: Time-course on effect of suramin (200 mg/ml) and/or TGF-p1 (1 ng/ml) on 
DNA-synthesis in KHOS-240S osteosarcom a cells as m easured  by [3H]thymidine 
incorporation. Control (untreated cells) is 100%. % of control=cpm (treated cells)/cpm 
(untreated cells). Results represent m ean of triplicate experiments with a S.E.M. less 
than 5%. ■  =TGF-p1, A  =suramin, O  =TGF-p1 and suramin. B: Same for MG-63 
osteosarcoma cells.
Addition of suram in to MG-63 showed a gradual inhibition of DNA synthesis over 
time. After 44 h r of incubation with suram in (200 mg/ml), DNA synthesis was only 
10% of its value in the u n trea ted  cells. The inhibitory effect of 1 ng/ml TGF-p1 alone 
on MG-63 cells w as m axim um  (40% inhibition) at 30 h r after addition, after which a 
gradual increase was seen. There was virtually no difference betw een DNA synthesis
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inhibition in MG-63 by trea tm en t w ith suram in (200 mg/ml) alone or in com bination 
w ith TGF-p1 (1 ng/ml).
Effect of suramin on binding of TGF-p1 to its receptor
In earlier perfo rm ed  experim ents, we show ed the presence of TGF-p binding 
receptors on the osteosarcom a cells tested  (13). We sought to provide evidence that 
the inhibitory effects of suram in  on DNA synthesis w ere caused by inhibition of 
TGF-p binding to its receptor. We cross-linked 125I-labeled TGF-p1 to its receptors, in 
the presence and absence of different concentrations of suram in. Figure 3 shows 
that suram in is able, dose-dependently to prevent binding of TGF-p1 to its receptor on 
MGH-OSA cells. Of in terest is the fact that DNA synthesis in MGH-OSA is inhibited by 
TGF-p1. Similar results w ere seen in cell lines that w ere stim ulated by TGF-p1 such 
as Saos-2 (data not shown). As is shown in Figure 3, excess unlabeled TGF-p1 
prevented binding of 125I-labeled TGF-p1 to its receptor showing specificity of the 
binding.
1 2  3 4
Type III ------p.
Figure 3. A: Affinity cross-linking of 
[125I]TGF-p1 to MGH-OSA cells. Lane 
1=[125I]TGF-p1+ 600 mg/ml suramin; lane 
2=[125I]TGF-p1+25 mg/ml suramin; lane 
3=[125I]TGF-p1+excess unlabeled TGF- 
p1; lane 4=[125I]TGF-p1. The different 
TGF-p receptors (type I, II, and III) are 
marked.
Discussion
The im portance of autocrine grow th control of m alignant cells, as popularized by 
Sporn and Todaro (7) is clearly recognized as one of the prom oters or initiators in 
certain  tum ors (8-10). Interference at the level of growth factor production or growth 
factor stim ulation could be a very attractive approach in these tum ors. Currently, 
however, trea tm en ts  based  on in terfe rence  of specific grow th factor-m ediated
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pathw ays are practically unavailable. A prototype of a potentially useful drug is 
suram in, an  old anti-parasitic  drug, which has been shown not only to block the 
activity of enzymes tha t are critical for cell growth and proliferation, such as DNA 
polym erase (17) and reverse transcrip tase  (18), but m ore im portantly, to inhibit 
growth factor binding (14-16). Among the growth factors it has been shown to inhibit 
are  epiderm al growth factor (EGF) (20), fibroblast growth factor (FGF) (20), platelet- 
derived growth factor (PDGF) (21), TGF-p (20, 22), insulin-like growth factor (IGF-I) 
(23-26). Multiple studies have been published on the inhibitory effects of suram in  in 
vitro  on DNA synthesis in m any different cell lines, all of which revealed sim ilar 
results, in th a t suram in  had  reversible inhibitory effects, m ost probably due to 
in terference of growth factor binding (20-27). Few studies have investigated the 
effects of su ram in  in v iv o , re su lts  of w hich w ere  generally  m odest, how ever 
w arran ting  fu rther investigation (14,15,28-30).
With bone being a large producer and storage site for TGF-p (12), and the known 
ability for auto-induction (2) we felt tha t this grow th factor was a logical candidate 
for autocrine growth control in bone. D erangem ent of norm al grow th control by 
abb eran t expression of TGF-p and/or receptors, could lead to tum origenesis of bone 
cells, e.g. osteosarcom a. Previously we have shown all the prerequisites for a TGF-p 
involving autocrine loop to be p resen t in osteosarcom a cells (13). The involvement 
of autocrine processes is furtherm ore suggested by the ability of the osteosarcom a 
cells to grow in a defined serum -free m edium  containing no added growth factors.
If autocrine control has a role in growth of osteosarcom a, interference with binding 
of the key growth factor could be a hypothetical therapeutic  approach. Therefore, 
we investigated the effects of suram in  on seven different osteosarcom a cell lines. 
Our re su lts  show  th a t su ram in  has a d ose-dependen t inh ib itory  effect on all 
osteosarcom a cell lines tested. Our experim ents clearly show th a t the cell lines 
tested  express specific cell surface binding sites for TGF-p, to which binding of 
radioactively labeled TGF-p1 was inhibited in the presence of suram in. W hether 
this is caused by in terference at the receptor level or by binding of the growth factor 
in solution was not addressed. The concentrations needed to prevent binding of 
TGF-p1 to its recep to r w ere in the sam e range as those inhibiting DNA-synthesis. 
These findings suggest tha t DNA synthesis inhibitory activity of suram in  could be 
re la ted  to in terference of binding of TGF-p in osteosarcom a cell lines th a t are  
s tim u la te d  by TGF-p (four out of seven  cell lines te s ted  (13)). However, in 
osteosarcom a cell lines tha t are inhibited by TGF-p1, such as MG-63 and MGH-OSA, 
the inhibitory effect of suram in and its relation to TGF-p is not as easy to explain. If 
TGF-p1 is the only autocrine factor controlling MG-63 and MGH-OSA cell growth,
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inh ib ition  of TGF-p1 b inding by su ram in  should  theo re tica lly  lead  to grow th 
stim ulation. In our experim ents, this was not the case, since suram in resulted  in 
grow th inhibition of MG-63 and MGH-OSA. This can be explained by suram ins 
“overruling" effect on cellular enzymes, such as DNA polymerase, thereby diminishing 
the effect of TGF-p blockage. T here m ight be o ther autocrine grow th factors (in 
addition to the inhibitory TGF-p) im portant for growth of these cell lines, which is 
also suggested by ability of MG-63 and MGH-OSA to reach  confluence under seru m ­
free conditions (data not shown). Recently authors have reported  on su ram in ’s ability 
to in terrup t autocrine loops; Pollak reported  th a t suram in blocks the IGF-I stim ulated 
proliferation of MG-63 cells by in terference w ith the in teraction of IGF-I and its 
recep to r (23), Morocz speculated on su ram in ’s growth factor in terference in lung 
cell lines (26), Minniti attribu tes su ram in ’s inhibitory effects on rhabdom yosarcom a 
cells to in terruption  of IGF-II autocrine grow th loop (25); and Ravera suggested a 
possible therapeutic  role for suram in in hum an b reast tum ors by in terruption  of 
IGF-I binding (24). Our cu rren t findings and  th e irs  a re  not contradictory, bu t 
em phasize that, in vitro  and even m ore so in vivo, a very complex system  of growth 
stim ulating and growth inhibiting factors is p resent, and binding of m ost of these 
growth factors will be influenced by suram in. Moreover, suram in  has m ultiple other 
effects on im portant enzyme system s, which m akes it hard  to a ttribu te effects of 
this drug to a specific cellular location. To our knowledge, this is the first repo rt on 
the in teraction of suram in  and TGF-p1 on osteosarcom a cell lines. We would like to 
em phasize that, although suram in  can have a potential role in m anagem ent of 
autocrine controlled tum origenesis, its precise effects need fu rther elucidation. 
However, a t this time, suram in is a useful tool in cytokine and growth factor research.
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Chapter 4
T ransform ing  grow th factor-p (TGF-p) is a m ultifunctional polypeptide th a t 
stim ulates extracellu lar m atrix  deposition and fibroblast proliferation. Because both 
these features characterize D upuytren’s contracture, we investigated a possible role 
for TGF-p in the etiology of this disorder. We studied receptor expression for TGF-p, 
effects of TGF-pi on DNA-synthesis, and in vitro production of TGF-pi and TGF-p2 
in both norm al and D upuytren-derived fibroblasts. We also studied the effects of 
epiderm al growth factor (EGF) on grow th of the different cell types. TGF-p receptor 
profiles w ere different betw een the two cell types, as w ere TGF-pi and EGF-induced 
stim ulation of cell growth. Both cell types secreted  both active and laten t TGF-p. 
Our results suggest tha t growth factors such as TGF-p and EGF m ay play a role in 
D upuytren’s contracture.
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Introduction
Since its description over 150 years ago, the etiology and pathogenesis of Dupuytren’s 
contracture rem ain controversial. The pathology seen in D upuytren’s disease consists 
of changes produced in the dermis and palm ar fascia; there is uncontrolled tissue 
pro liferation , w ith  augm enta tion  of m yofibroblasts and  enhanced  synthesis of 
ex tracellu lar m atrix  (ECM). The e rro r th a t initiates and p erpetuates this tissue 
proliferation is not known, although m any studies have reported  clinical, biochemical, 
epidemiological, and morphological changes (1 -6). With new developments in molecular 
biology and m ore insight into factors controlling cellular behaviour we might be able 
to uncover som e of the regulating factors in this disease. Recently, a possible 
relationship has been proposed betw een two m em bers of a large polypeptide growth 
factor family (platelet derived growth factor [PDGF] and basic fibroblast growth factor 
[bFGF]) and D upuytren’s disease (7,8). Each of these growth factors m ight be involved 
in the proliferation of myofibroblasts. Another m em ber of this polypeptide growth 
factor family is transform ing growth factor p (TGF-p), originally detected in tum or 
extracts and term ed “transform ing" since it was thought to induce or m aintain the 
neoplastic or transform ed cell phenotype (9,10). TGF-p is ubiquitous, in both norm al 
and neoplastic tissues, affecting growth and differentation in species ranging from 
Xenopus  to hum ans. Its has multifunctional and sometimes confusing effects, but in 
general TGF-p stimulates growth of mesenchymal cells, such as fibroblasts, and inhibits 
growth of ectoderm al cells, such as keratinocytes and lymphocytes (9-12). A wellknown 
effect of TGF-p is increased deposition of ECM, both through increasing its synthesis 
and decreasing its breakdow n (8-11). This biological effect is shown both in vivo and 
in vitro and has been linked to diseases as pulm onary fibrosis, and keloids (12-14).
TGF-p’s m echanism  of action is still unknown, but it is most probably m ediated 
through three different TGF-p cell surface receptors (15-17). All cells investigated 
have receptors for TGF-p, except retinoblastom a cell lines (18). The so-called type I 
and the type II TGF-p receptors are proteoglycans and have weights of 53 kDa and 70­
100 kDa respectively. The type III TGF-p receptor is a betaglycan, and has the highest 
m olecular weight (280-330 kDa).
Since TGF-p has stim ulatory effects on fibroblast growth, fibroblast m igration and 
ECM production -characteristics of Dupuytren’s contracture- we explored a possible 
role of TGF-p in this disease. More specificially we looked at the presence of TGF-p 
receptors on these cells, effects of TGF-p and epiderm al growth factor (EGF) on DNA- 
synthesis, and production of TGF-p1 and TGF-p2 by these cells. Comparisons were 
m ade with norm al skin derived fibroblasts.
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Material and Methods
Growth factors
Porcine TGF-p1 and porcine 125I-TGF-p1 w ere kindly provided by M.B. Sporn, NIH, 
Bethesda, MD; EGF was purchased  from  Collaborative R esearch Inc., Bedford, MA; 
neutralizing antibodies to TGF-p1 and TGF-p2, and control IgG w ere purchased 
from R&D Systems, Minneapolis, MN.
Cell culture
D upuytren tissue was obtained at the time of surgery  from  12 patients (11 m ale, 1 
female, m ean age was 54.8 years, range 42-72 years). All patients had  established 
Dupuytrens disease w ith 30o or g rea ter m etacarpophalangeal jo in t contractures or 
20o or g rea ter proxim al in terphalangeal jo in t contractures, or both. As a control, 
uninvolved skin tissue from  the sam e patien t w as used w henever feasible, and 
uninvolved skin was used from  an age-m atched group of nine patients undergoing 
other, nonneoplastic orthopaedic procedures. Tissue w as m inced into pieces sm aller 
than  1 mm and plated in 25 cm2 culture flasks, in Dulbecco’s Modified Eagle Medium 
(DMEM) (Gibco BRL, Grand Island, NY) containing 10% Fetal Calf Serum  (FCS), 
penicillin (100 U/ml) and streptom ycin (100 mg/ml) (M ediatech, W ashington, DC). 
Cultures w ere kept in 370C humidified air, containing 5% CO2. Cells w ere subcultured 
and used for experim ents betw een the th ird  and ninth generation. Representative 
results are  shown on 3-4 D upuytren derived cultures (Dup#1, #2, #3, and #4), and 
two norm al tissue derived cultures (Skin Fibroblast (SF)#1, and #2), each of these 
presenting a different individual.
TGF-p Receptor assay
The receptors for TGF-p w ere exam ined using a cross-linking m ethod, as described 
by M assague (19). In short, cells w ere plated in 6-well plates, and grown to confluence 
in DMEM plus 10%FCS plus antibiotics. At confluence the cell m onolayer was w ashed 
with bicarbonate-free MEM, 25 mM Hepes (pH=7.4), and 1 mg/ml bovine serum  
album in (BSA). Then 100 pM 125I-TGF-p1 was added, and the plate was put on a 
rotating platform  for 2.5 hours at 40 C. To show specificity of the binding we incubated 
a control w ith both iodinated and 100-fold excess unlabeled TGF-p1. Cells w ere 
w ashed, and a cross-linking agent (disuccinimydil suberate) was added for 1 hour. 
Finally the cells w ere solubilized using a m ixture of Triton X-100, Tris, and EDTA. 
The su p ern a tan t was sam pled and stored  at -700C until used. The solubilized cell 
proteins w ere separated  using SDS-Polyacrylamide gel electrophoresis under reduced
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conditions on a p recast 4-15% linear gradient gel (Bio-Rad, Richmond, CA). Gels 
w ere transferred  to filterpaper and exposed for 14 days to X-ray for autoradiography 
a t -700C. Expression of TGF-p receptor types was m easured  using laser densitometry.
Cellular proliferation studies 
Cells w ere routinely subcultured in 25 cm2 flasks. For proliferation studies, the 
cells w ere plated in 96-well plates at an  initial density of 4x103 cells/well in DMEM 
plus 10%FCS plus antibiotics for 24 hours to allow attachm ent of the cells. Afterwards 
the cells w ere brought in a quiescent state by serum  starvation for 24 hours. Different 
am ounts of TGF-p1 (1 or 5 ng/ml), EGF (8 ng/ml), or both w ere then  added in DMEM 
plus 0.2%FCS plus antibiotics. Since TGF-p1 induced m itogenesis involves an  indirect 
loop involving the production of PDGF (20), there  is a delay of at least 24 hours (20). 
The m axim um  peak stim ulus after EGF addition is after 18 hours or m ore; therefore 
we added 1.6 |mCi/well [3H]thymidine (NEN, Boston, MA) 20 hours after the addition 
of the respective growth factors. To m easure  the production of DNA, cells w ere 
w ashed with PBS and precipitated w ith trichloroacetic acid. DNA was then extracted 
w ith 0.3M NaOH, and aliquots w ere m easured  in a liquid scintillation counter.
Preparation of conditioned medium 
Cells w ere plated at 1.5x105 cells/well in 6-well plates in DMEM plus 10% FCS plus 
antibiotics. After 24 hours cells w ere w ashed extensively and concurrently incubated 
with serum -free DMEM/25 mM Hepes/0.5% BSA. After 48 hours conditioned m edium  
was sam pled and stored at -200C until use. Cell num bers, counted after sam pling 
the conditioned m edium , w ere shown to be equal am ong the cell types.
Mink lung cel (Mv1Lu)inhibition assay  
Mv1Lu cells (American Tissue Culture Collection, Rockville, MD) and plated in 
96-well p lates at 1.5x104 cells/well and left to attach  for 12 hours in DMEM plus 10% 
FCS plus antibiotics. After extensive w ashing w ith serum -free m edium , diluted 
sam ples of conditioned medium  w ere added into a total of 100 ml serum -free medium. 
After 48 hours the num ber of cells was estim ated w ith the colorim etric Tetrazolium  
Salt (MTT)-assay (21). This assay is based on reduction of MTT (Sigma Chemical, St. 
Louis, MO) by a m itochondrial succinyl dehydrogenase in viable cells to the purple 
coloured insoluble form azan precipitate. Relative cell num ber can be estim ated 
using a m icroplate colorim etric read er (570 nm  wave length). This assay was be 
very accu ra te  and reproducible (SEM less th an  3%). Because TGF-p is usually 
produced in a la ten t inactive form tha t can be activated by acidification or alkalini-
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zation, we tested  each sam ple before and after acidification. To specify the isoform 
of TGF-p that w as produced by the cells, we used antibodies to either TGF-pi or 
TGF-P2 at a final concentration of 30 mg/ml. Sam ples w ere p re-incubated  with 
antibodies for 1 hour at 370C before adding to the M vlLu cells. The neutralizing 
antibodies at this concentration completely blocked the M vlLu inhibitory effect of
0.3 ng/ml TGF-pi (data not shown).
Results
TGF-p receptor assay  
On all prim ary cultures of Dupuytren cells and norm al fibroblasts tested we found 
presence of three TGF-p receptor types. The type I receptor was expressed significantly 
less (Student t-test; p<0.05), or had a lower affinity for TGF-pi than the type II receptor 
in Dupuytren cultures. There was virtually no difference betw een binding of TGF-pi 
to these two receptor types in norm al fibroblasts. Binding was specific as shown by 
cross-linking in the presence of excess unlabeled TGF-pi. Representative results are 
dem onstrated in Figure 1.
Figure 1: Autoradiogram of representative affinity labelling experiments. Two examples 
of normal skin fibroblasts are shown (SF#1, and SF#2) and three Dupuytren derived 
fibroblasts (Dup#1, Dup#2, and Dup#3). Lanes indicated with - represent cross-linking 
with 125I-TGF-p1 alone, w hereas lanes indicated with + represent cross-linking with 
125I-TGF-p1 in the presence of excess unlabeled TGF-P1. Molecular weights are indicated 
on the right. TGF-p receptor forms I, II, and III are m arked on the left.
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Cellular proliferation 
Normal fibroblasts exhibited a g rea ter mitogenic response to EGF than  D upuytren 
cells (Fig. 2). Addition of TGF-ß1 alone (1 and 5 ng/ml) and in com bination with EGF 
(TGF-ß1 [5 ng/ml]/EGF [8 ng/ml]) w as m ore grow th stim ulatory for D upuytren cells 
than  for their norm al counterparts (figure 2). DNA-synthesis in some Dupuytren
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Figure 2: TGF-p1 and/or EGF stimulate DNA-synthesis in normal skin derived fibroblasts 
(n=9) and Dupuytren-derived fibroblasts (n=13). The m ean and SEM of triplicate 
determinations is shown. fZI =normal skin derived fibroblasts, ■  =Dupuytren-derived 
fibroblasts.
cultures was stimulated up to eightfold by addition of the combination TGF-pi (5 ng/ml) 
and EGF (8 ng/ml). TGF-pi (5 ng/ml) alone stim ulated m itogenesis up to fivefold in 
some D upuytren cultures. These effects w ere less im pressive in norm al fibroblasts. 
An interesting finding was that the sim ultaneous addition of TGF-pi and EGF resulted 
in synergistic stim ulation of DNA-synthesis in Dupuytren cultures w hereas this effect 
w as only additive in norm al fibroblasts.
Presence of TGF-p 
TGF-p is a very specific inhibitor of M viLu Mink Lung cells (22). Using a bioassay 
based on this feature we found presence of TGF-p in the conditioned m edium  of 
both cell types (Fig. 3). Acidification of the sam ples increased  M viLu inhibitory 
(=TGF-p) activity, which shows th a t both active and laten t TGF-p is p resen t (Fig. 3). 
Using specific antibodies neutralizing TGF-pi or TGF-p2 activity, we found tha t 
Dupuytren cells m ade mostly TGF-pi w hereas no difference betw een production of
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Figure 3: Presence of active and latent TGF-p in conditioned medium. Level of TGF-p 
was determined using the MV1LU Mink lung cell inhibitory assay. Inhibition of cell 
growth was m easured using the colorimetric MTT-assay. The higher the optical density, 
the more MV1LU cells, i.e. the less TGF-p in the conditioned medium. The m ean of 
triplicate determinations is shown, SEM was always lower than 5%. As control we 
assayed the effects of purified TGF-p1 on MV1LU cells (left side). SF=normal skin- 
derived fibroblasts, Dup=Dupuytren-derived fibroblasts. fZA =Acidified samples,
■  =Non-acidified samples.
SF 1 SF 2 Dup 1 Dup 2 Dup 3 Dup 4
Figure 4: Antibody neutralization of conditioned medium. Antibodies against either 
TGF-p1 or TGF-p2 at a final concentration of 30 mg/ml were incubated with diluted 
samples of conditioned medium. Blocking of inhibitory Mv1Lu (TGF-p like) action was 
m easured using the colorimetric MTT-assay. ■  =no antibody, 1221 =anti TGF-p1 
antibody, Ifff =anti TGF-p2 antibody.
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TGF-B Activity
Cell type____________________ Nanograms/ml._________ % Active TGF-B
Skin Fibroblast #1 9.5 21
Skin Fibroblast #2 13.3 6
Dupuytren #1 1.1 5
Dupuytren #2 5.2 3
Dupuytren #3 5.7 12
the two isoforms was seen in norm al cells (Fig. 4). Unexpectedly, norm al fibroblasts 
produced m ore TGF-p than  Dupuytren cells (Table i).
Discussion
The concept of cells producing and secreting  polypeptide grow th factors th a t 
subsequently bind to their own receptors, resulting  in a biologic response, was 
introduced as autocrine growth control in the early i9 8 0 ’s (23,24). Since then  it has 
become common knowledge th a t cells exist in a balanced system of various growth 
factors, including PDGF, FGF, EGF, insulin-like growth factor (IGF), and TGF-p. If 
tissue-hom eostasis is disturbed (e.g. following injury), adjustm ents in expression of 
growth factors or their receptors are p art of the repair m echanism s needed to restore 
the balance. Assuming th a t tum origenesis som ew hat resem bles a repa ir m echanism  
gone awry, it is not surprising th a t m any tum ors have been shown to express an 
increased synthesis of certain  grow th factors or their receptors, or both. TGF-p’s 
potential role in tum origenesis, however, is complicated by its bi-directional effects 
on growth (stim ulatory for m esenchym al cells and inhibitory for epithelial cells), its 
complex receptor system, and the fact th a t it is produced in a la ten t (inactive) form. 
Loss of growth-inhibitory control by TGF-p has been linked to epithelial tumorigenesis, 
w hereas increased  TGF-p expression could theoretically  lead to m esenchym al 
tum origenesis. These m echanism s can be explained by alterations in production, 
secretion, and subsequent activation of la ten t TGF-p, by changes in TGF-p receptor 
expression, and by alterations in post-receptor cell signalling. Although the exact 
roles of TGF-p in tum origenesis are still unclear, increased synthesis of TGF-p has 
been shown in diseases such as pulm onary fibrosis (i3), keloids (i4), m eningeom as 
(25), and gliomas (26), suggesting th a t high levels of TGF-p som ehow put these 
tum or cells at a growth advantage.
It is surprising that so far no report has suggested an autocrine m echanism  involving 
TGF-p in D upuytren’s disease, since this disease seem s to exemplify classic features 
of TGF-p overexpression, including hyperproliferation of fibroblasts and excessive
77
Chapter 4
production of ECM. Although in our study the th ree ingredients for an  autocrine 
loop (i.e., expression of growth factor, p resence of receptors, and responsiveness to 
exogenous growth factor) w ere shown both in Dupuytren and norm al cultures, there 
w ere some in teresting differences. F irst, Dupuytren cultures reacted  consistently 
with a stronger mitogenic response to exogenous TGF-pi (up to fivefold), than  norm al 
cultures. Second, the com bination of exogenous TGF-pi and EGF resu lted  in a 
stronger (up to eightfold) m itogenic response in Dupuytren cultures than  in norm al 
cultures. M oreover this effect w as synergistic in D upuytren cultures, w hereas only 
additive in the norm al cultures. Although these differences w ere consistent, mitogenic 
respones varied am ong the i2  Dupuytren cultures, which m ight reflect a specific 
stage of the disease process, since it is known th a t D upuytren’s disease evolves from 
a high-proliferative tow ards a low-proliferative stage (27). There have been reports 
on the effects of TGF-p and EGF on keloid (28) and neurofibrom a-derived cells (29), 
diseases with characteristics common to D upuytren’s contracture. They agree partly 
with our findings in th a t TGF-pi stim ulated the growth of these tum or cells in vitro 
(28,29) consistently higher than  in their norm al counterparts and tha t the effects of 
TGF-pi and EGF w ere synergistic in tum or cells, as opposed to additive in norm al 
cells (28). The recently reported  findings of increased presence of PDGF protein in 
D upuytren’s contracture as com pared w ith to norm al skin (7) could be explained by 
increased TGF-p expression, since it is well known tha t m itogenic effects of TGF-p 
on connective tissue cells are induced via a complex control of an  autocrine PDGF 
loop (20). Therefore, increased PDGF expression could be a norm al response to an 
abnorm al TGF-p expression. Third, norm al cells seem ed to produce m ore TGF-p 
than  Dupuytren cells, which would not directly fit w ith our m odel of increased TGF- 
p expression in Dupuytrens contracture. However, growth factors do not always 
accum ulate in the conditioned m edium  (28) and activation of la ten t TGF-p in vivo 
m ight be different betw een the two cell types.
Fourth, receptor-binding studies dem onstrate th a t both Dupuytren and norm al 
cultures have th ree  TGF-pi recep to r types, I, II, and III. An in teresting difference 
was th a t the type II receptor on Dupuytren cells bound m ore TGF-pi th an  the type 
I receptor. This can be caused either by a higher num ber of receptors or by a higher 
recep to r affinity for the ligand. Lately it has become clear th a t the type I and the 
type II receptors are  responsible for the biological actions of TGF-p w hereas the 
type III recep tor functions mainly as an  extracellu lar binding dom ain (30). Recent 
reports showed th a t a change in the expression of the type II and to a lesser extend 
the type I receptor resulted  in significantly different effects of TGF-p on growth 
control (3i-37). Analoguously, our finding of a higher expression or affinity of the
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type II versus the type I TGF-b receptor on Dupuytren fibroblasts than  on norm al 
fibroblasts m ight lead to a qualitative altered  growth p a tte rn  in favor of Dupuytren 
cells. Moreover, it m ight lead to a different transcriptional regulation for other features 
such as ECM production.
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Chapter 5
I. Summary
Debate over the cause of D upuytren’s disease has been ongoing since its well- 
know n descrip tion  over 170 years ago .1 However, m any recen t stud ies of the 
basic science of the d isease a re  beginning to e rase  som e of the enigm a of its 
etiology. T hroughout the 70’s and 80’s, research ers established the m yofibroblast 
as the hallm ark  of D upuytren’s disease by carefully studying and describing the 
ap p earan ce  of these cells and  th e ir re la tion  to the su rround ing  m atrix . More 
recently, efforts have focused on the factors controlling the (myo)fibroblasts such 
as free radicals and grow th factors. The expanding fields of cell biology, m olecular 
biology, and research  of o ther fibrotic diseases such as liver cirrhosis, lungfibrosis, 
atherosclerosis, and glom erulonephritis have, in particu lar, provided m any new 
insights in the pathogenesis of D upuytren’s d isease.2,3 This paper gives the clinician 
an  in tegra ted  overview of the cu rren t understand ing  of D upuytren’s disease as 
re la ted  to recen t advances in histology, cell biology (growth factors), free radicals, 
biochem istry, and immunology.
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II. Recent advances in
A. Histology
The m yofibroblast is a fibroblastic phenotypic varian t which was first described 
in 1971 by Gabbiani et al in contracting experim ental granulation tissue .45 A year 
later, the myofibroblast was described in Dupuytren’s tissue using electron microscopy 
(EM),6 and la te r confirm ed by others.7'9 M yofibroblasts have also been shown to be 
p resen t in m any o ther tissues such as hypertrophic scar tissue,10'12 frozen shoulder,13 
around m am m ary im plants14'16 and in desm oplastic strom a around neoplasm s.17'19 
Presence in these different tissue types can be categorized in th ree groups: repair 
or in flam m atory  conditions, fib rop ro life ra tive  conditions, and  in resp o n se  to 
neoplasia .19-21 Their role in these lesions is presum ably of tissue contraction. In the 
case of D upuytren’s contracture for example, prostaglandins can cause contraction 
and relaxation of Dupuytren m yofibroblasts in v itro , and are expressed in vivo  in 
the affected fascia.2223
The m yofibroblast has features in common with both sm ooth m uscle cells and 
fib rob lasts, as they  a re  ch a rac te rized  by a w ell-developed cytoplasm ic actin  
m icrofilam ent system  called a-sm ooth m uscle actin (a-SM actin) rem iniscent of a 
sm ooth m uscle cell. There are  five phenotypes based on the different inter-m ediate 
filament, smooth m uscle actin and myosin expression (V, VA, VAD, VD, and VA(D)M).19 
The types of m yofibroblasts expressed in the th ree  stages of D upuytren’s disease 
range from mostly VA in the proliferative stage, to decreased VAD and VD in the 
involutional phase, to almost exclusively type V in the residual phase.20 Myofibroblasts 
connect w ith each other through gap-junctions, and to the surrounding strom a with 
extracellular fibronectin fibers.19'21 In D upuytren’s fibroblasts, extracellular filaments 
containing fibronectin connect w ith in tra-cellu lar actin through a transm em brane 
association.24 This s tructu re  w as described by Singer, and was term ed fibronexus.25 
In the fibronexus, cells are interconnected with each other as well as with the collagen 
in the surrounding m atrix , thus theoreticaly providing the m yofibroblasts with a 
m eans to contract the m atrix. Others have called these connections m icrotendons.19
Since the initial description of the m yofibroblast in D upuytren’s tissue in the early 
70’s, num erous o ther studies have contributed to a m ore detailed understanding  of 
its histological appearance. Collectively, these studies describe how m yofibroblasts 
dom inate D upuytren’s tissue. One EM study,8 for instance, showed th a t all nodules 
in D upuytren’s tissue contained myofibroblasts. Other reports showed myofibroblasts 
to be p resen t in 26-100% of Dupuytren tissue sam ples, and m ost abundan t in the 
involutional (middle) stage of the disease relative to the proliferative (first) and the
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residual (last) phases.926'29 Finally, the presence of m yofibroblasts seem s to correlate 
w ith disease recu rren ce .3031
Histological studies of a-SM actin expression, the m ark er for m yofibroblasts, have 
also con tribu ted  significantly to our und erstan d in g  of D upuytren’s d isease ,2628 
eliminating the need for EM. Studies focusing on skin nodules and cords, for example, 
provide fu rth e r insight. Andrew  et a l32 show ed m yofibroblasts in 5/14 nodules 
exam ined, and a positive correlation betw een the num ber of m acrophages and 
myofibroblasts in the nodules. They also showed vimentin to be present in all nodules, 
while desm in w as nearly  absent. McCann et a l33 also studied skin and underlying 
cords, docum enting the presence of a-SM actin in the m ajority of the nodules and in 
some cases up to the epiderm al border. Furtherm ore, in a large proportion of the 
sam ples, the derm is and subcutis also revealed fibroblasts expressing a-SM actin. 
The authors suggest tha t there  is either expansion of active foci in the skin or an 
activation of targe t cells by an  unknow n cause. Removing these foci followed by full­
th ickness skin  g rafting  could thus exp lain  re p o rted  low re c u rre n c e  ra te s  of 
D upuytren’s disease following this specific surgical technique.3435
Some of the most current myofibroblast research is focused on understanding why 
the m yofibroblast d isappears in norm al healing wounds bu t persists (longer) in 
desmoplasia and fibroproliferative diseases. The most likely explanation appears to be 
in the control of apoptosis or programmed cell death of the myofibroblasts,36'38 suggesting 
tha t these cells are term inally differentiated.37 The inducers of apoptosis are unclear, 
although ce rta in  genes such as ced-3  and c-Myc  have been suggested .37 Other 
candidates for controling apoptosis a re  growth factors such as Transform ing Growth 
Factor-b (TGF-b), Platelet Derived Growth Factor (PDGF), and Tumor Necrosis Factor 
(TNF).37 Recently, a double-labeling technique using im m uno-histochem ical staining 
for a-SM actin and the TUNEL m ethod for apoptotic activity show ed tha t the cells 
undergoing  apoptosis in the late  involutional s tage in D u puy tren ’s tissue  are  
myofibroblasts, and are associated with expression of TGF-b in the sam e a reas .39 
Therefore it seems tha t there is not a complete loss, but ra th e r a changed control of 
apoptosis in Dupuytren’s tissue as com pared to norm al tissue. The authors suggested 
that a complete loss of apoptotic control could lead to m alignant myofibroblast growth.39
B. Cell biology/growth factors/cytokines
The concept of cells producing and secreting polypeptide grow th factors tha t 
subsequently  bind to their own recep to rs resu lting  in a biologic response was 
introduced as autocrine growth control in the early 1980’s.4041 Since then  it has
86
New insights in the development of Dupuytren’s contracture
become com m on knowledge th a t cells exist in a balanced system  of various growth 
factors and their receptors. These growth factors can function individually, or in 
conjunction w ith others. If tissue hom eostasis is d isturbed (e.g., following injury), 
adjustm ents in expression of growth factors and/or their receptors is p art of the 
rep a ir m echanism s needed to restore the balance. The hallm ark  of norm al repair 
or growth m echanism s is th a t once the appropriate  hom eostasis is reached , the 
autocrine and/or paracrine  loops adjust to their norm al state. A classic example 
of this process is w ound healing.42
Given th a t tum origenesis som ew hat resem bles a repa ir m echanism  gone awry, 
it is not surprising th a t m any tum ors have been shown to express an  increased 
synthesis of certain  growth factors and/or their receptors. Fibrom atoses, including 
D upuytren’s disease, can be classified as benign fibroproliferative tum ors,43 and 
it has been shown th a t cultured fibroblasts from D upuytren’s contracture display 
features in term ediate betw een those expressed by norm al hum an fibroblasts and 
“transform ed" (neoplastic) fibroblasts,44 As such, we can speculate on the possible 
au tocrine  and p a rac r in e  m echanism s, including the role of individual grow th 
factors, underly ing  D upuytren’s co n trac tu re . Likely cand ida tes should have a 
grow th stim ulatory effect on (myo)fibroblasts, possibly induce differentiation into 
m yofibroblasts, stim ulate  production  of ex trace llu la r m atrix  (ECM), and, once 
deposited, prevent the breakdow n of ECM.
Considering these p rerequ isites , the m ost likely candidates a re  the so-called 
fibrogenic cy tokines345 P la te le t Derived G row th F acto r (PDGF), T ransfo rm ing  
Growth Factor-b (TGF-b), basic Fibroblast Growth Factor (bFGF), Interleukin-1 (Il- 
1), and Tumor Necrosis Factor-a (TNF-a). In addition, m ost of these cytokines induce 
cell proliferation of endothelial cells, leading to ano ther im portant feature of tissue 
growth (in rep a ir as well as in neoplasia) called angiogenesis. This correlates with 
Kisher and Speer’s EM study, which showed that m ost Dupuytren’s tissue has occluded 
microvessels with increased layers of endothelial cells.46 Kisher and Speer speculated 
on an unknow n trigger th a t produces proliferation of endothelial cells leading to 
local hypoxia, and differentiation of pericytes into m yofibroblasts.
To my knowledge, only one study has screened D upuytren’s tissue for expression 
of a large panel of cytokines.47 Using RT-PCR (Reverse T ranscrip tase Polym erase 
Chain Reaction), Baird et al showed th a t mRNA for Il-1, TGF-b, and bFGF w ere 
significantly m ore abundant in D upuytren’s tissue than  in norm al tissue (p<0.01, 
<0.02, and <0.05 respectively). Elevated PDGF w as also detected, but these results 
w ere  no t s ta tis tica lly  sign ifican t. F u rth e rm o re , th e re  w ere  no d ifferences in 
expression of TNF-a, Il-6 and IGF-1. While this study has several shortcom ings (e.g.
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RT-PCR gives only qualitative inform ation on the presence of mRNA and therefore 
does not always rep resen t actual p rotein  secreted  by the cells tested , and it is 
som ew hat unclear if the extracted  mRNA rep resen ts  (myo)fibroblasts alone or if it 
includes bloodvessels and platelets), B aird’s resu lts47 are consistent w ith Kovac’s 
classification3 of the so-called fibrogenic cytokines.
In contrast to B aird’s study47 of a broad group of cytokines, m ost o ther reports 
have focused  on possib le  re la tio n s  b e tw een  one or two g row th  fac to rs  and  
D upuytren’s disease. These advances a re  sum m arized below:
Basic Fibroblast Growth Factor (bFGF)
The FGFs are  m em bers of a family of nine heparin-binding growth factors, with 
a core protein of 18kDa. They are  m itogenic for m esenchym al cells, but are  mostly 
known for their angiogenic activity, having no known effect on the production of 
e x tra ce llu la r  m a tr ix .20 They have tw o types of recep to rs : h e p a ra n  su lp h a te  
proteoglycans and tyrosine kinase recep to rs.48
Basic fibroblast growth factor (bFGF) has been shown to be expressed by and 
p resen t in D upuytren’s cells.47- 49'51 Based on in situ  hybridization, evidence was 
presented  th a t although bFGF and its receptor a re  d istributed throughout norm al 
and  involved fascia, the  levels of expression  w ere  significantly  h ig h er in the 
Dupuytren-derived fascia.50 In another report, the sam e authors provided evidence 
that different components of an autocrine loop involving bFGF w ere present in cultured 
Dupuytren derived fibroblasts, nam ely presence of mRNA of FGF (receptor) and 
proliferation in response to exogenous bFGF. However, no data w ere given on the 
expression of the actual bFGF protein.49 Berndt et al51 showed that expression of 
bFGF mRNA was localized in the fibroblast and myofibroblast in the proliferative 
nodules, while the protein bFGF was detected in proliferative areas. This observation 
led them  to believe that bFGF diffusing from the nodules was affecting the surrounding 
“norm al" cells in a paracrine fashion. According to Alioto et al,52 bFGF stim ulated the 
proliferation of norm al palm ar fibroblasts up to 200%, but stim ulated the diseased 
cells only up to 50%. Collagen production was elevated 20% in Dupuytren derived 
cells by bFGF but inhibited in norm al palm ar fascia fibroblasts. In contrast, non­
collagen synthesis was stim ulated 60% in Dupuytren cells by bFGF, and only 15 % in 
norm al cells. While these data strongly support Berndt et a l’s51 hypothesis that bFGF 
diffuses from the nodules to affect the norm al cells, a recent study evaluating presence 
of growth factors and myofibroblasts in contracted fibrotic capsules around hum an 
breast im plants showed no expression of bFGF.16 There is still m ore work to be done 
to establish w hether bFGF has a role in Dupuytren’s disease.
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Platelet Derived Growth Factor (PDGF)
Platelet derived growth factor is synthesized as a 30 kDa hetero- or hom odim er 
(AA, AB, or BB dim ers) th a t  s tim u la tes p ro lifera tion  of sm ooth  m uscle cells, 
fibroblasts, and glial cells, and is chem otactic for SMC and fibroblasts.53 PDGF 
derived its nam e from its first isolation from platelets about fifteen years ago, but 
now we know th a t sm ooth m uscle cells, endocytes, m onocytes, and fibroblasts 
produce this growth factor. So far, it appears tha t the m ost im portan t roles for 
PDGF are  in wound healing54-55 and early  developm ent. A berran t expression of 
the growth factor and/or its receptors has been linked to neoplasia .53
Since PDGF is one of the  fibrogenic grow th facto rs, d ifferen t au th o rs  have 
investigated a possible role for PDGF in D upuytren’s contracture. To date there  is 
am ple evidence to indicate th a t PDGF is expressed  in D upuytren’s tissue. For 
example, B adalam ente et al56 showed tha t PDGF was bound to the cell m em brane 
of (myo)fibroblasts involved in D upuytren’s disease. Intensity of staining for PDGF 
was increased in the proliferative-involutional phase as com pared to norm al tissue 
and residual stage D upuytren fibroblasts. Alioto et al52 showed tha t in v itro  PDGF 
stim u la ted  co llagen p ro te in  syn thesis in n o rm al cells up to 9%, and  22% in 
Dupuytren cells. Non-collagen protein synthesis in norm al cells w as m ore sensitive 
to PDGF than  in Dupuytren cells. PDGF stim ulated proliferation of both cell types 
equally  in a d o se-d ep en d en t fash ion  up to 100%. T erek  et a l57 used  in s i tu  
hybridization and polym erase chain reaction (PCR) to show tha t both the PDGF-B 
gene and PDGF receptor are  expressed in Dupuytren tissue, and localized it to the 
fibroblasts and fascia. However, PDGF is apparen tly  expressed  in D upuytren’s 
tissue at the sam e level as in norm al tissue.47 This, in com bination with its inability 
to induce a-SM actin in fibroblasts58 as will be discussed later, m akes PDGF an 
unlikely cand ida te  in the etiology of D upuytren’s d isease. M oreover, PDGF in 
D upuytren’s tissue this could be explained by increased TGF-b expression, since it 
is well known th a t m itogenic effects of TGF-b on connective tissue cells are induced 
via a complex control of an  autocrine PDGF loop.59 Therefore, increased  PDGF 
expression could be a norm al response to an  abnorm al TGF-b expression. At this 
time the m ost likely role (if any) for PDGF in D upuytren’s disease is th a t of a so- 
called com petence factor, serving as an  in term ediate in a m ultistep process leading 
to contracture of the palm ar fascia.
Transforming Growth Factor Beta (TGF-b)
TGF-b is a 25 kD homodimer, detected about 10 years ago in tum or extracts and 
term ed “transform ing" since it was thought to induce or m aintain  the neoplastic or
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transform ed cell phenotype. Of the 5 isoforms of TGF-b, only TGF-b1, TGF-b2, and 
TGF-b3 have been described in hum ans.60 TGF-b has been  shown to be widely 
expressed  in both  norm al and neoplastic tissues, playing an im portan t role in 
developm ent, hom eostasis, repair, growth and differentiation. In general, TGF-b is 
grow th-stim ulatory for m esenchym al cells such as fibroblasts, and growth inhibitory 
for ectoderm al cells, although its effects are  sometimes confusing. It affects all phases 
of w ound healing, including the inflam m atory phase, and the rep a ir phase with 
chem otaxis, angiogenesis, and ex tracellu lar m atrix  form ation (ECM).60'62 TGF-b 
in c reases  the  gene tran sc rip tio n  of m a trix  p ro te in s  such  as fib ronectin  and  
proteoglycans, w hile it inhibits the production of p ro teases, and  increases the 
production of pro tease inhibitors. There are also interactions betw een the ECM and 
TGF-b w hich can be bi-directional, and excessive ECM production can be caused by 
excessive TGF-b or ab erran t signals from the ECM.63 These features have been shown 
both in v ivo  and in v itro ,  and have been linked to diseases such as pulm onary 
fibrosis,6465 keloids,6667 glom erulonephritis,68 scar tissue,69 and in contracted capsules 
around b reast im plants.16 This prom pted B order70 to introduce this as the “the dark  
side of tissue repair." Most recen t data  suggest th a t the ratio  of TGF-b3 relative to 
TGF-b1/TGF-b2 is im p o rtan t for the developm ent of sca rring  and fibrosis.7172 
Desmouliere et al73 showed that TGF-b1 induced granulation tissue was characterized 
by myofibroblasts expressing a-SM actin, docum enting the ability of TGF-b to induce 
a myofibroblastic phenotype.
TGF-b is produced in a la ten t (inactive) form, but in vivo activation is so far 
incompletely understood. Its effects are  m ediated  through th ree different TGF-b cell 
surface receptors: type I, II and III. The type III receptor is a betaglycan, and m ost 
likely functions as a reservoir, is not involved in signal transduction , and distributes 
TGF-b to the type I and type II receptors. The m echanism s of action of the receptors 
and post-receptor signaling are  being increasingly understood, but m any questions 
rem ain  unansw ered .7475
A unique feature of TGF-b is that it is able to upregulate its own synthesis, thereby 
adding an endogenous amplification loop and rendering it a chronically elevated 
cytokine,76 resulting in a potentially harm ful feedback loop. Hypoxia -a condition locally 
present in fibrotic environment- can induce TGF-b1 up to 9-fold in hum an fibroblasts.77
We previously provided experim ental evidence for an  autocrine loop involving 
TGF-b in D upuytren’s tissue7879: TGF-b was shown to be produced by Dupuytren 
cells in v itro , Dupuytren cells th a t w ere growth stim ulated by exogenous TGF-b 
expressed TGF-b receptors, the type II receptor in D upuytren cells bound m ore 
TGF-b1 than  the type I receptor, either by a higher recep to r num ber or higher
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affinity for the ligand. M odulation of type I and type II receptors appears to be 
correlated  w ith disease states. In o ther diseases som ew hat sim ilar to D upuytren’s 
d isease , for exam ple sc a rr in g  an d  h y p e rtro p h ic  b u rn  sca rs , in c re a sed  and  
prolonged expression of TGF-b type I and type II receptors has been show n,11 as 
have differences in expression of TGF-b type I and II receptors in keloids.80
The presence and expression of TGF-b in D upuytren’s disease in vivo has also 
been confirmed. Using im m unohistochem istry, B adalam ente81 show ed presence 
of TGF-b1 in fibroblasts, capillary endothelial cells, norm al fascia, and in all 3 phases 
of D upuytren’s contracture (proliferative, involutional, residual). TGF-b2, on the 
other hand, was not identified in norm al fascia, although it was expressed in the 
proliferative and involutional phase, but not in the residual phases of D upuytren’s 
disease. Other studies have since confirmed the presence of TGF-b1 and -b2 in 
D upuytren’s tissue using in situ  hybridization51 and im m unohistochem istry.82 TGF- 
b also ap p a ren tly  affects collagen p ro te in  by D upuytren’s fascia-derived  cells 
differently than  norm al skin derived fibroblasts (although both a re  stim ulated).52 
However, no m itogenic effects of TGF-b on norm al or Dupuytren derived cells w ere 
found by these re search ers .52
In sum m ary, TGF-b seem s a very likely candidate in the etiology of D upuytren’s 
disease. As will be discussed below, m ajor research  efforts a re  currently  focused 
on the possible in teraction of TGF-b w ith GM-CSF in tissue fibrosis and possible 
im plications for trea tm ent.
GM-CSF
GM-CSF is m ostly know n for its stim ulato ry  effect on cells of hem atopoietic 
origin and its role in the inflam m atory response.83 However, it was recently shown 
to induce proliferation of m esenchym al cells17 through the form ation of granulation 
tissue containing m any m yofibroblasts rich in a-SM actin .18,58 GM-CSF is not able to 
induce a-SM actin in vitro suggesting this represen ts an  indirect effect.5884 Local 
application of GM-CSF in vivo results in accum ulation of m acrophages,84 which in 
tu rn  p ro d u ce  TGF-b lead in g  to a-SM ac tin  ex p ress io n  and  m y ofib rob lastic  
differentiation.85 Recent in vivo  evidence was provided tha t GM-CSF is able to induce 
TGF-b1 in a lung fibrosis m odel.86 GM-CSF and TGF-b are the only two cytokines 
th a t are able to induce a-SM actin rich m yofibroblasts in the skin in vivo ,58-84-85-86 and 
thus should be considered the m ost likely candidates for inducing the m yofibroblast 
phenotype in D upuytren’s disease.
Currently, to my knowledge, there a re  no data  on a possible relation of GM-CSF 
and D upuytren’s disease.
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g-Interferon
Interferons a re  a product of lymphocytes, and are capable of inhibiting collagen 
synthesis in vitro: g-interferon is believed to be the m ost potent.87 Interestingly, 
depressed levels of g-interferon production by peripheral blood m ononuclear cell 
fractions w ere shown in black patients w ith keloids.88 T reatm ent of Dupuytren- 
derived fibroblasts w ith interferon-g in vitro decreased the expression of protein 
and mRNA for a-SM actin significantly, suggesting a potential role for g-interferon 
as an  anti-fibrotic agent.178589'91 The first clinical study on the use of g-interferon in 
D upuytren’s disease was done by Pittet et al showing prom ising resu lts,90 but will 
need confirm ation in a larger series.
Transforming Growth Factor-a (TGF-a)
Although not a tru e  fibrogenic fac to r,3 a few rep o rts  have ap p eared  on the 
expression of TGF-a and EGF receptors (EGF-R) in D upuytren’s disease. Magro et 
a l92 used  the sensitive RT-PCR techn ique and  im m unohistochem istry  to show 
increased staining for TGF-a and EGF-receptors in the proliferative phase relative 
to norm al fascia, and decreased expression in the involutional and residual phases. 
A strikingly sim ilar p ictu re w as show n for a-SM actin , w hich is a m ark e r for 
m yofibroblasts. However, others could not detect EGF in D upuytren’s tissue using 
im m unohistochem istry .82
Our studies7879 show th a t EGF is stim ulatory for cell grow th in vitro  for both 
norm al and Dupuytren-derived cells, and tha t EGF and TGF-b1 are synergistic for 
cell growth in Dupuytren-derived cells (as opposed to additive in the norm al cells). 
This was sim ilar to findings in keloids.93 Given the limited (and inconsistent) data, it 
so far seem s unlikely th a t TGF-a is a m ajor player in the etiology of D upuytren’s 
disease.
Interleukin-1
Interleukin-1 is a 17 kDa protein produced mainly by activated monocytes and 
m acrophages. Many of its pleiotropic functions a re  sim ilar to TNF-a despite no 
significant structu ra l homology.94 Most of IL-1’s effects are related  to inflammation 
and w ound healing, and they are p art of the so-called fibrogenic cytokines.3 The 
relationship betw een Il-1 and Dupuytren’s disease is currently unclear. The only data 
so far have shown that Il-1 mRNA is m ore abundant in Dupuytren’s tissue than  norm al 
tis su e .47 The lack of convincing d a ta  and  the  fact th a t  Il-1 can n o t induce a 
myofibroblastic phenotype58 suggest that factors dow nstream  are m ore im portant.
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In sum m ary, of all the growth factors/cytokines having been studied so far for a 
possible role in the development of D upuytren’s contracture it seem s that TGF-b and 
possibly GM-CSF are  the m ost likely candidates, w hereas o ther growth factors such 
as PDGF, or bFGF probably play a m inor role.
C. Free radicals
In the 1980’s M urrell et al95'98 introduced the free radical theory, which suggests a 
relation between localized ischaemia, superoxide free radicals (02'), hydrogen peroxide 
(H202), hydroxyl radicals (OH'), and Dupuytren’s contracture. Free radicals are highly 
reactive atoms or molecules that exist independently and have a very short half-life, 
but are capable of inducing new free radicals.98 The free radical theory as it relates to 
D upuytren’s disease is based on studies suggesting th a t m icrovessel narrow ing  
secondary to age, smoking and other environm ental factors leads to localized hypoxic 
conditions. Such conditions trigger increased levels of xanthine oxidase, which catalyzes 
the conversion of hypoxanthine to xanthine to uric acid, and, ultimately, free radical 
generation. The free radicals subsequently would cause a proliferation of fibroblasts 
and deposition of collagen leading to tissue fibrosis and even lower local oxygen 
concentrations. The authors also speculated on a possible clinical/therapeutic role for 
allopurinol, which inhibits xanthine oxidase and thus prevents release of free radicals 
in the trea tm ent and prevention of D upuytren’s disease.99 However, the effect of 
allopurinol in Dupuytren’s contracture was later found to be not significant.100
While the free radical theory seems to offer a unified approach to the morphological 
and epidemiological findings in D upuytren’s tissue, little w ork has been done to push 
our understanding significantly forward.
D. Biochemistry
Extensive lite ra tu re  exists w ith respect to the biochem ical aspects of D upuytren’s 
disease, prim arily  on the com ponents of the extracellu lar m atrix  (ECM). The ECM is 
m ade of collagens, fibronectin, and proteoglycans, which form  a m atrix  to which 
cells attach by m eans of their surface receptors called integrins. The ECM is a dynamic 
structu re , constantly being broken down and rebuilt. While collagen expression 
(regulation) has been studied in m any fibrotic diseases including keloids, hypertrophic 
scar con tractu re ,101 and fibrous capsules around b reast im plants,102 the m echanism  
rem ains poorly understood.
An elevated level of to tal collagen in D upuytren’s tissue is considered  to be
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typical.729 103 104 In fact, it has been suggested tha t the collagen of D upuytren’s disease 
is rem iniscent of em bryonal or rep a ir tissue.103 The ratio  of different collagen types 
and their potential roles in diseased versus norm al tissue, however, has not been 
fully w orked out. For example, w hereas Brickley-Parsons et a l103 said tha t the ratio  
of type III versus type I collagen w as re la ted  to the degree of disease severity, 
G elberm an et al30 could not confirm these results. Two other stud ies104 105 showed 
tha t the there is increased expression of type III in clinically “norm al" fascia of 
patients w ith established D upuytren’s disease, suggesting the disease is w idespread 
throughout the fascia. M urrell et al106 107 dispute the causative role of the increased 
collagen III/I ra tio  in D upuytren’s d isease, citing the fact th a t in creased  cell 
proliferation leads to decreased  type I production, but the total of type III collagen 
produced per cell is unchanged, implying tha t “...nothing could be m ore norm al".
The only new information on collagen distribution in Dupuytren’s disease after these 
well-known papers from the early 1980’s are data on the expression of collagen VI, 
which is apparently  present in the proliferative phase, less so in the involutional 
phase, and absent in the residual phase of Dupuytren’s contracture.108 These authors 
suggest that type VI collagen functions as a tem porary scaffolding for the proliferating 
(myo)fibroblasts during the fibrotic process.
One of the o ther constituents of the ECM is fibronectin, an  adhesive glycoprotein 
tha t is p resen t in a soluble form in plasm a, but in an  insoluble form  in the ECM.109 
F ib ro n ectin  h as been  show n to play a ro le  in cell m ig ra tio n , adh esio n , cell 
m orphology and differentiation. D ifferent isoform s exist th a t a re  produced  by 
differential splicing of a single gene transcrip t. The specific roles for each isoform 
are unclear, but they have been shown to be expressed during developm ent and 
rep a ir,110 providing a m eans for the fibroblasts to connect to type I and III collagen. 
Total fibronectin (all isoforms) was shown to be upregulated  by TGF-b about 2-3 
fold in fibroblasts in vitro,109 mostly by increasing the ED-A isoform. The potent 
selective stim ulatory effect of TGF-b1 on in vitro  expression of fibronectin and its 
recep to r was also shown by Roberts et al111 in fetal hum an lung fibroblasts, and 
by Ignotz et a l112 in chick embryo fibroblasts. In D upuytren’s tissue, fibronectin 
ex p ress io n  h as  b een  d o cu m en ted  u sin g  in d ire c t im m u n o flu o rescen ce  w ith  
antibodies to total, ED-A, and ED-B fibronectin in proliferative and involutional 
areas (ED-A expressed m ore than  ED-B), and in residual tissue (only ED-A expressed, 
no ED-B). In norm al fascia there  w as very little -if any- to tal fibronectin, and no ED- 
A or ED-B.113 These findings w ere very sim ilar to o ther rep o rts .114115 The presence 
of an  em bryonic p a tte rn  of so-called oncofetal fibronectin (ED-A and ED-B) suggests 
the re la tio n  of D upuy tren ’s d isease to no rm al p rocesses such as healing  and
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granulation  w ith production of im m atu re  tissue.113114 More recently, double label in 
situ  hybridization show ed co-localization of mRNA for ED-B and a-SM actin in 
myofibroblasts in D upuytren’s tissue .116
The expression of the cellular receptor for fibronectin called a5b1 integrin and its 
ligand w ere  stud ied  in D u puy tren ’s d isease by M agro et a l117 using im m uno- 
histochem istry. They found th a t a5b1 in tegrin  show ed a sim ilar expression as 
fibronectin in strom al cells, being prom inent in the proliferative phase, decreasing 
in the involutional phase, and absent in the residual phase. The au thors suggest 
th a t the cells expressing a5b1 integrin a re  m yofibroblasts, thus serving as a link 
betw een the inside of the cell (a-SM actin) and the ECM.24 Thus, a5b1 integrin could 
play a role in the contractile forces generated  betw een the m yofibroblasts and the 
surrounding ECM. Studies tha t co-localize the presence of a5b1 integrin, fibronectin, 
and a-SM actin on the sam e cells would provide fu rther insight.
E. Immune system
The possibility th a t the im m une system  serves as an  underlying m echanism  of 
D upuytren’s disease has also been an  active a rea  of study. N eum uller118 studied 
the presence of HLA-DR3 in patients w ith D upuytren’s disease, and calculated an 
in c re ased  re la tiv e  risk  of 2.94 for people who ex p ress HLA-DR3 to develop 
D u p u y tren ’s d isease . T heir hypothesis is th a t au to -im m une m echan ism s a re  
underly ing  the d isease, although they adm it th a t the m ere  p resence of au to ­
antibodies to connective tissue com ponents does not necessarily imply a definite 
role in the developm ent of the disease. In the sam e paper they speculate on the 
activation of m ast cells by traum a, which in tu rn  would lead to re lease of cytokines. 
This would subsequently  lead to the fibrotic process by m eans of angiogenesis, 
fibroblast proliferation, and ECM production. Related findings w ere reported  by 
B aird  et a l119 who show ed in c re a sed  p re sen ce  of HLA-DR and  CD3-positive 
lym phocytes in D upuytren  tissue  as com pared  to no rm al p a lm ar fascia. The 
specim ens in this study w ere pooled, however, and it is unclear w hat percentage 
of the specim ens rep resen ted  proliferative, involutional or residual disease. This 
would have im plications for the am ount of blood vessels in the tissue, which could 
rep resen t the m ajority of the lymphocytes detected in the pooled specim ens ra th e r 
th an  the ex travasal inflam m atory cells. Unless presence of these lymphocytes is 
docum ented in the tissue itself, the im portance of these findings is unclear. The 
observations of N eum uller et a l118 and Andrew et a l32 suggest tha t the fairly low 
n u m b e r of m a c ro p h a g e s  in  D u p u y tre n ’s tis su e  c o n tra d ic ts  th e  su g g es ted
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im portance of inflam m atory cells in the pathogenesis of D upuytren’s disease.
O ther isolated  rep o rts  specu la te  on a link betw een  derm al dendrocytes and 
D upuy tren ’s d isease based  on im m unohistochem ical detection  of fac to r XIIIa 
(m arker for derm al dendrocytes) in D upuytren’s tissue,120 and presence of HLA- 
DR as well as CD68 positive cells, which have an  immunologic function, being of 
m acrophage lineage. The im portance of this finding is th a t m acrophages a re  
known to secrete cytokines including TGF-b and GM-CSF, which have a role in tissue 
fibrosis as discussed above.
Lastly, from  an  epidem iologic s tan d p o in t, the  re p o rte d  findings of a high 
prevalence of D upuytren’s contracture in the im m unocom prom ised HIV patients 
(36%)121 have been disputed by o thers.122
III. Discussion
Fibrotic disorders affecting organs such as kidney, lung, heart, and bone m arrow  
provide a m ajor cost to healthcare. W hereas fibrosis of the palm ar fascia known as 
Dupuytren’s disease is not a m ajor health  hazard, its pathogenesis is likely to be fairly 
sim ilar to these other fibrotic disorders. It has recently become clear that progressive 
fibrosis is a complex process involving a cascade of m olecular and cellular events, 
with TGF-b playing a pivotal role in the final com m on pathway.2 70
Although Dupuytren is not regarded  as an  inflam m atory disease, it seem s tha t in 
m ost re la ted  fibrotic diseases the presence of GM-CSF and m acrophages is related  
to the production of cytokines, including TGF-b. This results in chem otaxis, cell 
p ro life ra tio n , co llagen  p ro d u c tio n , m yofib rob last d iffe ren tia tio n  (a-SM ac tin  
induction), fibronectin  (receptor) production, and cell transfo rm ation .109112 The 
reported  co-localization of m yofibroblasts, grow th factors and fibronectin isoforms 
substan tia tes this theo ry .51115 Once this process is s ta rted , a positive feedback 
loop ensues, w ith autoinduction of TGF-b.76 Additionally, increased  fibrosis leads to 
local hypoxia, which is known to induce TGF-b in an  additional amplification step .77 
Other described m echanism s such as the production of free rad icals95'98 m ay well be 
p art of this complex m echanism .
Descriptive findings such as those on the absence or presence of m yofibroblasts, 
the type III/I collagen ratio, and epidemiologic data  such as the relation of race, 
smoking, diabetes, and epilepsy are  historically im portant, bu t will unlikely help 
us find the cause or a non-surgical cure for D upuytren’s contracture. The answ er
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will undoubtedly come from cell biological or m olecular biological advances. Each 
step is slowly being elucidated but m any questions still rem ain. W hat s ta rts  the 
cascade tha t leads to excessive fibroblast proliferation and ECM production sim ilar 
to w ound healing, and why does it not shu t itself off as a norm al rep a ir process? 
Is it sim ilar to o ther fibrotic diseases and are GM-CSF and TGF-b the key players? 
Can we m odulate  the m echan ism  of apoptosis of the m yofibroblast once the 
diagnosis of D upuytren’s disease is established? It seem s th a t investigation of 
GM-CSF expression in D upuytren’s tissue would be worthwhile.
Once all the steps of the cascade are elucidated on a cellular level, it will be interesting 
to see if this leads us back to the (historic) epidemiological data. Does Dupuytren’s 
contracture sta rt with local hypoxia, as seen in sm okers and diabetics123 124 or with 
repeated  m icrotraum a resulting in an  inflam m atory response with m acrophages and/ 
or platelets releasing specific fibrogenic cytokines, or is a genetic defect (apoptotic 
control) a t the core of the disease?
Although a num ber of im portant questions rem ain  unansw ered, w ork has begun 
to identify possible non-surgical trea tm ents for D upuytren’s and re la ted  diseases 
such as keloids, and hypertrophic scars based on the scientific evidence currently  
available. The m ost prevalent ideas for trea tm ent include alteration in the growth 
factor expression by local gene therapy, local application of growth factor antibodies, 
and blocking of receptor binding and/or post-receptor signaling. Experim ental studies 
attem pting to decrease scarring  and fibrosis have been targe ted  at m odulating the 
expression of TGF-b isoform s,72 for example, and prelim inary clinical reports are 
encouraging. Local application of antibodies to TGF-b resulted  in decreased scarring 
in an  experim ental derm al healing study in ra ts , and histological evaluation of those 
tissues revealed less m acrophages, blood vessels, lower collagen and fibronectin 
content.125 These findings are  in line with a la ter repo rt in which binding of TGF-b 
by decorin  p ro tec ted  ag a in st sca rrin g  in an  exp erim en ta l g lom eru lonephritis  
syndrom e w ithout detectable side-effects.68 Other trea tm en ts  could involve down- 
regula tion  of a-SM actin  expression w ith g-interferon, which has recently been 
shown in clinical studies of D upuytren’s d isease91 and keloids.89
At the end of his lecture in Hotel Dieu on the contraction of the palm ar fascia, 
Guillaume Dupuytren expressed the hope th a t “these hints m ay become useful to 
science and humanity, in m ultiplying observations on the cause, symptoms, and 
trea tm en t of this d isease".1 Now, m ore than  170 years later, although there is a 
m uch be tte r understand ing  of D upuytren’s contracture, surgical excision of the 
d iseased  fascia  rem a in s  the  b est tre a tm e n t available . A dvances in the basic 
sciences of the disease, however, will ultim ately provide us with be tte r options.
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Transforming Growth Factor-Beta (TGF-p) is a multipotent growth factor 
affecting developm ent, hom eostasis, and tissue repair. In addition, 
in c re a se d  ex p ressio n  of TGF-p h as  been  re p o rte d  in d iffe ren t 
malignancies, suggesting a role for this growth factor in tumorigenesis.
Using immunohistochemistry, the expression, prevalence and distri­
bution of TGF-p isoforms w ere evaluated in 25 high grade hum an 
osteosarcomas. The Cox proportional hazards models, and Kaplan-Meier 
curves w ere calculated correlating disease progression with TGF-p 
expression.
Expression of one or more TGF-p isoforms was found in all osteosarcomas. 
Immunoreactivity for TGF-b1 and -b3 was generally stronger than for 
TGF-b2. The cytoplasm of the tumor cells showed stronger staining than 
their surrounding extracellular stroma. Most notably, osteoclasts showed 
strong to intense staining for all three isoforms. In 11/25 specimens 
angiogenic activity was noted with staining of multiple small vessels in the 
tumor stroma. Expression of TGF-b3, but not of TGF-b2, or -b1 related to 
disease progression, such that there was a statistically significant decrease 
in disease-free interval as the immunoreactivity for TGF-b3 increased.
All osteosarcomas expressed TGF-p in the cytoplasm of the tumor cells 
as well as in their ex tracellu lar strom a. Presence of TGF-p in the 
endothelial and perivascular layers of small vessels in the tumor strom a 
suggests angiogenic activity of this growth factor. The expression of 
TGF-p3 was strongly correlated to disease progression (P=0.027). These 
data suggest that increased expression of TGF-p isoforms, especially TGF- 
p3 may play a role in osteosarcoma progression.
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Introduction
T ransform ing  grow th factor-p (TGF-p), originally  described  for its ability to 
transform  the phenotype of fibroblasts, is a m em ber of the large TGF-p superfam ily 
including TGF-P1-5, bone m orphogenetic proteins-2-8 (BMP2-8), inhibins, activins, 
and m ullerian  inhibiting substance (MIS).1 Of the 5 different TGF-p isoforms, only 
TGF-P1, -P2, and  -b3 a re  found in m am m alian  tissue . A lthough the  h ighest 
concentration of TGF-p is found in blood platelets, on a tissue-m ass basis, bone is 
the m ost abundan t source of these polypeptides.2 The different TGF-p isoforms share 
m any biological activities involved in norm al processes such as m orphogenesis and 
differentiation in em bryogenesis, tissue repair, and wound healing.134 In vitro  and 
in vivo  studies have shown tha t TGF-p1, -p2, and -p3 can regulate bone form ation 
by inducing osteoblast and osteoclast proliferation, extracellu llar m atrix  form ation, 
and bone-related protein production.56 The direct application of TGF-p to bone induced 
intram em braneous bone repair and repair of calvarial defects.7'9 The involvement of 
TGF-p in both osteogenic and chondrogenic bone formation occurs through its ability 
to recruit osteoblasts and osteoclasts to the injured areas and through its ability to 
stimulate the growth and the production of extracellular m atrix protein by these cells.59 
With its substan tial production and presence in bone and its known role in skeletal 
developm ent and rem odeling affecting both absorption (osteoclasts) and production 
(osteoblasts) of bone (at picom olar concentrations), a tight control m echanism  of 
TGF-p expression is needed .10
In addition to its ubiquitous presence in norm al tissues, increased expression of 
TGF-p has been reported  in m any different tum ors.11'26 Furtherm ore, increased  
expression of any one of the isoforms has been associated w ith progression and 
decreased survival.13 Because of the stim ulatory effect on the constituents of strom al 
tissue , ang iogenesis,2728 chem otaxis, and  en h an cem en t of cell m ig ra tion  and  
adhesion, TGF-p can provide tum or cells with a growth advantage. TGF-p also is an 
im m unosuppressan t29 and  its inhibiting effect on n a tu ra l k iller cells (NK) and 
lymphokine activated cytotoxic T cells (LAK) would resu lt in a decrease in immuno- 
surveillance and im m une cell-m ediated tum or destruction.
No inform ation is currently  available on the prevalence and distribution of TGF-p 
isoforms in hum an osteosarcom as, a m alignant bone tum or characterized by osteoid 
production of the tum or cells. It is the m ost common prim ary tum or of bone, affecting 
people in their second decade, m ales m ore often th an  fem ales. The etiology of 
osteosarcom a is still unknown, although m any suggestions have been m ade including
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m utations in supressor-genes (p53 and  re tinob lastom a (Rb)),30'32 and increased  
expression of growth factors including insulin-like growth factor (IGF),33 platelet- 
derived grow th factor,34 TGF-p35 and BMPs.36'38 Although significant im provem ents 
have been m ade in the survival ra tes of osteosarcom a patients using com binations 
of adjuvant chem otherapy, surgery, and rad iation  therapy, it is still im portan t to 
find m arkers identifying patients w ith a poor prognosis so th a t therapy  can be 
adjusted . The cu rren t study was u n d ertak en  to docum ent the p revalence and 
distribution of TGF-p1, -p2, and -p3 in high grade hum an osteosarcom a, seeking a 
possible correlation with disease progression.
Materials and Methods
Tissue specimens 
High grade, Stage 2B39 form alin fixed, paraffin em bedded appendicular skeleton 
p rim ary  classic osteosarcom as w ere selected  (n=25) from  the D epartm ents of 
Pathology at the M assachusetts General Hospital, Boston, and Children’s Hospital, 
Boston. Rather than  studying tum ors of different grade and/or stage this study focused 
on high grade Stage 2B lesions since this subgroup would benefit from a potential 
additional prognostic m ark e r such as TGF-p, th a t would identify those tum ors with 
a worse outcome. Specimens w ere decalcified p rior to paraffin embedding. Informed 
consent w as obtained  reg ard in g  the use of tissue for re sea rc h  purposes. The 
m ale:fem ale ratio  was 16:9, w ith ages ranging from 9-68 years. The m ean  and 
s tandard  deviation for age w as 33±22 for fem ales and 25±16 for m ales. Based on 
availability of the paraffin-blocks, specim ens w ere taken  from biopsies (n=21) or 
resections prior to chem otherapy (n=4). Prim ary tum ors w ere located at the following 
sites: proxim al hum erus (n=2), distal hum erus (n=1), proxim al fem ur (n=2), distal 
fem ur (n=17), proxim al tibia (n=1), distal tibia (n=1), and distal fibula (n=1). The 
specim ens w ere classified based on their histology as osteoblastic, chondroblastic, 
fibroblastic, teleangiectatic, giant cell, or mixed osteosarcom a (see Table 1 for patient 
data). All patients w ere trea ted  w ith adjuvant chem otherapy. For patients age <30 
years this com prised of a Pediatric Oncology Group protocol of doxorubicin, cis- 
platin, bleomycin, cyclophosphamide, actinomycin D, and m ethotrexate. Patients 
age >30 years recieved an  individualized protocol using sim ilar drugs at a lower 
concentration.
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Immunohistochemistry 
Sections of 4 pm were cut and transferred to silanized (3-aminopropyltrie-thoxysilane; 
Sigm a, St. Louis, MO) F isher-P lus slides (F ish er Scientific, F a ir Law n, NJ). 
Immunostaining was perform ed as described previously.4 Briefly, the slides were baked 
overnight a t 58 °C, and the tissue was deparaffinized in xylene, hydrated in sequential 
gradients of ethanol, and washed with 0.3% (v/v) Triton-X-100/tris-buffered saline 
(TBS) for 15 minutes at room tem perature (RT). Endogenous peroxidase was quenched 
w ith  0.6% hydrogenperoxide in m ethano l (v/v) for 45 m inutes, and  the slides 
subsequently  w ere trea ted  with hyaluronidase (1mg/ml in 100 mM sodium  acetate- 
0.85% NaCl [pH 5.5], Sigma) at 37°C. The slides w ere then  w ashed with TBS-0.1% 
bovine se rum album in (BSA) and blocked w ith goat serum  im m unoglobulin (Ig)G 
at 1 pg/ml in TBS-1.0% BSA for 20 m inutes at RT on a rocker platform . The tissue 
sections w ere then  incubated  overnight w ith antibodies to TGF-p1, TGF-p2, and 
TGF-p3 at a concentration of 1.0 pg/ml, at 4°C, in humido. The antibodies w ere 
raised  to synthetic peptides of each TGF-p isoform and the IgG w as peptide affinity 
purified. The preparation , characterization, and isoform specificity of the antibodies, 
by W estern blot analyses, are all described elsew here.4 These antibodies have been 
shown to be specific for each isoform of TGF-p and are  non cross-reacting. The 
antibody concentration used previously w as optimized using dilutions ranging form 
0-5 pg/ml. Non-immune rabb it IgG (Immunon, Pittsburgh, PA) at the sam e concen­
tration  as the TGF-p antibodies was used as a control to show antibody specificity. 
After incubation w ith the antibodies, the slides w ere w ashed extensively w ith TBS-
0.l% BSA, and biotinylated goat an tirabbit secondary antibody (Vectastain ELITE 
ABC Kit; Vector Laboratories, Inc., Burlingam e, CA) was applied to slides for 1 hour 
a t RT, followed by w ashing with TBS-0.1% BSA, and then  incubation with avidin- 
biotin complex for 1 hour at RT. To develop the color reaction, 0.05% 3,3'-diam ino- 
benzidine (DAB, Sigma) in 0.01% hydrogenperoxide and 0.05 M Tris w as added to 
the slides for 3 m inutes at RT. Finally, the slides w ere counterstained for 5 m inutes 
in Gill’s #2 hematoxylin (Fisher Scientific), and 10 seconds in 0.6% Lithium Carbonate 
(Fisher Scientific, Fair Lawn, NJ), the tissue was dehydrated  in graded ethanol and 
the slides w ere m ounted using Perm ount (Fisher Scientific). Staining w as evaluated 
by th ree investigators tha t w ere blinded to disease progression. Staining was graded 
on a scale of 0-4+, with 0 represen ting  no staining, and 4+ represen ting  intense 
staining. Increased staining at the edges of the tissue was considered artefact and 
disregarded during evaluation.
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Statistical evaluation 
Follow-up on the patients w as obtained through their office charts. Data in the 
statistical evaluation included the disease free interval, w hich rep resen ted  time 
from first surgery  to first evidence of m etastasis or recurrence if observed; otherw ise 
it rep resen ted  the time from the first surgery  to the end of the study. Overall survival 
was calculated as the time from  the first surgery  to the time of death. For statistical 
analysis im m unoreactivity w as divided in two groups: low im m unoreactivity (1+/2+) 
and high im m unoreactivity (3+/4+) for each TGF-p isoform. The data w ere analyzed 
using Cox proportional hazards models and Kaplan-M eier curves40 to determ ine if 
immunoreactivity for TGF-p isoforms was significantly related  to disease progression.
Results
Immunoreactivity for TGF-p isoforms in osteosarcomas 
Expression of one or m ore TGF-p isoforms was found in all the Stage 2B classic 
osteosarcom as studied (Table 1) (Fig. 1A and 1B). (One sm all cell osteosarcom a 
specim en did not im m unostain for any TGF-p isoform; this tum or was not included 
in our analysis). Absence of im m unostaining of the classic osteosarcom as using 
nonim m une rabbit IgG indicated th a t the results obtained w ere specific (Fig. 1D). 
Im m unoreactivity for TGF-p1 and -p3 generally was stronger th an  for TGF-p2. 
Minimal to m oderate staining for TGF-p1 was observed in 14 of 25 tum ors (56%), 
for TGF-P2 in 17 of 22 (77%), and for TGF-p3 in 11 of 25 (44%). Strong to intense 
im m unoreactivity was observed in 11 of 25 (44%), 5 of 22 (23%), and 14 of 25 (56%) 
for TGF-p1, -p2, and -p3 respectively.
TGF-p isoforms w ere not p resent in m ineralized bone of osteosarcom as. Uninvolved 
bone in the resected specimens also had absence of staining of m ineralized matrix. In 
general the osteocytes em bedded in the inner areas of the trabuculae in osteosarcom a 
bone w ere negative for TGF-p. Normal unm ineralized bone m atrix  showed little or no 
staining, w hereas newly form ed unm ineralized pathologic bone showed light to 
m oderate staining. The cytoplasm of the osteosarcom a cells generally showed stronger 
staining for TGF-p com pared to the surrounding extracellular strom a. Most notably, 
th e  tu m o r osteocy tes em b ed d ed  in  w oven tu m o r bone w ere  m ore stro n g ly  
immunoreactive for all TGF-p isoforms compared to the osteocytes embedded in norm al 
lam ellar bone. The cytoplasmic expression of TGF-p in occasional chondrocytes 
observed in either pathologic fracture callus or in growth plate was inconsistent, with 
im munostaining ranging from m inim al to m oderate. Actively resorbing osteoclasts,
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which were observed mainly at the outer edges of pathologic bone and in lesser quantity 
in norm al m ineralized bone, showed strong to intense staining for all three isoforms. 
In nearly 50% of the tum ors (11 of 25) angiogenic activity was noted by the presence 
of multiple small vessels in and around tum or strom a. The endothelial cells and 
perivascular m uscle cells of these vessels stained for all TGF-p isoforms, although 
immunoreactivity was m ore intense for TGF-p1 and -p3 than  for TGF-P2 (Fig. 1C). 
Although vessels in norm al strom a showed a sim ilar staining pattern , there were 
significantly fewer vessels p resent in the norm al tissue as com pared to tum or strom a. 
Grading of all specim ens w as found to be consistent and reproducible betw een 
observers and betw een observations.
Intense immunoreactivity for TGF-p3 is related to disease progression
For statistical calculation, the specim ens w ere divided into 2 groups: those with 
low (1+ to 2+), and those w ith high (3+ to 4+) immunoreactivity. We then  analyzed 
the relationship of TGF-p im m unostaining to disease progression separately  for each 
isoform. First we included the different variables given each TGF-p isoform. We 
found th a t age (p=0.35), gender (p=0.20), tum or site (p>0.2), histology (p>0.05), and 
surgery  (limb salvage vs. am putation) (p>0.1) a re  not statistically significant re la ted  
to disease progression. In teraction effects w ere considered, but found to be not 
significant.
Next, Cox proportional hazards m odels w ere fitted w ith each TGF-p isoform, 
adjusting for age and gender differences betw een the groups w ith low and high 
TGF-p immunoreactivity. Table 2 shows the Cox proportional hazards models that 
best explain the relationships betw een TGF-p isoforms and disease progression. 
The levels of TGF-p1 and -p2 im munostaining w ere not related  significantly to disease 
progression (p=0.75 and p=0.15, respectively). In contrast, im m unoreactivity for 
TGF-p3 w as re la ted  to disease progression, given th a t there  w as a statistically 
significant decrease in the disease free period as staining increased from low to 
high (P=0.027) (Table 2). The h azard  ratio  calculated for patients in this study with 
high levels of TGF-p3 shows th a t they w ere 5.07 times m ore likely to have disease 
progression than  those with low levels of TGF-p3, and th a t this risk for fem ales was 
5.26 times tha t for m ales (Table 2). Kaplan-M eier disease free survival curves plotted 
separately  for m ales and females indicate a relationship betw een TGF-p3 and gender 
(data not shown), but this in teraction is not significant (p=0.182). Kaplan-M eier 
disease free survival curves w ere also plotted versus the level of each TGF-p isoform 
in the tumor. High levels of TGF-p3 correlate with disease progression (Fig. 2C) 
(p=0.027). Although a sim ilar trend  was observed for TGF-p1 (Fig. 2A), this w as not
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Table 1
Patient Data
Patient
no. Gender
Age
(yrs) Site Histology Surgery
Métastasés (at 
recurrence)
TGF-ß 1 
staining
TGF-/32
staining
TGF-/33
staining
Disease free
interval
(mos) Status
1 F 31 PH Ost LS • 3+ 3+ 2+ 20 Alive
2 M 21 PFe Ost LS 1 + 2+ 2+ 12 Alive
3 M 16 DH Ost LS L 2+ 2+ 1+ 22 DOD
4 M 17 DFe Ost LS L 2+ 1+ 3+ 21 DOD
5 M 48 DFe Ost LS L/B 2+ NA 3+ 4 DOD
6 F 61 DFe Ost LS L 2+ 1+ 2+ 11 DOD
7 F 9 DFe Ost LS L 3+ 2+ 3+ 7 Alive
8 M 21 DFe Ost LS 3+ 3+ 2+ 48 Alive
9 M 10 PH Ost LS L 3+ 2+ 3+ 8 DOD
10 F 56 DFe Ost Amp L 1+ 2+ 1+ 45 Alive
11 M 14 DFe Ost LS L/B 3+ 2+ 3+ 23 Alive
12 F 12 DFe Ost Amp L/A 4+ 4+ 3+ 9 DOD
13 F 20 DFe Ost LS L 3+ 2+ 3+ 13 DOD
14 M 12 DT Ost Amp 2+ NA 3+ 37 Alive
15 M 30 DFi M LS 2+ 2+ 1+ 66 Alive
16 F 25 DFe M LS L 1+ . 2+ 3+ 3 DOD
17 M 10 DFe Chon LS 4+ 3+ 3+ 49 Alive
18 M 37 DFe Fibr LS L 2+ 4+ 3+ 32 DOD
19 F 19 DFe Fibr LS 2+ 1+ 2+ 17 Alive
20 M 14 PT Fibr LS L 3+ 2+ 3+ 32 Alive
21 M 68 DFe Fibr LS 2+ 2+ 3+ 60 Alive
22 F 65 DFe Fibr LS 2+ 2+ 2+ 59 Alive
23 M 31 DFe GC LS L 4+ NA 4+ 14 Alive
24 M 31 DFe Tel LS 1+ 1+ 2+ 87 Alive
25 M 21 PFe Tel LS L/B 3+ 2+ 2+ 33 Alive
TGF: transforming growth factor; F: female; M: male; P: proximal; D: distal; H: humerus; Fe: femur; T; tibia; Fi: fibula; Ost: osteoblastic; M: mixed; Chon: chondroblastic; Fibr: fibroblastic; GC: giant cell; Tel: 
teleangiectatic; LS: limb salvage; Amp: amputation; L: lung; B: bone; A: abdomen; NA: not available; DOD: dead of disease.
statistically significant (p=0.75) (Table 2). No correlation was seen betw een the 
expression of TGF-p2 and disease progression (p=0.15) (Fig. 2B) (Table 2).
When we analyzed the effects of TGF-p isoforms on survival (time from first surgery 
to death), using Cox proportional hazards models, neither TGF-p1 (p=0.43) nor TGF-p2 
(p=0.86) w ere significantly re la ted  to survival. For TGF-p3, we only considered 
patients with recu rren t or m etastatic disease w hen evaluating survival, given the 
re la tionship  betw een this isoform  and disease progression  (Table 2) (Fig. 2C).
Figure 1: Immunohistochemical localization of transforming growth factor-ß (TGF-ß) 
in osteosarcoma. Immunoreactivity is represented by a brown color developed by avidin- 
bio tin  com plex and  3 ,3 ’d iam inobenzid ine (V ectastain ELITE ABC Kit, Vector 
L aboratories, Burlingam e, CA). A) TGF-ß3 im m unoreactivity  in an osteoblastic 
osteosarcoma (Patient 9). There is strong staining (3+) in tumor cells, with light (1+) to 
moderate staining (2+) in tum or strom a and an absence of staining in mineralized 
tumor m atrix (x100). B) anti-TGF-ß3 immunoreactivity in a fibroblastic osteosarcoma 
(Patient 18). There is strong staining (3+) in tum or cells and m oderate staining (2+) in 
tumor stroma (x100). C) Immunohistochemical staining for TGF-ß2 in endothelial and 
perivascular smooth m usculature of multiple small vessels in tumor stroma (Patient 4) 
(x80). D) Control, non-immune rabbit immunoglobulin G. Osteoblastic osteosarcoma 
(Patient 3). There is an absence of staining indicating that the results are specific (x100). 
The individual photographs may not always correctly represent the m ean immuno- 
reactivity intensities represented in Table 1.
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Table 2
Multivariate Cox Proportional Hazards Model on Disease Free Time3
Variable
Hazard
ratio P value 95% Cl
Male 0.27 0.052 (0.07, 1.01)
Age 0.97 0.189 (0.93, 1.01)
High TGF-01 1.23 0.745 (0.36, 4.19)
Male 0.11 0.008 (0.02, 0.56)
Age 0.93 0.006 (0.89, 0.98)
High TGF-/32 0.3 0.145 (0.06, 1.51)
Male 0.19 0.013 (0.05, 0.70)
Age 0.99 0.411 (0.96, 1.02)
High TGF-/33 5.07 0.027 (1.20, 21.4)
95% Cl: 95% confidence interval; TGF: transforming growth factor.
a Cox proportional hazards model that best explains the relationships for each transforming growth 
factor-/? isoform and disease-free time.
According to the analysis, the level of TGF-P3 staining w as not significantly re la ted  
to patien t survival (p=0.39), although it is noted th a t these resu lts m ay be due to 
the sm all sam ple size (n=15). The findings imply th a t low im m unoreactivity  for 
TGF-P3 indicates longer d isease free survival, but does not necessarily  correlate  
w ith survival time.
Figure 2: Kaplan-Meier plots of the disease free time in patients with high grade 
osteosarcoma that had low versus high expression of A) transforming growth factor 
(TGF)-ß! (n=25); B) TGF-B2 (n=23); or C) TGF-B3 (n=25).
Discussion
TGF-b has m ultiple roles in norm al processes such as developm ent, grow th, 
differentiation, and tissue repair with complex effects on almost all cell types.1 Effects 
of TGF-b on cellular proliferation are characteristically  inhibitory for epithelium - 
derived cells, and stim ulatory for m esenchym e-derived cells. Although no significant
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qualitative or quantitative differences have been identified betw een the th ree TGF- 
p isoforms regarding their effects on the skeletal system, their differential expression 
during m ouse em bryogenesis and developm ent suggest th a t they each have specific 
ro les.34 Previous im m unohistochem ical studies have shown th a t TGF-p2, and TGF- 
p3 generally w ere expressed in transitional chondrocytes, w hereas TGF-pi was 
expressed m ore highly in osteogenesis a reas.3 4 41 In vivo studies showed that injection 
of TGF -p i in the subperiosteal region of ra t  fem urs resu lted  in a stim ulation of new 
bone form ation resem bling embryologic bone form ation and fractu re repair.9
The biological activities of TGF-p th a t enable norm al grow th control, repa ir and 
hom eostasis, such as both stim ulatory and inhibitory effects on cell proliferation, 
angiogenesis, cell m igration, chem otaxis, and cell adhesion, m ay becom e dys­
regulated  leading to tum origenesis.12742 This could be the resu lt of changes in the 
expression of one or m ore of its isoform s and/or its recep to rs or postrecep to r 
pathw ays. These observations, in addition to the im m unosuppressive activity,29 and 
the auto-inductive43 and cross-regulatory capacity of TGF-p isoforms have led to the 
evaluation and subsequent implication of TGF-p in the developm ent and progression 
of different tu m ors.11'26 For example, using transfection studies resulting in increased 
expression of active TGF-pi in fibrosarcom a cells in vivo, it was shown that increased 
T G F-pi sy n th es is  p ro v id es  a s ig n ifican t ad v a n ta g e  for tu m o r fo rm a tio n .44 
F u rth erm o re , the d ifferent TGF-p isoform s have been  co rre la ted  w ith  disease 
progression and decreased patien t survival in various neoplasm s (Table 3). The 
seemingly paradoxic increased  expression of TGF-p in epithelium -derived tum ors 
(because TGF-p inhibits epithelial cell proliferation) can be explained by the loss of 
inhibitory control in addition to paracrine effects on strom a production, angiogenesis, 
and im m unosupression. Less is known regard ing  autocrine loops involving TGF-p 
in m esenchym e-derived tum ors, in which the increased  TGF-p could theoretically 
stim ulate cell proliferation. An im m unohistochem ical study by McCune et al.19 on 
the expression of TGF-p in sm all round cell tum ors affecting the skeletal system  in 
children reported  th a t in both Ewing’s sarcom as and the (m esenchymally derived) 
rhabdom yosarcom as there w as increased  im m unostaining for TGF-pi and TGF-p3, 
but no staining for TGF-p2. In contrast to these findings we found w eak to m oderate 
staining for TGF-pi in 9 of 9, light to m oderate staining for TGF-p2 in 6 of 9, and 
m o d era te  to s tro n g  im m unoreac tiv ity  for TGF-p3 in 9 of 9 Ewing sa rco m as 
(unpublished data). Because TGF-p2 is m ost highly associated with bone and has a 
h igher specific activity for bone induction,5 one would expect to find TGF-p2 in 
bone. However, the different antibodies used in these studies could be re la ted  to the 
d ifferen t resu lts. Recently, two stud ies rep o rted  on the im m unohistochem ical
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Table 3: Expression of TGF-p isoforms in cancers related to disease progression“
Pancreatic carcinom a12
Predominantly autocrine mode of action 
TGF-p2 associated with advanced tumor stage
Lack of expression of all TGF-p isoforms correlates with increased survival
Colon carcinom a
Intense immunoreactivity for TGF-pi correlates with progression
Endom etrial carcinom a
Switch from paracrine/autocirne to predominantly paracrine mechanism of action 
Glandular cells lost ability to respond to stromal cells 
TGF-pi and TGF-p2 expression is associated with malignancy
Breast carcinoma
Intense immunoreactivity for TGF-pi correlates with progression
Gliomas (unpublished data)
Predominantly autocrine mode of action 
TGF-pi as a m arker for carcinogenesis
High expression correlates with short term survival in glioblastoma 
Osteosarcomas’1
Intense immunoreactivity for TGF-p3 correlates with progression
TGF-p: transforming growth factor-p. “Modified form Gold LI, Korc M. Expression of 
transforming growth factor-pi, 2 and 3 mRNA and protein in human cancers. Dig Surgery 
1994;11:150-6. bCurrent study.
localization of TGF-p in the m esenchym ally-derived Kaposi sarcom as.1126
We previously showed tha t all prerequisites for an autocrine loop involving TGF-p 
(presence of TGF-p receptors, production of active and laten t TGF-p, effect on DNA 
synthesis by adding exogenous TGF-p, and obviating effect of TGF-p by antibodies 
to TGF-p) a re  p resen t in vitro  in hum an osteosarcom a cell lines.35 These findings 
are  supported  by the cu rren t study, in which it was shown tha t hum an osteosarcom a 
tissue expresses TGF-p. In general there was higher expression of TGF-pi and -p3 
than  TGF-p2 in the osteosarcom a cells and their surrounding strom a. The absence 
of TGF-p in m ineralized bone has also been noted in another im m unohistochem ical 
study.41 It is possible th a t once TGF-p becomes em bedded in the calcified m atrix  the 
antibody is unable to bind the protein. The fact th a t bone is an  abundan t source of 
TGF-p supports this. Alternatively, TGF-p m ay not be p resen t in ossified bone. It is 
interesting to note th a t although TGF-p has been shown to stim ulate extracellu lar 
m atrix  production, it inhibits m atrix  m ineralization for reasons th a t currently  are 
unclear.10 Areas of active rem odeling and/or tum or invasion showed high expression
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of TGF-p in the local osteoclasts. The presence of TGF-p in the osteoclasts m ay be 
due to autocrine production by the osteoclasts, or to the binding of TGF-p stored in 
the m atrix. Because TGF-p is secreted  as a la ten t molecule, the regulation of TGF-p 
activity is dependent on w hether it is locally activated. Although the antibody used 
in these studies cannot differentiate active from laten t TGF-p, it is likely th a t a t least 
p art of the TGF-p re leased  by solubilization of the m atrix  becom es activated by the 
acidic pH and lysosome-like m icroenvironm ent, below the ruffled bo rder of the 
osteoclast.45 A num ber of m echanism s can be responsible for the increase of TGF-p 
in the tum orous bone and osteosarcom a cells, including increased production by 
the osteosarcom a cells induced by an  unknow n factor, re lease of bound TGF-p by 
solubilization of the m ineralized bone and tum or m atrix  by osteoclasts and tum or 
cells, and/or uptake from the bloodstream . The last explanation is unlikely, because 
of the th ree isoforms only TGF-pi is detectable at physiologically significant levels 
in hum an plasm a.46 It is known th a t osteoblast and osteosarcom a cells have high 
affinity receptors for TGF-p,6 and th a t they proliferate and produce extracellu lar 
m atrix  proteins in response to TGF-p at levels as low as 0 .i  ng/m l.59 Thus, w hether 
the increased presence of TGF-p results from increased autocrine production of 
TGF-p by the osteosarcom a cells or from release of stored  TGF-p from the m atrix , a 
significant effect on the osteosarcom a cells and the norm al osteoblasts can be 
expected. Moreover, TGF-p isoforms are auto-inductive and cross-inductive,43 adding 
an  endogenous amplification loop. The angiogenic activity of TGF-p has been well 
docum ented.2728 The presence of m ultiple sm all vessels th a t w ere im m unoreactive 
for the different TGF-p isoforms in both the endothelial and perivascular layers 
suggest th a t this growth factor also m ay have angiogenic activity in osteosarcom as 
fu rther prom oting the growth of these tum ors.
Currently, the expression and distribution of TGF-p in hum an osteosarcom a tissue 
has not been reported . Two groups have exam ined expression of certain  growth 
factors in hum an osteosarcom as: BMP-2 and BMP-4, which are  m em bers of the 
TGF-p superfamily, w ere found to be expressed in a subset of hum an osteosarcom as, 
w ith correlation to histologic subtype, and poor clinical outcom e and response to 
chem otherapy.36'38 More recently, increased  expression of IG F-i, IGF-2 and IGF- 
receptors was found in hum an osteosarcom as, but not in a non-osseous norm al cell 
lin e .33 The m ost im p o rtan t p rognostic  v a riab le  in high g rad e  n o n m etas ta tic  
conventional osteosarcom a was reported  to be tum or necrosis following neo-adjuvant 
chem otherapy.47 W hereas m utations in tum or supressor genes such as p53 and Rb 
have been shown to be involved in carcinogenesis, p53 m utations have not yet proven 
to be of prognostic value in osteosarcom a patien ts.31 However, loss of heterozygosity
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of the Rb gene appeared to be an  early predictive feature of osteosarcom a,30 although 
no information regarding the grade of the tum or was given. Of recent significance, 
elevated expression of P-glycoprotein, a m em brane bound channel im portant for drug 
binding and tran sp o rt out of the cell, has been show n to be re la ted  to disease 
progression.48
This study presented  data on the expression, prevalence, and distribution of TGF-p 
isoforms in hum an osteosarcom as. Significant levels of TGF-p isoforms are present in 
this neoplasm, suggesting an  autocrine/paracrine role for this protein in malignancy. 
Expression of TGF-p3 was shown to be related  to disease progression, and therefore 
could be used as a possible (prognostic outcome) m arker to subclassify high grade 
osteosarcom as. W hether the increased expression of this m ultipotential growth factor 
is the cause or m erely the result of increased cellular proliferation is unclear from 
this study. Most likely it is p a rt of a complex m ultistep process involving alterations in 
the response to TGF-p at different levels of tum origenesis and progression.
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Cell Type Specific Modulation of Hox 
Gene Expression by Members of the 
TGF-p Superfamily: A Comparison 
between Human Osteosarcoma and 
Neuroblastoma Cell Lines
Peter Kloen1, M arleen H.P.W.Visker2, Wiebe Olijve2, E verardus J. J. van Zoelen34, 
Christine J.C. Boersm a2.
D epartm ent of Orthopaedic Surgery1, M assachusetts General Hospital, and H arvard 
Medical School, Boston, MA, USA, and D epartm ents of Applied Biology2 and Cell 
Biology3, University of Nijmegen, Toernooiveld, Nijmegen, The N etherlands.
B iochem ical an d  B iophysica l R esearch Com m unications 233:365-369 , 1997.
Homeobox gene expression in osteoblast-like cells was investigated using the 
polymerase chain reaction (PCR). A total of 13 homeobox genes was detected in U-2 OS 
(hum an osteosarcom a) and MC3T3-E1 (mouse osteoblast) cells by sequencing cloned 
PCR products. Using specific prim ers, a different p a tte rn  of Hox gene expression 
was shown for the neuroblastom a cell line SK-N-SH relative to U-2 OS and MC3T3- 
E1. Additionally, we showed th a t expression of HOXC6 in U-2 OS and SK-N-SH was 
differentially regulated by rhBMP-2, TGF-pi and activin-A. This suggests tha t specific 
Hox genes m ay be targe t genes for TGF-p superfam ily m em bers, and allows us to 
fu rther understand  the complex functions of these growth factors and how they 
re la te  to growth and development.
Modulation of Hox gene expression by TGF-p superfamily m em bers
The v erteb rate  Hox genes encode a closely re la ted  subset of hom eobox containing 
transcrip tion  factors, consisting of at least 38 m em bers tha t a re  conserved over 
m any species. The hom eobox of these transcrip tion  factors encodes for a 61 amino 
acid hom eodom ain th a t binds specifically to DNA. M am m alian Hox genes are  
physically  linked  in  fou r ch ro m o so m al c lu s te rs  (Hox loci A-D), lo ca ted  on 
chrom osom es 2, 7, 12, and 17 respectively (1, 2). Their position along the 5'-3 ' 
transcrip tional axis is re la ted  to their location along the an teroposterior axis of the 
embryo (3), as well as to their appearance in time (4) (spatiotem poral colinearity 
(5)). The transcrip tional regulation of hom eobox genes is complex and still poorly 
understood, although it is clear tha t m any factors a re  involved. Hox genes have 
been shown to be responsive to retinoic acid (RA) (4) and basic fibroblast growth 
factor (bFGF) (6). M embers of the transform ing growth factor-p (TGF-p) superfamily, 
such as bone m orphogenetic proteins (BMPs), activins, and TGF-p, are also possible 
regu la to rs  of hom eobox genes, given th e ir pivotal roles in norm al grow th and 
developm ent. The Drosophila homologue of BMP-2 and BMP-4, decapentaplegic 
protein (DPP), enhances the expression of the homeobox gene labial (7) and ectopic 
expression of DPP alters the expression of various homeobox genes both at ectopic 
and adjacent sites (8). A close correlation has been shown betw een expression of 
BMP-2 and particu lar Hox genes in the developing limb (9). In addition, several Hox 
genes a re  expressed during BMP-induced ectopic bone form ation (10). Based on 
these studies we hypothesized tha t homeobox gene expression in cells representative 
of the skeletal system  is regulated  by TGF-p superfam ily m em bers.
We initially investigated the expression of Hox genes in osteoblast-like cells using 
the polym erase chain reaction (PCR), based on a strategy described by M urtha et al. 
(11). Osteoblast-like cell lines used w ere the hum an osteosarcom a cell line (U-2 OS) 
and  the m ouse osteob last cell line MC3T3-E1 (12). Next, we studied  w he ther 
expression is m odulated by 3 m em bers of the TGF-p superfam ily (BMP-2, TGF-p1, 
and activin-A) in U-2 OS. To study w hether expression and regulation of Hox genes 
was cell type-specific, Hox gene expression and effects of BMP-2 and TGF-p on Hox 
gene expression w ere also studied in the hum an neuroblastom a cell line SK-N-SH.
Material and methods
Cell lines and growth factors
U-2 OS, a hum an osteosarcom a cell line, and SK-N-SH, a hum an neuroblastom a 
cell line (both from American Type Culture Collection), w ere subcultured in Dulbecco’s
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M odified Eagle M edium  (DMEM) contain ing  penicillin  (50 IU/ml), strep tom ycin  
(50 pg/ml), and 10% new born calf serum  (NCS). The m ouse osteoblast cell line 
MC3T3-E1 (12) w as grow n in «.-minim al essen tial m edium  (aMEM) containing 
penicillin (50 IU/ml), streptom ycin (50 pg/ml), and 10% fetal calf serum  (FCS). 
Recom binant bone m orphogenetic protein-2 (rhBMP-2) w as a generous gift from 
the Genetics Institute (Cambridge, MA, USA). Hum an TGF-p1 was purchased  from 
R&D Systems (UK), and hum an activin-A was a generous gift from D. Huylebroeck, 
Celgen, University of Leuven, Belgium.
Cells w ere growth arrested  at near-confluence by incubation with serum -free DMEM 
(U-2 OS), aMEM (MC3T3-E1) or DMEM with 1% NCS (SK-N-SH) for 72 h, after which 
growth factors w ere added: rhBMP-2 (50 ng/ml), TGF-p1 (2.5 ng/ml), and activin-A 
(25 ng/ml). After 24 h (U-2 OS) and after 48 h (U-2 OS, and SK-N-SH), cells w ere 
w ashed with phosphate-buffered saline (PBS) and stored as a pellet a t -80°C until 
mRNA isolation.
mRNA-isolation and RT-PCR
mRNA isolation and RT-PCR w ere perform ed as previously described (13) with 
m inor modifications. mRNA was extracted using the Micro-Fast Track mRNA isolation 
kit (Invitrogen Corp., San Diego, CA). For each sam ple approxim ately 15 ng mRNA 
was reverse transcribed  using 50 pM of oligo(dT) prim er and 200 units SuperScript- 
II (Gibco-BRL) in a total volume of 30 pl.
Thereafter, 2 pl of the reaction  volume w as amplified by PCR using 0.5 pM of each 
sense and  an ti-sense  prim er, 150 pM dNTPs, 1.5 mM MgCl2 and one unit Taq 
polym erase (Gibco-BRL) in a to tal volume of 20 pl. PCR m ixtures w ere tran sferred  
directly from ice to 95°C for 10 seconds, followed by a specific num ber of amplification 
cycles consisting of 95°C (10 seconds), annealing tem peratu re  (see Table I) for 30 
seconds, 72°C (1 minute), and a final extension step at 72°C for 7 m inutes (Perkin- 
Elm er Geneamp PCR system  2400). The num ber of cycles w as either sa tu ra ting  (45 
cycles) or limiting (see sem iquantitative RT-PCR).
Degenerate PCR prim ers were designed using the sequence of the conserved region 
of the homeobox domain, amplifying the repertoire of homeobox genes expressed in 
the cells. The prim er sequences are: CA(A/G) (A/G)T(C/G) AA(A/G) (A/G)T(C/T) TGG TT(C/ 
T) CA(A/G), and (A/G) (A/C) (A/C/G) (C/T)T(A/G) GA(A/G)(C/T)TG GA(A/G) AA(A/G) G 
respectively. The expected PCR product was 115 basepairs and was amplified during a 
45 cycle PCR with an  annealing tem peratu re  of 51°C. Products w ere visualized on 
2% agarose gels after staining w ith ethidium  brom ide (0.5 pg/ml).
PCR products w ere directly cloned (PGEM-T-vector, Promega), and their sequences
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Table 1: Primer sequences designed for the present study, based on sequences that 
have been published in the EMBL database for m urine and hum an Hox genes.
Prim ers to: 5'-3' sequence annealing temp.
HoxA1 -F GGG AAA GTT GGA GAG TAC GGC 60°C
-R CCT CAG TGG GAG GTA GTC AG
HoxA7 -F GCC GGA CAA CAA ATC ACA GG1 60°C
-R GCC TGG CCC TTT ACT CCT1
HoxA9 -F CCA ATA ACC CGG CTG CCA ACT G1 60°C
-R TCA CTC GTC TTT TGC TC(T/G) GTC C1
HoxB9 -F TGC GAG CGC GCG GAT AAT G1 57°C
-R CTT TAC TCT TTG CCC TGC TCC
HoxC6 -F CTT TTA CCA GGA GAA AGA CAT G 60°C
-R CAA GGG CAG TCC TGG TCA C
HoxC8 -F ACA AAC TTA CAG CCG GTA TC1 55°C
-R CCT TAG TCC TTA TTT TCT TCC1
HoxC9 -F GTT ACG ATG TCG GCG ACG GG 60°C
-R GTG TCG GCG CCG AGG TGG G
Gbx1 -F GCC CTC AAG CTC AGT GAG G2 57°C
-R GGG TGC CCA TTC AGG GCC2
PBGD -F TGT GGT AAC GGC AAT GCG G3 60°C
-R CCA GGG CAT GTT CAA GCT CC3
Accession numbers are: M20215, M15927, X06024 (hoxa-1); U104231 (HOXA1); M17192 
(hoxa-7); M28449, M36677 (hoxa-9); X13537 (guinea pig HoxA9); M34857, M27244 
(hoxb-9); X16172 (HOXB9); X12504 (hoxc-6); S69027, M16938 (HOXC6); X07439, 
Y00215 (hoxc-8); M62698 (cat HoxC8); M37568 (rat HoxC8); X55318 (Hoxc-9); H83603 
(HOXC9); M81662, M81663 (gbx1); L11239 (GBX1).
1 Sequence based on the m urine gene sequence only. For HoxA9 and HoxC8, the most 
conserved regions were selected by alignment to other species. Murine Hoxa-9 was 
aligned with guinea pig HoxA9 and m urine Hoxc-8 was aligned with cat and ra t HoxC8.
2 As only a partial homeobox sequence of m urine gbx1 has been published (15), the 
primers were designed to fit to the hum an GBX1.
3 Based on the hum an sequence only (14).
w ere analyzed using the Pharm acia Sequencing kit. Classification of the sequenced 
clones was based on homology with known hum an and m urine Hox-sequences (as 
published in the EMBL database) using the Fasta com puter analysis program  (Caos/ 
Camm, the Netherlands). Based on sequences in the EMBL database, PCR prim ers 
were designed to specifically amplify some of the identified homeobox genes (Table 1). 
PCR conditions w ere optimized for each prim er set.
Southern hybridization 
After separation  by agarose gel-electrophoresis, plasm id DNA or PCR fragm ents 
w ere transferred  onto Hybond-N m em branes (Amersham) and hybridized with [32P]-
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labeled ssDNA probes in 5xSSC, 0.5% SDS, containing 0.1% laurylsarcosine-sodium  
salt and 1% blocking reagen t (Boehringer M annheim) at 65°C overnight. Mem branes 
w ere subsequently w ashed under increasingly stringent conditions (last 15 m inutes:
0.1x SSC with 0.5% SDS at 65°C) prior to autoradiography. Probes used w ere the 
isolated hom eodom ains of HOXB9, HOXC6, and HOXC9. For hybridization of the 
blotted sem iquantitative RT-PCR products the complete coding sequence of HOXC6 
was used.
Semiquantitative RT-PCR 
A sem iquantitative PCR was perform ed in two ways. First, 10-fold serial dilutions 
of cDNA tem plate (1x/10x/100x/1000x) w ere amplified through 45 cycles to identify 
changes in the expression of a specific homeobox gene in cells trea ted  under different 
conditions. W hen differences w ere found, they w ere confirm ed by reducing the 
num ber of PCR cycles, avoiding the p lateau  level for amplification. The num ber of 
cycles was determ ined em pirically to resu lt in product tha t w as ju st visible on gel by 
ethidium  brom ide staining. To norm alize the am ounts of cDNA used in each PCR, 
porphobilinogen deam inase (PBGD), a housekeeping gene (14), served as in ternal 
control (Table 1).
Results
Amplification of homeobox gene subsets in U-2 OS and MC3T3-E1 
A total of 13 hom eobox genes w ere detected  in osteoblast-like cells based on 
sequencing of cloned PCR products th a t had  been  am plified from  cDNA using 
degenerate hom eobox prim ers (Figure 1). Initially 10-20 clones derived from each 
U-2 OS and MC3T3-E1 PCR products w ere sequenced. In both cell lines HoxC9 was 
m ost frequently detected. Subsequently, o ther clones represen ting  U-2 OS cDNA 
w ere identified by m eans of hybridization w ith probed Hox genes tha t had been 
identified earlier (HOXB9, HOXC6, and HOXC9). MC3T3-E1 clones w ere selected by 
m eans of digestion with Ava II, which digests the homeobox dom ain region of m urine 
Hoxc-9 but not th a t of m ost o ther m urine Hox genes. Of 40 U-2 OS clones, 11 tha t 
did not hybrid ize w ith  HOXB9, HOXC6, or HOXC9 w ere  fu r th e r ana lyzed  by 
sequencing. This approach led to the identification of an  additional 4 Hox genes 
(HoxA1 1/11, HoxA4 2/11, HoxA9 1/11, and HoxB3 1/11) (Figure 1). The rem aining 
clones represen ted  HoxC6 (4/11), and HoxA10 (2/11), which had  been identified in 
the  f irs t g roup  of seq u en ced  clones. T he seq u en ces  of HOXA9 an d  HOXC9
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HoxA
2  3  
□  □
4  5  6  7  9■ □ □ m □ ■ ii□  □  □
HoxB □  □
3 4  5  6  7  8  9
M l  I I  1 VZk I 1 liTTTTl 1 I I  I I  I I  I
□  □
9  10  11 12  13
■  □  □  □  □
1 3  4  8 9  10  11 12  13
HoxD □ □ □ □ □ □ □ H n n n n n
paralogs l  2 3 4 5 6 7 8 9 10 11 12 13
Gbxl m
m u - 2  OS 
MC3T3-E1 
B i  both MC3T3-E1 and U-2 OS 
| | not detected
F ig u re  1: Hox genes 
detected in osteoblast like 
cells by seq u en c in g  of 
cloned PCR products that 
had been amplified from 
cDNA using  d eg en era te  
homeobox primers. Boxes 
are aligned vertically in 
their paralog subgroups, 
and horizontally based on 
their chromosomal position.
hom eodom ains have not been published previously and are shown in Figure 2. 
Plasmid DNA of 8 out of 21 MC3T3-E1 clones was not digested with Ava II. Sequence 
analysis of these clones revealed another 5 Hox sequences (Hoxb-6, Hoxb-8, Hoxc-6, 
Hoxd-8, and Gbxl).
Comparison o f  homeobox gene expression in U-2 OS, MC3T3-E1, and  
SK-N-SH
Based on the Hox gene sequences tha t have been subm itted to the EMBL database, 
we designed PCR prim ers to specifically amplify the separate  Hox genes in th ree 
different cell lines (see Table 1). Integrity of the PCR product w as confirmed by 
Southern blot hybridization (data not shown). The Hox genes th a t w ere identified in 
the th ree cell lines using specific Hox prim ers are depicted in Table 2. An additional
Human HoxA9 75
Mouse Hox A9 1 4 0
Human HoxA9 25
Mouse Hox A9 1 9 0
Human HoxC9 74  
Mouse HoxC9 9 7 7
Human Hox C9 24  
Mouse HoxC9 1 0 2 7
Figure 2: Sequences of HOXA9 and HOXC9 homeodomains, as identified in U-2 OS 
cells. The sequences of the mouse and hum an homologues are 100% identical at the 
amino acid level.
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Hox gene
Cell line
U-2 OS MC3T3-E1 SK-N-SH
A1 + + +
A7 - + -
A9 + + -
B9 + + +
C6 + + +
C8 + + +
C9 + + +
Gbxl + - -
Table 2: Comparison of Hox genes detected in U-2 OS, MC3T3-E1, and SK-N-SH cell 
lines using specific PCR prim ers. The specific prim er for Gbx1 only recognizes the 
hum an sequence, w hereas the HoxA7 prim er only recognizes the mouse sequence.
Hox gene was detected in U-2 OS and MC3T3-E1 cDNA using specific PCR prim ers for 
HoxC8, which had not been found to be expressed in U-2 OS and MC3T3-E1 in the 
initial cloning experim ents. Unexpectedly, we observed GBX1 expression in U-2 OS 
but not in MC3T3-E1 cells, while Gbx1 w as originally only detected  in clones 
containing amplified Hox dom ains form  MC3T3-E1 cells. This m ay be due to the fact 
th a t p rim ers w ere designed to the hum an  sequence, because only the homeo- 
boxdomain sequence of m urine gbx1 has been described (15). Another striking result 
was th a t the Hoxa-7 expression w as detected in m urine MC3T3-E1 osteoblasts but 
not in hum an U-2 OS osteosarcom a cells. This m ay be due to the fact tha t only the 
hom eodom ain of HOXA7 has been described. Therefore, prim ers w ere designed to 
regions upstream  and dow nstream  of the hom eodom ain of m urine Hoxa-7, selecting 
the m ost conserved regions by alignm ent to o ther species (Table 1). In a control RT- 
PCR experim ent HOXA7 could not be amplified from norm al hum an osteoblasts 
(data not shown). The app aren t lack of expression of HOXA7 is likely due to species 
differences. In the neuroblastom a cell line SK-N-SH we found expression of HOXA1, 
HOXB9, HOXC6, HOXC8, and HOXC9 but no HOXA7, HOXA9 or GBX1, showing tha t 
Hox expression in cell lines is clearly cell-type dependent.
TGF-b superfamily members modulate expression of Hox genes 
To study possible m odulation of Hox gene expression by activin-A, rhBMP-2, and 
TGF-P1, a sem iquantitative PCR approach was used. The cDNA of growth factor 
trea ted  and un trea ted  cell lines w as initially screened for differences in Hox gene 
expression using increasing dilutions of tem plate with satu ra ting  PCR conditions. 
Based on this we observed clear differences in expression of HoxC6. Minimal or no
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effects w ere seen on the expression of HoxAi, HoxA9, and HoxC8 in both cell lines 
(data not shown). By reducing the num ber of PCR cycles to unsatu ra ting  conditions 
we could m ore precisely define the m odulating effect of each grow th factor on the 
expression of a particu lar Hox gene. Differential effects of rhBMP-2, TGF-pi, and 
activin-A w ere found on the expression of HOXC6 in both U-2 OS and SK-N-SH. 
HOXC6 expression in U-2 OS cells w as dow n-regulated by rhBMP-2 and activin-A 
(Figure 3A), w hereas in SK-N-SH cells HOXC6 was unaffected by rhBMP-2 and up- 
regulated  by TGF-pi (Figure 3B). Effects w ere p resen t after 24 hours as well as 
after 48 hours treatm ent.
F igure  3: M odulation of Hox gene 
expression  by TGF-p superfam ily  
members in A) U-2 OS cells, and B) SK- 
N-SH cells. The top row of each figure 
shows duplicate experiments of cDNA 
template of U-2 OS (A) or SK-S-NH (B) 
amplified using HOXC6 primers. cDNA 
was obtained from cells treated with 
different growth factors, and a control. 
The bottom row represen ts 10-fold 
se ria l d ilu tions of cDNA tem plate  
amplified with PBGD primers, as an 
internal experimental control for the 
amount of template used.
Discussion
Since a relationship betw een norm al grow th/differentiation and tum origenesis 
has been well established, it is not surprising th a t abnorm al homeobox expression 
has been linked to neoplasia (16). The oncogenic potential of Hox genes in mouse 
fibroblasts has been described (17, 18), and altered  expression of several homeobox 
proteins has been found in tum ors (19-25) and haem atopoietic m alignancies (26). It 
is still largely unknow n w hat causes the ab e rran t expression of homeobox genes in
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growth disturbances such as limb m alform ations and tum ors. One m echanism could 
be autocrine and/or paracrine  effects of growth factors. With bone being a large 
producer and storage site for TGF-p and BMPs, the potential effects on growth, 
skeletal pattern ing , limb developm ent, and skeletal neoplasia through m odulation 
of Hox expression are  significant. Having shown previously (27) tha t osteosarcom a 
cell lines, including U-2 OS, produce active and laten t TGF-p1 at levels used in our 
curren t studies, in addition to BMPs (28), we speculate tha t m odulation of expression 
of specific Hox genes by TGF-p1 superfam ily m em bers m ay affect the differentiation 
and neoplastic behavior in osteosarcom a cells.
This study docum ents for the first time th a t a t least 13 hom eobox genes are  
expressed in osteoblast-like cells. The to tal num ber of hom eobox genes expressed 
in both cell lines m ight be larger than  the 13 th a t we detected, since our degenerate 
prim ers do not recognize all homeobox sequences, and a limited num ber of clones 
was screened. This was fu rther dem onstrated  by the fact th a t although HoxC8 was 
not detected by cloning of the hom eobox region as amplified with the degenerate 
prim ers, HoxC8 could be detected at ra th e r low levels in all th ree cell lines if specific 
HoxC8 prim ers w ere used. RT-PCR amplification of Hox gene transcrip ts with prim ers 
tha t recognize specific Hox genes showed th a t the sam e Hox genes w ere expressed 
in osteosarcom a cells as in the osteoblast cell line MC3T3-E1. The only difference 
observed (HoxA7) appeared to be due to a species difference in sequence or expression 
of HoxA7, as also in osteoblasts isolated from hum an bone HOXA7 w as not detected 
(results not shown).
The regulation of Hox gene expression is still incompletely understood. Several 
studies have shown tha t RA is an  im portant inducer of Hox genes in vitro  (4, 29). Its 
m echanism  in em bryonal carcinom a cells involves a cascade m odel of sequential 
transcrip tional activation of Hox genes in a 3 '-5 ' polarity (30). Its effects in vivo 
have also been shown in studies which docum ent the induction of HoxC6 by placem ent 
of an  RA-soaked bead in the an terio r limb bud (31). In addition, hom eobox genes 
m ay auto- and/or cross-regulate each other, or even share  the sam e prom oters (32), 
m aking their regulatory  pathw ays even m ore complex. Only th ree  studies have 
reported  on m odulation of homeobox genes by m em bers of the TGF-p superfamily: 
activin-A induced expression of MIX-2 in Xenopus (33); BMPs induced several 
homeobox genes indirectly during BMP-induced ectopic bone form ation (10); and 
BMPs w ere shown to induce the expression of the hom eobox-containing genes Msx-
1 and Msx-2 in developing teeth  (34). These studies mostly imply differentiation 
effects during em bryogenesis. Our studies have now identified differential effects of 
th ree m em bers of the TGF-p superfam ily on the expression of HOXC6 in U-2 OS and
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SK-N-SH. The fact th a t we see regulation of Hox genes in cell lines by m em bers of 
the TGF-p superfam ily (after relatively short incubation times), suggests a m uch 
directer role of Hox genes in the signal transduction  of these growth factors. The 
finding tha t regulation of HoxC6 expression by m em bers of the TGF-p family is 
clearly cell type-specific is very in teresting  with reg ard  to the role th a t Hox-genes 
are supposed to have in cell and tissue differentiation and determ ination of cell- 
fate. Our observation th a t HoxC6 is regulated  by rhBMP-2, activin-A, and TGF-p is 
perfectly in line with studies dem onstrating tha t m em bers of the TGF-p superfam ily 
regulate neu ra l cell adhesion m olecule (N-CAM) expression (35-37) and with other 
studies showing th a t HoxC6 itself is a potent regu la to r of N-CAM expression. N-CAM 
and other cell adhesion and substra te  adhesion m olecules m odulate cell surface 
events, cellular responses and cellular differentiation through adhesion, a m echanism  
im plicated in m etastasis.
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Discussion:
a look at the past, present and future.

Discussion
A look back
The studies incorporated in this thesis evaluate autocrine m echanism s involved in 
m usculoskeletal neoplasms. First the role of Transforming Growth Factor-b (TGF-b) 
w as investigated in two forms of m esenchym al neoplasm s, one benign (Dupuytren’s 
disease), and  one m alignan t (osteosarcom a). This reflects the hypothesis th a t 
autocrine loops are not only characteristic of cancer cells, but also can lead to benign 
neoplasia since the ingredients (growth factors and their receptors) are  p resen t in 
both processes. A possible therapeutic venue was then  investigated by using suram in 
to block TGF-b binding in osteosarcom a cell lines. In vitro  da ta  from  the first 
investigations w ere expanded to the in vivo situation by correlating the expression 
of TGF-b isoforms to disease progression. And finally, a possible relation was studied 
betw een TGF-b superfam ily m em bers and their ability to induce hom eobox genes.
It is an  old concept th a t neoplasia is an  aberrance of norm al processes such as 
rep a ir and inflam m ation,1925 but it was not until the increased understanding  of the 
biochem ical processes underlying norm al growth and repa ir tha t the sim ilarities 
betw een cancer and inflam m atory/repair processes began to unfold. The basis of 
this relationship w as introduced as the autocrine hypothesis,15-40-47-48-51 which can be 
described as developm ent of m alignancy by endogenous production of peptides 
(growth factors) tha t prom ote autonom ous growth by acting on their own receptors 
at the cell surface, leading to uncontrolled growth, invasion and m etastasis. The 
grow th of the cancerous cells is relatively autonom ous, m eaning it is independent of 
exogenous signaling. The concept of autocrine growth prom pted a unified search  
for a m olecular and cellular basis of m alignant transform ation .12-37'40-48'51 The ideal 
candidates to explain such aberrance are  growth factors, given th a t 1) the tum or 
cells, or their direct environm ent, can produce, excrete and respond to abnorm al 
levels of growth factors them selves; 2) the tum or can express abnorm al levels of 
grow th factor receptors; and 3) th ere  can be abnorm al post-receptor signaling 
(amplification). In addition to au tocrine m echanism s, the concept of p a racrin e  
m echanism s in which growth factors are secreted that affect not the cells that produce 
them  them selves, but ra th e r the neighboring cells and tissues, has shown to be of 
im portance in tumorigenesis. By stimulating deposition of extracellular m atrix around 
the tumor, an  optimal growth environm ent is created. It is unclear w hat causes 
ab e rra n t expression of grow th factors, bu t it is known th a t abnorm al levels of 
expression of growth factors and their receptors can be induced by oncogenes. 
Examples are  the s is  oncogene, which codes for the B-chain of platelet-derived 
growth factor (PDGF), the erb-B1 gene, which codes for the epiderm al growth factor 
(EGF) receptor, and the ras  gene, which is involved in post-receptor signaling. Despite
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the nam e, oncogenes are also p art of norm al physiological processes, and it is thus 
not the m ere presence or absence of these genes, but their loss of regulation th a t is 
associated with pathology.56
At the onset of the w ork described in this thesis there  was no inform ation of 
possible involvement of TGF-b autocrine loops in m usculoskeletal diseases. The vast 
m ajority of papers described evidence for TGF-b aberrancies in ectoderm al-derived 
tum ors, i.e. carcinom as of tissues such as breast, colon, lung or prostate. Interestingly, 
given th a t ab e rran t autocrine loops involving TGF-b appear to be at the basis of 
m alignant transform ation, skeletal tissue would seem  at high risk of developing 
such a m echanism  since they have a 100-fold higher presence of TGF-b relative to 
soft tissues.40 The prototype bone cancer is osteosarcom a, a m alignant bone tum or 
charac te rized  by the production of osteoid.17 In o rder to evaluate the possible 
autocrine loop in osteosarcom a, an  in vitro  study of 7 osteosarcom a cell lines was 
conducted (chapter 2). Indeed all four ingredients for an  autocrine loop in these 
cells w ere shown in the m ajority of cell lines tested: they w ere growth stim ulated by 
exogenous TGF-b, they expressed TGF-b receptors, active and laten t TGF-b was 
excreted by the cells and addition of TGF-b antibody abrogated  the proliferation. 
The fact th a t addition of TGF-b antibody decreased  the p ro liferation  of these 
osteosarcom a cells under serum -free conditions in vitro  suggests th a t the TGF-b 
autocrine loop can be in terrup ted  by exogenous antibodies. In addition, the am ount 
of active TGF-b excreted  in vitro  as m easu red  in the conditioned m edium  was 
com parable to the am ounts th a t w ere used in the mitogenic assays, suggesting that 
this is a fairly accurate  reflection of the in vitro  condition.
If autocrine growth stimulation involving TGF-b is one of the underlying mechanisms 
in the development of osteosarcom as, then preventing binding of TGF-b to the cell 
surface receptors of the osteosarcom a cells could be a therapeutic  venue. One of the 
drugs currently  being investigated is suram in, an  old an ti-parasitic  drug tha t was 
shown to prevent binding of different types of growth factors, one of which was 
TGF-b.32,33,44 Addition of suram in to cultures of osteosarcom a cell lines show ed a 
decrease in cellular proliferation in a dose-dependent m anner. Moreover, it was 
shown tha t binding of radio-labeled TGF-b w as prevented by suram in in a dose- 
dependent m anner (chapter 3).
Following the work on osteosarcom a cell lines, the next step was to investigate the 
ex vivo  situation in a fibroproliferative disorder of the palm ar fascia of the hand, 
called Dupuytren’s contracture or Dupuytren’s disease5 (chapter 4). This is an enigmatic 
con trac tu re  of the pa lm ar fascia initially described by the fam ous Guilleaum e 
Dupuytren in the beginning of the 19th century.18 It is characterized by excess deposition
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of extracellu lar m atrix  and proliferation of (myo)fibroblasts, a m esenchym al cell. 
The origins of this disease have intrigued m any scientists and surgeons, and m any 
causes for its etiopathogenesis have been published, a review of which is p resented  
in chapter 5. Different groups have investigated a relation betw een growth factors 
and D upuytren’s contracture. However, to our surprise , a t the onset of this thesis no 
one had studied a relation betw een TGF-b and this disease. It seem ed tha t TGF-b 
was the ideal candidate for this role. It w as known to cause excess m atrix  production 
in addition to increased fibroblastic proliferation, two features characteristic for 
D upuytren’s disease. It was shown in the studies presen ted  in this thesis th a t an 
autocrine m echanism  involving TGF-b is one of the final com m on pathw ays in the 
developm ent of the contracture. In addition the TGF-b recep to r profile as studied 
with cross-linking was clearly different on Dupuytren tissue derived cells as com pared 
to norm al fibroblasts.
To fu rther understand  the autocrine m echanism  of TGF-b in osteosarcom a it was 
also necessary  to expand the investigations to the in vivo  situation. Using immuno- 
h is to ch em is try , a ll th re e  TGF-b iso fo rm s w e re  sh o w n  to be e x p re s se d  in 
osteosarcom as, and the level of expression of at least one isoform -TGF-b3- was 
shown to be re la ted  to disease progression (chapter 6). In o ther w ords, the m ore 
TGF-b3 is expressed in osteosarcom a, the w orse the prognosis for the patient.
These findings have been confirmed by m any other studies that investigated various 
neoplasm s. Interestingly, m ost these o ther studies have investigated carcinom as, 
w hich rep resen t ectoderm al tissues such as epithelium . Since it is well-known th a t 
epithelial cells a re  generally grow th-inhibited by TGF-b, it is counter-intuitive th a t 
increased expression of a growth factor th a t is inhibitory for growth would lead to 
uncontrolled growth. Even the popular hypothesis th a t these cancer cells have 
developed a resistance to the growth inhibitory effects of TGF-b does not explain 
solely the increased  level of expression of TGF-b in these tum ors. Is there another 
function of the increased TGF-b? It could indeed be the im m unosuppressive abilities 
of TGF-b th a t causes decreased  im m unosurveillance of the body and a decreased 
ability to fight off cancer cells. A nother explanation for the increased expression of 
TGF-b in carcinom as is its ability to provide the tum or with a niche for expansion by 
developing a strom a for the tum or w ith its angiogenic and m atrix  stim ulating 
potential. The only o ther m esenchym al tum or th a t has been evaluated extensively 
regarding a possible autocrine loop involving TGF-b is the glioblastoma multiforme.27'29 
These d a ta  a re  generally  in ag reem en t w ith  ours. The difference is th a t they 
subdivided the tum ors in different ploidies, showing tha t hyperdiploidy is associated 
w ith m itogenic stim ulation by TGF-b. A m ore recen t rep o rt showed th a t TGF-b
137
Chapter 8
antisense therapy eradicated established in tracranial ra t gliomas,20 but these authors 
m erely a ttribu ted  this to the reestab lishm ent of cellular im munity of NK and LAK 
cells. These efforts are still a t an  early stage, but it is expected that the use of TGF-b 
in im m unogene therapy  for cancer m ay be im portant.
It is obvious tha t the developm ent of an  osteosarcom a cannot be solely dependent 
on the expression of one single growth factor. W hat is not clear, however, is w hat 
causes the increased expression of TGF-b isoforms in these tum ors as we detected 
them . Furtherm ore, w hat happens at the post-receptor signaling level, given tha t 
certain  genes will need to be tu rned  on and others will be tu rned  off by TGF-b 
signaling? One of the genes tha t will m ost likely be upregulated  is TGF-b itself, 
which, as discussed previously, has been shown to have an  auto-inductive capacity.55
Another gene family th a t is likely to be linked to TGF-b superfam ily signaling are 
the hom eobox genes, w hich not only have w ell-know n roles at early  stages of 
developm ent, but also have a large role in the establishm ent of the skeletal system, 
and, specifically, the lim bs.233143 W ith the theory  th a t m alignancy is caused by 
dysregulation of norm al physiological processes, it seem ed p ruden t to investigate 
w hether homeobox genes were up-or down-regulated in osteosarcoma cells by TGF-b 
superfam ily m em bers (chapter 7). By using RT-PCR technique we first studied the 
expression of homeobox genes in three different cell lines, after which we determ ined 
sem i-quantitatively tha t TGF-b1 and BMP-2 w ere able to regulate their expression. 
Our findings have been reinforced by the recen t findings th a t hom eobox genes w ere 
either m u tated  or increasingly expressed in certain  cancer types.127131416
In summary, the data in this thesis w ere the first to show evidence for an  autocrine 
loop involving TGF-b in two different m usculoskeletal disorders. In addition we 
showed tha t TGF-b superfam ily m em bers can regulate homeobox genes. As is often 
seen in any scientific investigation, the answ ering of one question raises m any new 
ones. The on-going investigation and elucidation of these will undoubtedly allow us 
to establish a be tte r understanding  of these diseases, and progress tow ards m ore 
effective treatm ents.
A look at the present
During recent years a large am ount of inform ation has appeared  on the m olecular 
s tructu re  of TGF-b receptors and their signal transduction in term ediates, the Smads 
(see ch apter  1). Since the publication of our data  described in ch apter 2 , a t least two 
other studies have attem pted  to correlate TGF-b receptor levels w ith their biological 
effects, one focusing on glioma cells,35 the o ther on clonal osteoblastic cells.52 
Analogous to ours, in these studies no clear correlation could be found betw een the
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biological effect of TGF-b (growth stim ulation or growth inhibition) and receptor 
levels as determ ined by chem ical crosslinking. Recently, it has become evident tha t 
functional TGF-b-receptor complexes preferentially  contain two type I and two type
II receptors. Upon crosslinking of these complexes the iodinated TGF-b appears to 
bind preferentially  to the type I receptors, and therefore the type I recep to r bands 
shown in fig. 2 of chapter 2 m ost likely reflect the active tetram eric receptor complex, 
while the indicated type II bands m ay rep resen t inactive dim eric complexes of two 
type II receptors w hich are  only formed w hen type II receptors a re  p resen t in excess 
of the type I recep to rs.35 Looking at our data  from tha t viewpoint, it appears tha t 
high levels of active TGF-b recep tor complexes are m ore associated w ith growth 
inhibition, while lower recep to r levels seem  to parallel growth stim ulation. The 
observation tha t HOS cells are not affected in their proliferation by TGF-b m ay 
indicate th a t grow th stim ulatory and growth inhibitory effects are  in balance, or 
th a t some in tracellu lar second m essenger requ ired  for TGF-b signaling is m issing in 
these cells.
W hen evaluating the effects of suram in  on proliferation of osteosarcom a cells in 
vitro (chapter 3), this drug appeared to be very promising for the trea tm ent of various 
tum ors including osteosarcom as. However, it has become m ore and m ore clear in 
recen t years, th a t suram in  acts in a very non-specific m anner, and its clinical use is 
ham pered  by toxic reactions including adrenocortical insufficiency and peripheral 
polyneuropathy. In addition its exact m echanism  of action is still unknown. It is 
expected tha t by fu rther developm ent of suram in  analogues m ore specific an ti­
tum or effects m ay be obtained, m aking it clinically usable.
Our data  published in chapter 4 on the role of TGF-b in D upuytren’s contracture 
have been confirm ed by la te r im m unohistochem ical34 and in-situ  hybridisation 
studies.6 Besides TGF-b, PDGF has also been im plicated in this disease, but since 
TGF-b is able to induce PDGF expression in m esoderm al cells, these two models do 
not have to be m utually exclusive (reviewed in ch apter 5  and in ref. 4). The data  in 
chapter 4 concentrate on the role of TGF-b1 and TGF-b2 in D upuytren’s contracture, 
and no additional inform ation has since then  become available on a potential role 
TGF-b3 in this disease. The assay used in this study to determ ine the concentration 
of TGF-b activity in conditioned m edia by its ability to inhibit proliferation of MvlLu 
m ink lung cells is still widely used, although recent studies indicate tha t this assay 
m ay be influenced by the presence of hepatocyte growth factor/scatter factor, which 
has been shown to counteract the growth inhibitory effect of TGF-b in this assay.11
Finally, our data  from ch apter 6 in which a relation of a TGF-b isoform to disease 
progression in osteosarcom a patients was docum ented, have recently been reinforced
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by Franchi et al.,22 while the role of homeobox proteins in TGF-b signaling (chapter 
7) has been confirmed by a recen t study from  our group in which it is shown that 
induction of the cell adhesion factor NCAM in osteoblast-like cells by the TGF-b 
superfam ily m em ber BMP-4 is m ediated  by hom eobox proteins.8
A look at the future
The added value of the w ork presen ted  in this thesis is the implication of TGF-b in 
the developm ent and behaviour of m esenchym al tum origenesis. No d ata  w ere 
available at the onset of this w ork tha t showed a correlation suggesting this. Data 
w ere initially obtained by testing  the hypothesis in v itro , a fte r w hich this was 
expanded in v ivo .
Having established the evidence that aberran t expression of TGF-b is related  to a 
certain disease, w hat does this m ean for the clinician and m ore importantly the patient? 
It would be naive to suggest that a single growth factor such as TGF-b, no m atter how 
complex, w idespread and enigmatic its roles m ay be, could be responsible for the two 
entities studied in this thesis. It is well-known that tumorigenesis is a multistep process, 
including growth factors, suppressor genes and oncogenes.12>37'39,48'50,56 Multiple errors 
in each of these steps are needed to establish a neoplastic phenotype. Keeping this in 
mind, it is also obvious tha t the best way to finding a cure to a certain  disease is to 
elucidate its exact pathogenesis. Data presented herein will help us further understand 
the diseases studied. With the development of a staging system, limb salvage surgical 
techniques, adequate diagnosis and chemo-therapy, the 5-year survival of patient 
with osteosarcom a has greatly increased in the last decennia (being currently around 
75-80%), yet there is still room for im provem ent.17
Thus, the clinical value of the presented thesis is mostly on increased understanding 
of autocrine m echanism s in m esenchym al tum ors. An option for m onitoring the 
d isease  and  thus signaling  possible re cu rre n ce  of an  o steosarcom a could be 
m easu rem en t of TGF-b levels in p lasm a or u rine  as has been done for o ther 
tum ors.30,46,53,54 In addition the resu lts described in chap ter 6 suggest a diagnostic 
role for m easuring  the level of TGF-b3 expression as a prognostic m ark er in patients 
w ith high grade osteosarcom as. This could subselect those patients th a t historically 
w ere in the sam e group (IIB) for m ore aggressive chem otherapy or surgical resection.
On the therapeutic  side one can theorize on the use of TGF-b antisense therapy. 
This was recently reported  by F akhrai et al.20 in a study in which they eradicated  
in tracran ia l gliomas in ra ts. Their explanation w as m erely on the reestablishm ent
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of cellular immunity, ra th e r than  decrease of mitogenic stimuli of TGF-b. However, 
if TGF-b is likely to be the proliferative stim ulus, as in our studies, or if it has been 
converted from  autocrine inhibitor to m itogen thereby  conferring a D arw inian 
advantage to tum orous subpopulations as shown in o ther studies,26-27-41-42 then  the 
role of TGF-b antisense therapy  would have additional therapeutic  potential. Until 
the complete understanding  of the complex roles of TGF-b, caution is w arran ted  
against the clinical system ic  application of this growth factor or its inducers or 
depressors since it is likely to effect m ultiple tissues and systems. Two of the few 
studies th a t have investigated this concept are by B order et al.910 who showed a 
protective effect of decorin  -a n a tu ra l inh ib itor of TGF-b- ag a in st sca rrin g  in 
experim ental kidney disease in ra ts. On the o ther hand, the local application of 
TGF-b antibodies could be a m ore feasable approach in local fibrotic conditions 
such as in active D upuytrens disease or perhaps after resection of the contracture 
preventing recurrence or extension. Recently, re la ted  in vivo  studies have shown 
this to be feasible.36,45
Although our data  on the anti-m itogenic effects of suram in  are im pressive in vitro, 
and have also been shown in o ther cell types,323344 its clinical use is as of yet not 
established. Its use has been complicated by difficulties in obtaining adequate levels 
w ithout toxicity. Its role m ight m erely be an  adjuvant role by inducing a growth 
arrest which could increase the sensitivity of the tum or as a whole to m ore established 
chem otherapeutics. So far, although su ram in  is curren tly  a phase II/III drug in 
evaluation as a angiogenesis drug, its m echanism  is considered unclear w ith non­
specific, multi-site effects.34 Development of related  drugs is to be expected. Although 
one of the roles of TGF-b is re la ted  to its angiogenic properties, it seem s th a t 
investigation of o ther angiogenic growth factors such as vascular endothelial growth 
factor (VEGF) and angiostatin is as of yet of m ore im portance.21
In conclusion, one can say tha t enorm ous advances in the understanding  of hum an 
disease have been m ade in the last decennia. With the em phasis on the unraveling 
of the causes of cancer, the understanding of norm al processes such as development, 
grow th and rep a ir have benefitted trem endously. The control of m alignancy in 
hum ans by m anipulation of growth factors is not yet established, but is certain  to be 
available in the future. With the developm ent of techniques for gene transfer (e.g. 
using retroviruses) we m ight soon have a m eans of influencing and even controlling 
the local presence of growth factors and their receptors. If th a t is the case, the next 
century will undoubtedly show an increase in therapeutic  venues of TGF-b in the 
trea tm en t of not only cancer, bu t also of degenerative , autoim m une and even 
traum atic  d isorders.1024
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Summary
Summary
Chapter 1 forms the outline of this thesis. An introduction is given on the concept of 
autocrine growth control. This m echanism  involves production of growth factors that, 
after having been excreted, bind to the p roducer’s own specific receptor to elicit a 
response. Autocrine loops are now known to be p art of m any different processes, 
including norm al growth, development, and repair. The function of growth factors is 
thus to coordinate and regulate the activities of cells, m aintain ing hom eostasis. 
However, aberrancy of these loops has been shown in disease states such as fibrosis, 
atherosclerosis and cancer. The disturbances in the autocrine loop can be located at 
the level of growth factor production, receptor expression or at post-receptor signaling. 
The growth factor that forms the basis of this thesis is transform ing growth factor 
beta (TGF-p), the prototype of a family of m ultipotential proteins whose biological 
roles have perplexed the scientific world since its original description. TGF-p affects 
multiple m echanism s in almost all species; in hum ans it is mostly known for its roles 
in embryonic development and growth control as well as in homeostasis, im m uno­
suppression, wound repair and cancer. An overview is given of the characteristic 
functions of TGF-p, its receptors and post-receptor signaling in norm al and pathological 
processes, specifically as they re la te  to the skeletal system , tissue fibrosis and 
malignancy.
Chapter 2  contains an in vitro  evaluation of several aspects of an  autocrine loop 
involving TGF-p in osteosarcom a cell lines. By using cross-linking techniques with 
radio-labeled TGF-p it is shown tha t all cell lines tested express TGF-p receptors, 
although the expressed profile of the th ree different types of receptor is som ewhat 
variable. Effects of exogenous TGF-p on cellular proliferation is also determ ined, 
showing th a t the m ajority of the osteosarcom a cell lines are growth stim ulated under 
such conditions. However, no correlation is observed betw een the receptor-type ratio 
and growth effects of exogenous TGF-p. Production of TGF-p by these cell lines is also 
m easured using the mink-lung cell inhibition assay. The results show th a t the am ount 
of TGF-p produced is sim ilar to the am ount observed as having the m ost effect on cell 
proliferation. Expression of TGF-p by these cell lines is confirmed at the mRNA level 
using the polym erase chain reaction (PCR). According to these studies, all ingredients 
for an  autocrine loop involving TGF-p are p resent in osteosarcom a cells. These results 
are fu rther corroborated by using anti-TGF-p antibody to abrogate the autocrine 
proliferative activity. Together, this w ork dem onstrates the im portance of TGF-p 
autocrine control in the etiology of osteosarcom as.
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In Chapter 3, the in vitro effects of suram in on osteosarcom a cells are described. 
Suram in has long been used as an  anti-parasitic drug, and has recently been found to 
prevent binding of a variety of growth factors to their receptors. As such, its use as an 
autocrine loop m odulator has been suggested, thereby opening a therapeutic venue 
for diseases caused by ab erran t growth control such as cancer. Our in vitro  studies 
show that in the presence of a clinically achievable concentration of suram in, the 
binding of TGF-p in osteosarcom a cells is inhibited. In addition, the proliferation of all 
seven cell lines tested decreased significantly in a dose-dependent m anner when treated 
with suram in. Although these results are promising, the m echanism  of action of this 
drug rem ains incompletely understood. That, together with its significant side-effects 
render suram in’s clinical use for cancer treatm ent not yet feasible.
In Chapter 4, a classic feature of TGF-p as it relates to hum an disease is investigated. 
One of the features of prolonged overexpression of TGF-p is the accum ulation of 
excessive ex tracellu lar m atrix  resulting in fibrosis. This has been shown in different 
organs including lung, liver, bone m arrow  and kidney. In this chapter, the relationship 
betw een TGF-p and an  enigm atic fibrotic disorder affecting the hand  palm  known 
as Dupuytren’s contracture or D upuytren’s disease is studied. Using an ex vivo  model 
by establishing prim ary cultures from D upuytren’s (m yofibroblasts, we investigate 
production of TGF-p by these cells, expression of TGF-p receptors, and effects on 
proliferation (growth) in the presence of two different grow th factors (TGF-p and 
EGF), or com binations thereof. The results are com pared to sim ilar experim ents 
using prim ary cultures of norm al hum an fibroblasts. The com parison shows that 
the ratio  of the TGF-p receptors type I and II is different in the two cell types, which 
could explain their different behaviour. Both norm al and Dupuytren fibroblast types 
are  also shown to produce active and laten t TGF-p. However, the proliferation of 
Dupuytren cells is stronger stim ulated in the presence of TGF-p and a com bination 
of TGF-p and EGF than  in norm al fibroblasts. These results show that growth factors, 
and specifically TGF-p play a role in D upuytren’s disease.
In Chapter 5, an  overview is given on the cu rren t understanding  in the etiopatho- 
genesis of D upuytren’s disease. Different philosophies have been presented  th rough­
out the years from biochemical, epidemiological, histological and cellular/m olecular 
biological viewpoints. During the completion of this thesis, a final com m on pathw ay 
has s ta rted  to em erge. At this time, it seem s th a t growth factors and specifically 
TGF-p play a m ajor role in the behaviour and origin of D upuytren’s disease. It is to
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be expected tha t once the exact m echanism  of this entity is elucidated, less invasive 
trea tm en t options such as local application of antibodies will develop.
In Chapter 6, the in vitro  findings of chapter 2 (evidence of an  autocrine m echanism 
involving TGF-p in osteosarcom a) is extended to the in vivo situation. The expression 
of TGF-p isoforms (TGF-pi -p2 and -p3) in high-grade osteosarcom as is investigated 
using immunohistochemistry, and a correlation betw een the presence of each isoform 
and disease progression is studied. Using Kaplan-M eier analysis, the am ount of 
TGF-p3 p resen t in these tum ors is shown to be correlated  with disease-free time, 
suggesting th a t an  increased presence of TGF-p3 som ehow places the osteosarcom a 
at an  advantage. This correlation has since been implied in m any other cancers 
including breast, lung and liver. In addition, this chap ter provides a review of the 
cu rren t understanding  of the etiopathology of osteosarcom a.
In Chapter 7, the expression of homeobox genes (Hox genes) in th ree different 
m esenchym al cell lines is investigated, as well as their possible regulation by TGF-p 
superfam ily m em bers. The Hox genes under investigation have significant roles in 
the developm ent and pattern ing  of the appendicular system, and have been shown 
to be expressed aberran tly  in certain  tum ours. The studies in this chapter, based on 
PCR and Southern hybridization, show th a t specific Hox genes are  targets for the 
TGF-p superfamily. This regulation seem s cell-type re la ted  in th a t neuroblastom a 
cells a re  d ifferen tly  affected  th a n  o steo sarco m a cells. Specifically HOXC6 is 
differentially regulated  by TGF-pi, rhBMP-2 and activin-A. These findings allow us 
to further understand the complex interplay betw een growth factors and their relation 
to the developm ent of norm al and diseased states.
Chapter 8  contains the discussion of the thesis. The data  of the preceding chapters 
are  evaluated in relation to the m ost recen t advances and understanding  of TGF-p 
and its roles in disease. Implications for future research  and possible therapeutic 
applications are given.
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Dankwoord
Professor van Zoelen, toen ik vanuit Boston een plek in N ederland zocht om mijn 
TGF-p onderzoek te voltooien kw am  ik al snel m et Uw expertise op het gebied van 
groeifactoren in aanraking. Overeenkomstig de planning die wij in 1995 gem aakt 
hebben, is het uitgem ond in een proefschrift over TGF-p dat de b asaa l w e ten ­
schappelijke en klinische aspecten  van deze groeifactor com bineert op het gebied 
van het bew egingsapparaat. Gedurende het schrijven van dit proefschrift zijn Uw 
inzicht, kennis en begeleiding van grote w aarde geweest. Tijdens de laatste drukke 
ja re n  van m ijn opleiding in Boston heeft U mij nooit m et vragen over het proefschrift 
lastig gevallen. Toen ik recentelijk terugkw am  n aa r A m sterdam  heeft een gestage 
stroom  van e-mails en discussies echter dan de laatste  fase van het boekje bew erk­
stelligd. Ik dank U voor Uw niet aflatende steun  en toewijding om het geheel sam en 
te voegen voor m ijn promotie.
Professor Olijve, als hoofd van de afdeling Toegepaste Biologie creëerde u voor 
mij de m ogelijkheid om zes m aanden  basaal w etenschappelijk onderzoek te doen in 
Nijmegen. Uw geduld m et opnieuw een arts  die zonodig basaal w etenschappelijk 
onderzoeker wil zijn, w aardeer ik zeer. U en professor van Zoelen hebben nooit 
getwijfeld aan  het licht aan  het einde van de tunnel. Het w as nooit mijn intentie om 
pas de laatste twee w eken van m ijn verblijf m et de uiteindelijke resu lta ten  te komen.
Dr. Mankin, de basis van dit proefschrift ligt bij U in Boston. U was het die mij 
introduceerde in de enigm a’s van TGF-p. Wat voor mij eerst één ja a r  van onderzoek 
in Boston zou w orden, w erden er twee, gevolgd door de opleiding tot orthopaedisch 
chirurg aan  H arvard Medical School. Gedurende deze acht ja ren  hebben U en Uw staf 
mij veel m eer b ijgebracht dan orthopaedie alleen. Het was een geweldige tijd, 
veeleisend, leerzaam , soms afm attend, m aar vooral onvergetelijk. Het is een eer door 
U opgeleid te zijn als orthopaedisch chirurg en wetenschapper.
Dr. Leslie Gold, onze sam enw erking begon na m ijn vele telefoontjes en faxen om 
jouw TGF-p antilicham en te verkrijgen. Het uiteindelijke resu ltaa t van ons w erk is 
beschreven in hoofdstuk 6 w at voor mij één van de favoriete onderdelen vorm t, te 
w eten de succesvolle translatie  van een proefondervindelijk ju ist bevonden basaal 
w etenschappelijk idee n aa r de klinische situatie.
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Dr. Christine Boersm a, als m ijn begeleidster in het laboratorium  in Nijmegen zat 
je  in een race om een project te com pleteren in zes m aanden, en tegelijkertijd mij 
de beginselen van PCR, Southern hybridisaties en DNA sequencing bij te brengen. 
Ik geloof niet dat het PCR ap p a raa t langer dan acht u u r uit is gew eest al die tijd. 
Dankzij jouw vele talenten  en enthousiasm e hebben we hoofdstuk 7 echter geklaard, 
w aarvoor enorm e dank.
Professor M arti, U was m ijn prom oter voor de orthopaedie lang voordat ik ooit 
van TGF-p gehoord had. Uw adviezen rondom  m ijn opleiding in Boston zijn van 
grote w aarde geweest. Dat ik dit ja a r  voor m ijn “registratie" bij U kon kom en, geeft 
mij uiteindelijk het beste van beide w erelden.
Beste ouders, jullie s teun  en in teresse tijdens al m ijn om zwervingen zijn een 
voorrecht geweest. Jullie hebben mij de mogelijkheden geboden die tot dit proefschrift 
hebben geleid. Dat zal ik nooit vergeten. Als dank is dit proefschrift voor jullie 
geschreven.
Beste Jan, m ijn indertijd onnozele vraag  wie voor jullie gynaecologen de buik 
openm aakt, heeft jou  wellicht gestim uleerd mij ook nu net w eer een academ isch 
stapje voor te blijven. Het is een genoegen en eer jou  als zw ager en hooggeleerde 
om advies te kunnen vragen tijdens de voorbereidingen van dit proefschrift.
Lieve Dana, zonder jouw emotionele en intellectuele steun was dit proefschrift mij 
heel w at zw aarder gevallen. Jij hebt mij m et ervaring, kennis, liefde, enthousiasm e 
en flexibiliteit niet alleen bijgestaan bij de wetenschappelijke, m aar ook de opleidings- 
perikelen. Om deze redenen en nog vele andere, d raag ik dit proefschrift aan  jou op.
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